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 Chronic myeloid leukemia (CML) is caused by the constitutive kinase activity of 
the fusion oncoprotein BCR-ABL.  Conventional therapy in CML utilizes tyrosine kinase 
inhibitors (TKIs), small molecules that target the ATP-binding pocket in the BCR-ABL 
kinase domain.  Despite their success in treating this disease, continued use of TKIs can 
lead to drug resistance due to point mutations in the kinase domain.  Additionally, non-
specific (non-BCR-ABL) kinase inhibition by these TKIs can cause toxic off-target 
effects.  To function as an aberrant kinase, BCR-ABL must first homo-oligomerize via a 
coiled-coil (CC) domain located at its N-terminus.  Thus, inhibiting BCR-ABL 
oligomerization abolishes its function as an oncoprotein. 
 Designing an inhibitor of the 72-amino acid BCR-ABL CC domain is the focus of 
this dissertation.  To engineer a construct capable inhibiting oligomerization, strategically 
designed mutations were incorporated into an isolated BCR-ABL CC domain with the 
goal of promoting higher affinity binding to endogenous BCR-ABL while at the same 
time disfavoring binding to our isolated CC construct.  The designed construct, called 
CCmut3, was tested in vitro in leukemia cells containing both wild-type and mutant BCR-
ABL.  Overall, in vitro treatment with CCmut3 resulted in a decrease in BCR-ABL kinase 
activity, induction of apoptosis, and a reduction in the proliferation and transformative 
ability of CML cells.  Next, combining CCmut3 with ponatinib, a recently approved BCR-
!! iv!
ABL TKI, was also explored.  This combination resulted in improved BCR-ABL 
inhibition and a lowering of the dose of ponatinib necessary for efficacy. 
Finally, the later chapters in this dissertation focus on possible methods in which 
the deliverability and stability of CCmut3 can be improved.  Truncation and helical 
capping were both attempted, however, neither provided an inhibitory advantage over the 
full-length CCmut3 construct.  Thus, current designs are focusing on creating a 
hydrocarbon stapled and truncated CCmut3 peptide, expected to result in a translatable 
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Chronic myeloid leukemia (CML) is caused by the presence of the Philadelphia 
chromosome, a truncated chromosome 22 formed by a reciprocal chromosomal 
translocation between chromosomes 9 and 22.  This Ph chromosome in turn forms the 
BCR-ABL1 gene, resulting in the appearance of the BCR-ABL fusion oncoprotein.  A 
constitutively active nonreceptor tyrosine kinase, BCR-ABL aberrantly activates cell 
signaling pathways promoting cellular growth and survival, leading to a leukemogenic 
phenotype.  Conventional CML therapeutics target the tyrosine kinase domain of BCR-
ABL, interfering with ATP binding and thus inactivating downstream signaling.  Despite 
showing a high success rate, point mutations in the BCR-ABL tyrosine kinase domain 
can prevent tyrosine kinase inhibitor (TKI) binding and eliminate their therapeutic 
efficacy. Therefore, alternative therapies are required.   
To function as an oncoprotein, BCR-ABL must homo-oligomerize via a coiled-
coil (CC) domain located at its N-terminus.  Previous work has shown that removing this 
coiled-coil domain, thus preventing homo-oligomerization of BCR-ABL, abrogates the 
oncogenic activity of BCR-ABL.  Therefore, design of a BCR-ABL coiled-coil inhibitor, 
that would be efficacious in both native and mutant BCR-ABL, is the focus of this work.  
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The overall goal is to create a coiled-coil inhibitor that favorably binds to BCR-ABL 
while disfavoring homo-oligomerization with itself.  The design process of this inhibitor 
is described in detail in Chapter 2.  Further, combination treatments using this coiled-coil 
inhibitor along with the most recently FDA-approved BCR-ABL tyrosine kinase 
inhibitor, ponatinib (described in detail in Chapter 3), is discussed in Chapter 4.  Next, 
attempts to improve the deliverability and stability of this coiled-coil inhibitor through 
helical truncation and helix capping are described in Chapter 5.  Finally, Chapter 6 
focuses on the current and future directions of this project, most notably the design of this 
coiled-coil inhibitor as a stapled peptide.  Following the background and significance, the 
aims and hypotheses of this research project are introduced. 
 
Background 
Chromosomal translocations and their implications in cancer 
Genetic change in DNA is a well-known cause for the onset of many cancers (1).  
Some DNA changes as small as mutation of a single nucleotide, if occurring in specific 
genes, can have a negative impact on the risk of developing cancer (2, 3).  However, in 
other cases, rearrangement of entire chromosomes can occur, resulting in the production 
of proteins capable of promoting the onset and growth of cancer (1).  These instances, 
known as chromosomal translocations, have been known to cause many hematologic 
malignancies (4, 5) and even some solid tumor cancers as well (6).  Translocations occur 
as one portion of a chromosome breaks off from its respective chromosome and is 
transferred to another, nonhomologous chromosome (7).  This results in deletion or 
realignment of genetic material that can have effects ranging from production of 
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oncoproteins (8) to inactivation of genes that produce tumor suppressors (9, 10).  One of 
the most well studied chromosomal translocations is the Philadelphia (Ph) chromosome, 
which leads to the production of the oncoprotein BCR-ABL and is causative of chronic 
myeloid leukemia. 
 
Introduction to CML and BCR-ABL 
Each year, nearly 6,000 new cases of chronic myeloid leukemia (CML) are 
diagnosed in the United States (11).  CML is a myeloproliferative cancer originating from 
pluripotent stem cells located in the bone marrow.  Onset of CML is due to the 
t(9;22)(q34;q11) reciprocal chromosomal translocation resulting in the formation of a 
shortened chromosome 22, known as the Philadelphia chromosome (12, 13).  During this 
translocation process, portions of chromosome 9 (near the ABL1 gene) and chromosome 
22 (near the breakpoint cluster region, or BCR) break and swap places, aligning the BCR 
and Abl1 genes.  This newly formed fusion gene, BCR-ABL1, is eventually translated into 
the protein responsible for the oncogenicity seen in CML (discussed below).  As CML is 
described as a chronic disease, onset often does not occur until later in life, with an 
average age at diagnosis around 64 years (11). 
 Physiologically, CML is characterized by an expansion of white blood cells 
(WBCs) from the myeloid (nonlymphocytic) stem cell lineage.  Stem cells originating in 
the bone marrow can follow one of two lineages: myeloid or lymphoid.  The lymphoid 
lineage includes many of the WBCs important to the immune system, beginning with 
lymphoblasts, which can mature into B lymphocytes, T lymphocytes, and natural killer 
cells.  On the other hand, cells from the myeloid lineage include red blood cells (RBCs), 
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platelets, and myeloblasts.  These myeloblasts, upon maturation, develop into WBCs, 
namely eosinophils, neutrophils, and basophils.  It is from this compartment, myeloblasts 
and beyond, whose unregulated growth leads to the development of CML (Figure 1.1). 
 CML is characterized into three phases based on the amount and types of cells 
present in the blood: chronic phase (CP-CML), accelerated phrase (AP-CML), and blast 
crisis (BC-CML).  Chapter 3 provides a detailed description of these phases.  Briefly, 
according to the World Health Organization (WHO), CP-CML is defined in patients 
having less than 10% blast cells (myeloblasts) in the blood and bone marrow.  Because 
these patients generally only show mild or vague symptoms, if any (14), CP-CML is 
often diagnosed via a standard complete blood count (CBC) where the blood sample will 
show an elevation of WBCs.  Diagnosis can be confirmed using a bone marrow biopsy in 
which the cells present will be microscopically analyzed and/or cytogenetically tested 
using karyotyping, fluorescence in situ hybridization (FISH), or polymerase chain 
reaction (PCR) for the presence of the Ph chromosome or the BCR-ABL gene. 
 If the CML advances into the accelerated phase, according to the WHO 
classification, 10-19% of the cells in the blood and bone marrow will be blast cells (15, 
16).  Additionally, among other signs, patients will display a high basophil count (≥20%) 
in relation to the WBC differential gathered from the CBC.  Finally, the most telling 
characteristic of BC-CML is the expansion in the number of blast cells found in the blood 
and bone marrow.  Large clusters will often be present, representing ≥20% of these cells 
(15, 16).  Prognosis for the patients decreases as the CML phase advances toward AP-








Figure 1.1.  Blood cell lineage.  Hematopoiesis begins with a hematopoietic stem cell, 
becoming either a common myeloid or common lymphoid progenitor.  Immune cells, 
including B cells, T cells, and natural killer (NK) cells arise from a lymphoid progenitor.  
Myeloid progenitors can further become erythrocyte progenitors, leading to the formation 
of either erythrocytes or platelets.  A myeloid progenitor can also follow a white blood 
cell (WBC) lineage, developing into a myeloblast and further a granulocyte.  Unregulated 
expansion of granulocytic eosinophils, neutrophils, and/or basophils (red-dashed box) 























BCR-ABL and its domains 
The BCR-ABL oncoprotein, a product of the Ph chromosome forming a fusion 
between the Bcr and c-Abl proteins, causes the pathogenesis seen in chronic myeloid 
leukemia (17).  In the case of CML, BCR-ABL exists as a 210 kDa protein (p210).  
Depending on the location of breakpoint in Bcr, formation of 185 kDa (p185) and 230 
kDa (p230) proteins may also occur.  However, these variants are often associated with 
the onset of different types of leukemia (18-20).  In healthy cells, the Bcr protein is 
thought to play a kinetic role in vasculature, and is expressed in both hematopoietic and 
epithelial cells, potentially plasma membrane bound (21, 22).  Though its function has 
not been extensively studied, Bcr-null mice were shown to develop normally (23).  c-Abl, 
on the other hand, is a ubiquitously expressed nonreceptor tyrosine kinase whose 
subcellular location, either cytoplasmic and nuclear, depends on the cell type and intra- 
and extracellular stimuli (24, 25).  A member of the Src family of kinases, c-Abl is 
known to play roles in a number of cellular processes including proliferation and survival 
(26), cell differentiation, cell division, and DNA stress response (27).   
Taken together, CML pathogenesis is a result of the c-Abl tyrosine kinase 
constitutive activity in the fusion BCR-ABL protein, which ultimately promotes 
deregulated growth of cells leading to a leukemia phenotype (28).   While c-Abl 
functions in normal cells by shuttling between the nucleus and the cytoplasm (25), BCR-
ABL (in CML) exclusively localizes to the cytosol where it can be found bound to actin 
(29).  Functionally, BCR-ABL is comprised of the following 6 distinct domains: CC 
oligomerization, serine/threonine kinase, and Dbl/Pleckstrin homology on the Bcr 
portion; tyrosine kinase, DNA binding, and actin binding on the Abl portion (Figure 1.2).   
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Figure 1.2.  BCR-ABL domain map.  BCR-ABL domains are labeled as follows: CC = 
Coiled-Coil (Oligomerization Domain) (30); S/T Kinase = Serine/Threonine Kinase (31); 
DH/PH = Dbl Homology / Pleckstrin Homology (32, 33); Y-Kinase = Tyrosine Kinase; 
DB = DNA-Binding (34); AB = Actin-Binding (35-37); SH3 = Src Homology 3 ; SH2 = 
Src Homology 2; NLS = Nuclear Localization Signal; NES = Nuclear Export Signal; G-
actin = Globular Subunit of Actin; F-actin = Fibrous Subunit of Actin.  Numbers above 
domains represent approximate amino acid residues. 
 
The two most important domains for the function of BCR-ABL, the N-terminal 
oligomerization domain and the tyrosine kinase domain, are discussed in more detail 
below. 
 
Coiled-coil dimerization domain 
Located at the N-terminus of the BCR-ABL fusion protein is the oligomerization 
domain, also referred to as the coiled-coil (CC) domain.  This 72-amino acid domain is 
responsible for BCR-ABL homo-oligomerization, and as oligomerization is essential for 
BCR-ABL activity, is imperative for BCR-ABL to function as an oncoprotein (30, 38).  
As such, blocking this domain and therefore preventing BCR-ABL oligomerization has 
been shown to inhibit proliferation of CML cells (39) and increase BCR-ABL sensitivity 
to imatinib, an approved BCR-ABL tyrosine kinase inhibitor (40).  Structurally, the CC 
domain is comprised of two α-helices (α-helix1 and α-helix2) connected through a 
flexible linker.  α-helix1, the shorter, N-terminal helix, consists of amino acids 5-15 while 






Figure 1.3.  Structure of the BCR-ABL coiled-coil (CC) domain.  A) BCR-ABL CC 
monomer is comprised of two α-helices separated by a flexible linker: α-helix1 (residues 
5-15) and α-helix2 (residues 28-67).  B) Two BCR-ABL CC domain monomers interact 
to form a dimer.  This dimerization results in activation of the BCR-ABL kinase.  Pymol 












Upon oligomerization, two α-helix2 domains from separate BCR-ABL monomers 
align and interact in an antiparallel manner (Figure 1.3B) (41).  Most of the interhelical 
interactions involving dimer stability are included in this α-helix2 interface.  During the 
dimerization process, though, the two α-helix1 domains undergo domain swapping, in 
which they are wrapped behind and pack against the backside of the α-helix2 domain of 
the opposite monomer.  Overall, this dimerization interface includes 217 van der Waals 
interactions, seven salt bridges, and three hydrogen bonds (30).  Targeting this BCR-ABL 
CC domain with a rationally designed inhibitor is the overall focus of the work described 
in following chapters.   
 
Tyrosine kinase domain 
While the CC domain is essential for BCR-ABL dimerization and functionality, 
the tyrosine kinase domain is responsible for the activation of proliferation and survival 
pathways leading to CML pathogenesis (28, 42).  Located N-terminally on the Abl 
portion of the BCR-ABL protein, the tyrosine kinase domain is the site responsible for 
BCR-ABL autophosphorylation and the constitutive activity characteristic of this 
oncoprotein (43).  Upon adenosine triphosphate (ATP) binding (in the active site) to this 
tyrosine kinase domain, trans-autophosphorylation occurs in which one BCR-ABL 
monomer can phosphorylate another BCR-ABL monomer, further activating cell 
signaling pathways (13).  Thus, ATP binding to this domain is essential for BCR-ABL 
activity (44).  As such, the tyrosine kinase domain represents a valid therapeutic target for 
inhibition of BCR-ABL.  This concept has been addressed in the last 20 years with the 
advent of tyrosine kinase inhibitors, or TKIs.  These small molecules were designed to 
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bind with high affinity to the ATP-binding pocket in the BCR-ABL kinase, preventing 
autophosphorylation from occurring and thus reducing the proliferation of CML cells (45, 
46).  Specific tyrosine kinase inhibitors and their roles in CML are discussed later in this 
chapter.  Allosteric inhibitors of this kinase domain, also showing clinical promise, are 
discussed further later in this chapter as well (47). 
 
Molecular biology of CML 
Essential for downstream signaling in CML is the phosphorylation of a tyrosine 
residue located at position 177 (Tyr177) on the BCR portion of the fusion protein (48-
50).  Ultimately, phosphorylation of this residue is resultant from the constitutive activity 
(and trans-autophosphorylation) from the tyrosine kinase domain (51).  Phosphorylation 
of Tyr177 facilitates interaction between BCR-ABL and the SH2 domain of the GRB2 
protein, which in turn recruits GAB2 and SOS and leads to activation of RAS signaling 
(13, 52, 53).  Additionally, this GRB2/GAB2/SOS causes constitutive activation of the 
PI3K/AKT and ERK (MAPK) pathways (also can be facilitated by the adaptor protein 
CrkL binding to BCR-ABL (54)).  Altogether, activation of these pathways promotes 
unregulated proliferation and survival, leading to growth and expansion of CML cells 
(55-60). 
Another important aspect in BCR-ABL signaling is the activation of signal 
transducer and activator of transcription 3 and 5, or STAT3 (61) and STAT5 (62, 63).  
Constitutively active in CML, STAT3 and STAT5 are transcription factors that can be 
either directly or indirectly phosphorylated (thru JAK2 signaling) by BCR-ABL (59, 64).  
Functionally, phosphorylated STAT3 or STAT5 activates transcription of genes related to 
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proliferation and survival of cells, whereas lack of this phosphorylation results in 
elimination of the leukemia phenotype of myeloid cells (65).  Figure 1.4 provides a 
snapshot of some of the up-regulated pathways due to BCR-ABL activation in CML. 
While inhibiting these other signaling pathways could provide a means to halt CML 
pathogenesis (discussed in detail later in this chapter) (59), conventional approved 
therapies target the source of this activation: the BCR-ABL tyrosine kinase domain. 
 
CML Therapy 
Prior to the introduction of tyrosine kinase inhibitors, a limited number of only 
moderately successful treatment options existed for CML patients.  These options 
included busulfan (a chemotherapeutic agent), hydroxyurea (a DNA synthesis inhibitor), 
and interferon-α (an inhibitor of cell division), or combinations of the three.  Of these, 
IFN-α historically showed the best results, though relatively moderate (complete 
hematologic response in 46% to 80% of patients, complete cytogenic response in 13% to 
32% of patients), for treatment of CML (66).  Regardless of the treatment administered, 
none truly affected the disease progression, and thus patients in all cases would inevitably 
advance into later, untreatable stages of CML.  The only curative therapy remained 
allogeneic stem cell transplantation (alloSCT).  Despite showing high success rates with 
relapse occurring in only around 10% to 20% of patients (67), alloSCT is a risky 
procedure that adversely carries a high potential for treatment-related mortality (66).  The 
need, thus, was high for a successful, easy to administer CML therapy.  Understanding 
the molecular biology and pathogenesis of CML, it was thought that targeting BCR-ABL 







Figure 1.4.  BCR-ABL signaling pathways in CML.  BCR-ABL up-regulates numerous 
pathways in CML.  Trans-autophosphorylation results in the phosphorylation of Bcr 
residue Y177.  Upon phosphorylation, Y177 recruits the GRB2/GAB2/SOS complex, 
which can activate numerous downstream pathways including RAS, JAK2, PI3K/AKT, 
and STAT3/5 signaling.  Ultimately, activation of these pathways results in transcription 
of genes responsible for the survival and proliferation of cells.  Blue circles (with white 
letter P) represent phosphorylation events.  Abbreviations: CC = coiled-coil domain; S/T 
kinase = serine/threonine kinase; DH/PH = Dbl homology / Pleckstrin homology domain; 
SH2/3 = Src homology 2/3 region; Y-kinase = tyrosine kinase domain; NLS = nuclear 
localization signal; DB = DNA-binding domain; AB = actin-binding domain; G-actin = 
globular subunit of actin; F-actin = fibrous subunit of actin; NES = nuclear export signal; 
GRB2 = growth factor receptor-bound protein 2; GAB2 = GRB2-associated binder 2; 
SOS = son of sevenless; STAT = signal transducer and activator of transcription; JAK2 = 
Janus kinase 2; RAS = Ras kinase; ERK = extracellular signal-regulated kinases; CrkL = 
































Beginning in 2001 with the approval of imatinib mesylate (Gleevec® or 
Glivec®), CML started to become a manageable disease with a more optimistic outlook 
on overall survival (44, 73).  Discovered through a high-throughput screening approach 
combined with rational design using structure-activity relationships, imatinib was 
originally designed as an inhibitor of the platelet-derived growth factor receptor 
(PDGFR), but was also found to have potent and selective inhibition of Abl family 
kinases, which includes BCR-ABL (44, 74).  In early phase clinical trials, imatinib, when 
administered orally, not only was well tolerated without dose-limiting toxicity, but also 
showed induction of complete hematologic responses in 53 of 54 patients (75).  These 
promising results helped imatinib move forward in clinical trials, where it eventually 
showed far superior results when compared to current therapies, vastly improving both 
the survival and quality of life of those treated (76-78).  Following its FDA approval in 
2001, imatinib continues to be used successfully in many CML cases to halt progression 
of the disease. 
Although imatinib provided a means to successfully treat CML, not all patients 
show positive responses following its use.  In fact, a number of patients show resistance 
to the drug for one or multiple reasons.  The most common mechanism of resistance to 
imatinib occurs due to mutations in the BCR-ABL kinase domain, preventing the TKI 
from binding to BCR-ABL and thus eradicating its use.  (A more comprehensive 
discussion of TKIs and resistance can be found in Chapter 3.)  As such, this phenomenon 
demonstrated a need for the development of new inhibitors that may overcome BCR-
ABL resistance to imatinib (79, 80).  To address this issue, new tyrosine kinase inhibitors 
were designed and developed (81-83).  Still able to bind to BCR-ABL to inhibit its kinase 
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activity, these new TKIs were designed to structurally bind in different ways and utilize 
different active site contact points to avoid inactivity from commonly seen mutations 
following imatinib treatment (47, 84).  These drugs include dasatinib (BMS354825, 
Sprycel®), nilotinib (AMN107, Tasigna®), and ponatinib (AP24534, Iclusig®).  
Bosutinib (SKI-606, Bosulif®), another BCR-ABL TKI, is approved for intolerant CML; 
however, it appears to be a “me too” drug as it does not provide any expanded mutational 
coverage over any of the other approved TKIs, and will not be discussed further.  
Chemical structures of these tyrosine kinase inhibitors appear in Figure 1.5. 
 
 
Figure 1.5.  Chemical structures of approved TKIs for CML.  All chemical structures 
were drawn using ChemSketch. 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Ima%nib ! ! ! ! ! ! ! !!!!!!!Dasa%nib!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Nilo%nib ! ! ! ! ! !!!!!!!!!!!!!!!!!!!!!!!!!Pona%nib!
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Nilotinib, a compound structurally similar to imatinib, was designed based on the 
imatinib-ABL complex, with the idea of seeking more potent inhibition.  It was shown to 
inhibit ABL with around 30-fold greater potency than imatinib and was able to suppress 
many of the imatinib-resistant BCR-ABL mutants (79, 84, 85).  Success in clinical trials 
led to its FDA approval in 2007 for resistant or intolerant CML and further for newly 
diagnosed CML in 2010 (86).  Dasatinib, a dual Src/ABL kinase inhibitor, was found to 
inhibit ABL with as much as 300-fold greater potency in vitro (84) and up to 20-fold 
greater potency in vivo than imatinib (87).  Additionally, it was shown to be active 
against 14 of 15 imatinib-resistant mutants (87, 88).  Dasatinib was FDA approved in 
2006 for resistant or relapsed CML and in 2010 as an option for frontline CML treatment.   
While dasatinib and nilotinib were able overcome most of the BCR-ABL 
resistance mutants that commonly surfaced, neither were able to bind to and inhibit BCR-
ABL with the threonine to isoleucine mutation at residue 315, or T315I.  This T315I 
mutation, along with other newly discovered BCR-ABL mutants resistant to either 
nilotinib or dasatinib, was the reason for development of the most recently approved TKI, 
ponatinib.  Designed based on the structure of the ABL active pocket containing the 
T315I mutation, ponatinib possesses an ethynyl linker capable of bypassing the steric 
interference known to be caused by the isoleucine residue at position 315 (89, 90).  This 
strategic design led to potent inhibition of both wild-type and mutant BCR-ABL with 
nanomolar affinity (89).  Successful clinical trials especially in patients with the T315I 
mutation (91-93) led to accelerated FDA approval in December 2012 (94).  In October 
2013, however, sales and marketing of ponatinib were suspended following the 
termination of a phase III clinical trial due to severe, and even fatal, side effects (95-97).  
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By the end of 2013, the FDA had approved resumption of ponatinib sales with an 
expanded black box warning for use in patients for whom no other TKIs are indicated or 
in patients who possess T315I-positive CML (98, 99). 
It should be noted, however, that despite providing mutational coverage for the 
T315I mutant in BCR-ABL, problematic mutations do still exist for ponatinib (103).  
Along with the T315M single mutant, many compound mutations (2 or more mutations in 
a single BCR-ABL molecule), especially some T315I-inclusive compound mutations, are 
currently not targetable using ponatinib (103, 104).  Most of these, however, also cannot 
be targeted using any of the other approved TKIs (103, 105, 106).  A comprehensive 
review on ponatinib, BCR-ABL mutations, the mechanisms by which they surface, and 
TKI treatment is affected by these mutations can be found in Chapter 3. 
 
STIM Trial 
A concern that remains regarding TKI therapy for CML is whether or not therapy 
can be discontinued with recurrence of the disease.  Currently, patients take TKIs 
continuously as a way to manage, and not necessarily cure, their leukemia; Table 1.1 lists 
the prescribing information for each of the approved tyrosine kinase inhibitors.  As 
shown, patients are taking one or multiple pills daily with their disease progress 
monitored a few times annually by their doctors.  In 2007, a clinical trial (the STIM trial, 
or Evaluation of the Persistence of the Complete Molecular Remission After Stopping 
Imatinib Chronic Myeloid Leukemia) was designed to determine whether or not patients 
who have shown optimal response to frontline imatinib therapy could successfully be 
taken off of imatinib therapy without the disease returning (107, 108).  Results from this  
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Table 1.1.  Approved tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid 
leukemia (CML) and their indicated uses, CML phases for which they are indicated, and 
the dosage regimens (98, 100-102).  Abbreviations: Ph+ = Philadelphia chromosome 
positive; CP = chronic phase; AP = accelerated phase; BC = blast crisis; Q.D. = once 
daily; B.I.D. = twice daily.  





trial were presented recently by Michael Deininger, MD, Ph.D. at the Huntsman Cancer 
Institute Fourth Annual Hematology Review (February, 2014).  Briefly, TKI 
discontinuation was successful in 40% of patients who had shown a complete molecular 
response on imatinib.  Additionally, in those patients who did not show success, 
resumption of therapy regenerated responses in nearly all cases.  Finally, because the idea 
of stopping TKI therapy is still in a trial phase, patients require closer, more frequent 
monitoring than those continuing to take TKIs.  It should be noted, also, that data are 
currently being collected on patients who have stopped taking second generation 
Drug Indication CML Phase Dose 
Imatinib Newly diagnosed Ph+ CML CP 400 mg Q.D. 
Newly diagnosed Ph+ CML AP, BC 600 mg Q.D. 
Nilotinib Newly diagnosed Ph+ CML CP 300 mg B.I.D. 
Resistant or intolerant Ph+ CML CP, AP 400 mg B.I.D. 
Dasatinib Newly diagnosed Ph+ CML CP 100 mg Q.D. 
Resistant or intolerant Ph+ CML CP, AP 140 mg Q.D. 
Ponatinib Ph+ CML with T315I mutation CP, AP, BC 45 mg* Q.D. 
Ph+ CML where no other TKI therapy 
is indicated 
CP, AP, BC 45 mg* Q.D. 
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inhibitors (nilotinib and dasatinib) in a trial setting, and the results look similar to those 
seen with imatinib (109). 
 
BCR-ABL targeted alternatives to TKI therapy 
The lack of a 100% response rate and the increasing amount of resistance forming 
against TKIs in CML has opened the idea to finding other therapies for this disease.  One 
possibility in the case of TKI resistance involves targeting other domains of BCR-ABL 
that are also important to leukemogenesis.  These domains include the CC domain (39, 
110), the SH2-kinase interface (111), the BCR-ABL myristate pocket (47, 112, 113), and 
the ABL switch control pocket (114).   
 
CC therapeutics 
Following publication of the BCR-ABL CC domain structure in 2002 (30), it was 
believed that designing an inhibitor of this domain could prevent BCR-ABL 
oligomerization and in turn prevent leukemogenesis.  Beissert et al. pioneered this work 
by using an isolated BCR-ABL CC peptide as an inhibitor of dimerization (40, 110).  
Moderate successes were seen; however, it could be inferred that this CC peptide was just 
as likely to interact with itself as it was to interact with endogenous BCR-ABL since the 
sequences were identical.  In 2011, our lab vastly improved this system by designing a 
CC inhibitor, called CCmut2, which favored hetero-dimerization with wild-type BCR-ABL 
(39).  When introduced into a cell with endogenous BCR-ABL, CCmut2 favored hetero-
dimerization with BCR-ABL while also disfavoring homo-dimerization with other 
CCmut2 molecules.  A further refinement, CCmut3, is the overall focus of this dissertation 
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and is discussed in Chapters 2, 4, 5, and 6.  Ultimately, CCmut3 represents a major 
improvement in the binding to BCR-ABL and further disfavoring of homo-dimerization 
between two CCmut3 molecules (115-119). 
 
SH2-kinase interface 
Recent developments have shown success in targeting allosteric regulatory 
domains in oncoproteins (120).  One such allosteric site in BCR-ABL is the SH2 (Src 
homology 2) domain.  In general, SH2 domains are highly conserved protein domains 
that bind phosphotyrosine substrates and facilitate protein-protein interactions (121).  In 
the case of BCR-ABL, kinase activity is dependent on a tight interaction between the Abl 
SH2 domain and the N-terminal lobe of the kinase domain (122).  Thus, the SH2 domain 
is seen as an allosteric activator of tyrosine kinase activity in BCR-ABL (47).  Disruption 
of this interaction has been attempted using engineered, single-domain proteins known as 
monobodies.  Two specific monobodies, termed HA4 and 7c12, bound with high affinity 
to this SH2-Abl interaction site and showed proof-of-principle inhibition of Abl (123) 
and BCR-ABL mediated activity, respectively (111).  Though delivery in these 
experiments involved transduction via lentivirus, further alterations to and development 




Another BCR-ABL allosteric site suitable for therapeutic inhibition is the 
myristate pocket.  Located toward the C-terminal end of the ABL kinase domain, this 
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pocket is available to accommodate binding of a myristoyl group.  Upon binding, a 
myristoyl group would induce a conformational change in the kinase domain, causing 
inactivation of the kinase (43, 47).  In its native state in CML, however, BCR-ABL is not 
myristoylated; thus, the kinase is not inactivated by this mechanism (47).  One molecule 
that is known to bind to this myristoyl pocket and inhibit BCR-ABL is GNF-2 (84, 112).  
Therapeutically, it showed the ability to inhibit growth of CML cells including those with 
common kinase domain mutations (except for T315I) and even showed greater 
effectiveness when administered in combination with TKIs (112, 113, 124, 125). 
 
ABL switch control pocket 
One molecule that has garnered interest recently in the area of non-TKI CML 
therapeutics is DCC-2036 (rebastinib, Deciphera Pharmaceuticals), an inhibitor of the 
ABL switch control pocket (114).  Though not an ATP-competitive inhibitor, DCC-2036 
binds to a “switch pocket” (adjacent to the ATP-binding pocket) in ABL, locking BCR-
ABL in a catalytically inactive conformation (84, 126).  Thus, binding tightly in this 
specific pocket prevents BCR-ABL from activating its kinase, which further prevents 
activation of downstream signaling pathways.  DCC-2036 displayed nanomolar inhibition 
of native BCR-ABL and BCR-ABL with a number of kinase domain mutations, 
including T315I (114), and has recently completed a phase I safety and preliminary 





BCR-ABL Independent Resistance 
Point mutations in the BCR-ABL kinase domain are not the only reason for 
intolerance to TKIs.  Some cases of CML have shown BCR-ABL independent growth, 
where despite therapeutic inhibition of BCR-ABL (with TKIs, for example), cells 
continue to show a leukemia phenotype.  As with other small molecules, one mechanism 
of speculated resistance involves the under-expression of (organic cation transporter) 
OCT1 in CML, which could limit the concentration of TKI reaching the cell (128).  
Additionally, overexpression of drug efflux pumps such as P-glycoprotein could have the 
same effect, reducing intracellular concentration by pumping TKI out of the cell (129).  A 
final mechanism of TKI resistance is known as BCR-ABL kinase-independent resistance. 
Despite BCR-ABL inhibition with TKIs, this type of resistance can involve kinase-
independent activation of signaling pathways that promote cellular growth and survival 
(130).  In some cases, the same pathways normally up-regulated by BCR-ABL (JAK-
STAT, PI3K/AKT, for example) will continue to be up-regulated, however, controlled by 
BCR-ABL kinase-independent mechanisms.  Other cases may involve activation of 
different pathways caused by overexpression of other kinases (Lyn, Src family kinases, 
for example) (131, 132) or induced by alternative growth factor signaling (IL-6, for 
example) (133).  While there are no currently approved therapeutics to treat patients who 
display any of these types of BCR-ABL-independent resistance, allogeneic stem cell 
transplants can still be used as salvage treatment.  Combination approaches targeting both 
BCR-ABL and downstream signaling molecules, however, are under study by the 
Deininger Lab (University of Utah) (133, 134) and other research groups (135, 136).  
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Introduction to alpha-helices and dimerization motifs 
As previously mentioned, BCR-ABL activity as an oncoprotein is dependent on 
oligomerization at the N-terminal coiled-coil (CC) domain, which leads to formation of a 
BCR-ABL dimer and subsequently a tetramer (forming a dimer-of-dimers).  Briefly, the 
BCR-ABL CC domain is a 72-amino acid structure formed by two separate α-helices 
connected by a flexible linker.  Because this CC domain is essential for oncogenicity, it 
represents a valid therapeutic target for inhibition of BCR-ABL and CML.  Thus, in order 
to develop a successful inhibitor of this domain, it is important to fully understand α-
helical and CC structural motifs, and the role they play in BCR-ABL dimerization. 
 
α-helices 
α-helices represent a secondary structural motif commonly found in proteins.  
Each turn of an α-helix contains approximately 3.6 amino acid residues, encompassing a 
vertical distance of approximately 5.4 Å (137).  Because of this spacing pattern of the 
amino acid residues, α-helices display a characteristic bonding pattern, in which the 
residue at position i+4 donates a hydrogen bond via its amine (NH) group to the carbonyl 
(=CO) group present on the amino acid four residues previous at position i.  As each 
residue in the helix is involved in hydrogen bonding, this specific bonding pattern is 
ultimately responsible for the high stability of this secondary structure.  Three-
dimensional folding of the protein into this structure occurs in a “zipper like” manner, 
where each turn of the helix, beginning at the N-terminus, is formed sequentially (138).  
As more helical turns form and the peptide begins to take shape, more hydrogen bonds 
are arranged in the pattern described above, increasing the overall stability of this motif.  
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Finally, because of the hydrogen bonding pattern characteristic to the α-helix, the four C-
terminal residues contain carbonyl oxygen atoms not involved in hydrogen bonding.  At 
the same time, the four N-terminal residues contain amine groups also not involved in 
hydrogen bonding.  In some cases, these unbound carbonyl and amine groups can be 




Whether influencing signaling pathways, chaperoning for intracellular transport, 
or acting as enzymes, protein-protein interactions drive the functionality of 
macromolecules and dictate cellular processes (139-141).  Often times, these interactions 
will occur between different proteins, resulting in the formation of hetero-oligomeric 
structures.  In some cases, however, interactions may occur between monomers (or 
higher order oligomers) of the same peptide or protein, forming macromolecular 
structures known as homo-oligomers.  Domains known as dimerization motifs, which 
vary in overall structure, function to facilitate specific interactions between proteins.  
Because the interactions between proteins are often highly specific, dimerization motifs 
in deregulated proteins can be potential therapeutic targets in a number of cancers (142).  
Common dimerization motifs include coiled-coils, zinc finger motifs (143-147), helix-
loop-helix motifs (148-151), and leucine zippers (152-154).  In the case of BCR-ABL, 
oligomerization is mediated a coiled-coil dimerization domain, thus only this motif will 




Strings of α-helices together (at least two or more) may form an important, 
ubiquitous structural motif known as coiled-coils, or CCs (155).  Whereas it was noted 
that α-helices contain approximately 3.6 residues per turn, coiled-coils, which are slightly 
more tightly packed, contain approximately 3.5 residues per turn (156) and encompass a 
vertical distance of approximately 5.15 Å to 5.20 Å (137, 157).  Because of this slight 
difference in the number of residues per turn, exactly 7 amino acid residues represent two 
full turns of a CC helix, which signifies a heptad repeat.  It is important to note that these 
residues, or the positions of the residues, included in the two full turns are denoted as a, 
b, c, d, e, f, g. Within a coiled-coil, and part of what allows the helices to form a coiled-
coil, these heptad repeats are often represented by the characteristic pattern: HXXHCXC, 
where H represents a hydrophobic residue, C represents a charged residue, and X 
represents any other (though often polar) residue (Figure 1.6A).  While not every heptad 
repeat of a coiled-coil will show this exact repeating pattern, most of them do.   
Importantly, interactions between multiple coiled-coils are sequence specific with side 
chains often interacting in a “knobs-into-holes” manner (156, 158).  When looking at the 
interactions between two or more helices, the hydrophobic surfaces (residue positions a 
and d) are often in continuous contact, leading to the formation of a hydrophobic core at 
the interface (159).  Further interaction specificity is facilitated by the nature of the 
charged residues (residue positions e and g) that participate in interhelical electrostatic 
interactions.  Because coiled-coils play a large role in protein-protein interactions and 
thus play a role in many biological processes (160), they could represent an opportune 





Figure 1.6.  Coiled-coil helical wheel diagrams.  A) General structure of a coiled-coil 
heptad repeat looking down the helix from the N-terminal end.  Residues in the heptad 
repeat are assigned positions a, b, c, d, e, f, g. Heptad repeat often follows the pattern: 
HXXHCXC; H = hydrophobic residue (green); X = any residue (white); C = charged 
residue (blue).  B) Antiparallel interaction between coiled-coils.  Ionic interactions 
(dotted lines) often present between g-g’ and e-e’ residues (blue); hydrophobic 
interactions (dotted lines) often present between d-d’ and a-a’ residues (green).  C) 
Parallel interaction between coiled-coils.  Ionic interactions (dotted lines) often present 
between g-e’ and e-g’ residues (blue); hydrophobic interactions (dotted lines) often 





















































































between coiled-coils are so highly specific, the rational design of a coiled-coil targeting a 
specific protein should minimize the opportunity for interactions with other coiled-coils  
throughout the cell.  This may lead to enhanced target affinity of a designed therapeutic 
as well as reduce the onset of potential side effects that would otherwise arise.  Finally, 
because there are so many contact points involved in CC interactions, inhibiting these 
domains with small molecules would be a highly difficult task.   
Successfully designing a CC inhibitor first requires a firm understanding of the 
target sequence and structure.  With regard to the BCR-ABL, the two coiled-coil domains 
interact in an antiparallel manner (30) (Figure 1.6B).  As such, based on the helical wheel 
diagram, interactions in the BCR-ABL CC dimer occur between “like” positions (Figure 
1.6B); hydrophobic interactions occur between a-a’ and d-d’ and electrostatic interactions 
occur between e-e’ and g-g’ (differing from the a-d’, d-a’, e-g’, and g-e’ interactions 
common to parallel coiled-coils (161) (Figure 1.6C)) .  Therefore, we can design an 
inhibitor of this domain by hijacking these interaction patterns.  For example, knowing 
that electrostatic interactions in this case occur between e-e’ and g-g’, an inhibitor can be 
created that binds more tightly to endogenous BCR-ABL based on this pattern.  By 
analyzing the specific sequence of the BCR-ABL CC domain, e-e’ and g-g’ positions that 
currently lack an ionic interaction (or that contain an unfavorable ionic interaction) can 
be located.  Into a rationally designed CC inhibitor, we can insert favorable charged 
residues at these locations that would in turn facilitate salt bridge formation.  This 
process, mutating residues to create an “ideal” CC inhibitor, was the basis of work 
published by Dixon et al. (39) in the Lim Lab. 
In this work, BCR-ABL oligomerization was disrupted using a rationally 
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designed CC inhibitor (called CCmut2) based on the method described above.  Here, the 
design of CCmut2 was two-fold: increase CCmut2:BCR-ABL hetero-dimer interaction 
through incorporation of salt bridges, and decrease CCmut2:CCmut2 homo-dimer interaction 
through incorporation of charge-charge repulsions.  Thus, not only were charged residues 
incorporated to facilitate stronger interaction with and stronger inhibition of BCR-ABL, 
but other charged residues were also included at different e and g positions to facilitate 
electrostatic repulsions between two CCmut2 molecules.  It was believed that inhibiting 
CCmut2 homo-dimerization would increase the amount of CCmut2 available to interact with 
BCR-ABL.  Testing of CCmut2 showed improved oligomeric properties with the BCR-
ABL CC and also showed the ability to prevent proliferation of CML cells (39).  
Further study of CCmut2 and the BCR-ABL CC led us to discover one more 
location in which a residue could be mutated to enhance the inhibitory effect of BCR-
ABL.  This improved iteration of the CCmut2, which we called CCmut3, utilized the 
principle coiled-coil interaction pattern (described above) to further destabilize 
CCmut3:CCmut3 homo-dimerization by incorporating one extra electrostatic repulsion 
(115).  In this sense, we replaced a positively charged lysine at residue 39 with a 
negatively charged glutamate (K39E mutation) to result in this homo-dimeric 
destabilization.  Incorporation of this K39E mutation increased the tendency of CCmut3 to 
interact with BCR-ABL, maintained the BCR-ABL inhibition capability, and continued 
to prevent proliferation of CML cells.  This project, utilizing CCmut3 and delivering as 




Transfection of plasmids as proof of principle for peptide drugs 
Prior to developing peptide drugs, proof-of-principle experiments can be carried 
out initially using transient transfection of plasmid DNA that encodes the peptide to be 
studied.  Here, quick, simple, and cost-efficient molecular biology techniques can be 
utilized to design and purify the plasmid necessary for protein expression.  Once 
transfected into the cell, the plasmid DNA can transport into the nucleus to undergo 
transcription, creating mRNA, which can further be translated into the protein or peptide 
(drug) of interest. 
Once the plasmid DNA has been designed and purified, the plasmids can be 
artificially introduced into cells using chemical, physical, or biological methods.  While 
use of chemical (polycationic polymers or lipids) and biological (viral transduction) 
methods have become more widespread in the field of in vivo experimental gene therapy 
(162-164), the physical method (electroporation) remains fairly impractical due to the 
need to electrically shock cells to facilitate plasmid DNA entrance (165, 166).  The 
method chosen for proof-of-principle studies will depend on the type of cell being used, 
as some cell lines are more difficult to transfect than others (M. Kakar, dissertation).  In 
our case, K562 (human, BCR-ABL+ CML) cells were used for proof-of-principle studies.  
Historically, all three methods have been attempted in the Lim Lab for transfection; some 
methods have shown greater success than others.  Specifics about the techniques that 
utilize all three of these strategies are described below, and a graphic representing each 









Figure 1.7.  Methods of DNA transfection.  A) Use of polycationic lipids: Negatively 
charged DNA is incubated with a polycationic lipid, resulting in a positively charged 
complex capable of entering cells. B) Electroporation: DNA is first mixed with 
electroporation buffer.  Following a short electrical pulse, the cell membrane becomes 
compromised and DNA enters the cell. C) Viral delivery: viruses encoding plasmid DNA 
internalize and release DNA into the cell.  In this and both other cases, upon entrance into 


































































































































































Chemical method: use of cationic lipids 
The first technique attempted for K562 cell transfection of plasmid DNA in the 
Lim Lab involved the use of cationic lipids in a process known as lipofection (Figure 
1.7A) (167).  In this process, prior to transfection, negatively charged plasmid DNA (or  
other genetic material such as shRNA, for example) is incubated with a mixture of 
cationic lipids, leading to formation of overall positively charged lipid-DNA complexes.  
The net positive charge on the lipid-DNA complex allows it to overcome electrostatic 
repulsion from head groups in the cellular phospholipid bilayer, promoting cell 
internalization via endocytosis (168).  Following endosomal or lysosomal degradation, 
the DNA is then freed and able to traffic into the nucleus (169).  Common cationic lipids 
used for this purpose include the linear or branched polymer polyethyleneimine (PEI) 
(170) and a liposome-based product known as Lipofectamine (Life Sciences).  Reagent 
selection often depends on the type of cell being transfected, as tranfection efficiency in 
many types of cells will react differently to the reagent chosen. 
In the case of K562 cells, this method is not suitable for efficient DNA 
transfection.  In 2008, Mudit Kakar and colleagues utilized seven different polycationic 
systems in an attempt to transfect of K562 cells.  Transfection efficiencies ranged from as 
low as 1% to as high as near 25% (M. Kakar, dissertation).  The inefficiency is 
expectedly due to the high concentration of glycosaminoglycans (GAGs) found in the 
extracellular membrane of K562 cells.  Previously, it has been reported that high 
concentrations of membrane GAGs inhibit transfection of cells using polycationic 
methods (171).  Many reasons have been speculated for this phenomenon, including poor 
DNA internalization and inefficient endosomal escape (172, 173).  Regardless of the 
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reasoning, use of polycationic systems was deemed unsuitable for K562 cells.   
 
Physical method: electroporation and nucleofection 
A physical means by which DNA can be transfected into live cells is a method 
known as electroporation, a technique that utilizes short electrical impulses to cause brief 
physical disruption and permeabilization of cell membranes (Figure 1.7B) (165).  Prior to 
transfection, DNA is often mixed with a buffer that aids in the DNA uptake process.  This 
DNA-buffer mixture is then mixed with cells and prepared for transfection.  During the 
physical electroporation process, the DNA-buffer-cell mixture is subjected to short 
electrical impulses, often along the magnitude of kilovolts/cm for any amount of time 
between microseconds and milliseconds (174), which compromises the integrity of the 
cell membranes.  This brief semi-permeabilization of the cell membranes allows the 
DNA to enter into the cytoplasm of cells, where it can then further translocate into the 
nucleus for transcription upon cell division (165, 174-176).   
As with the use of cationic lipids, transfection efficiency using this method varies 
amongst cell types and specific cell lines.  Parameters that may be altered to increase 
efficiency may include varying the time and intensity of electric pulses, varying the 
amount of DNA used, and how the cells are allowed to recover from the electric pulses.  
Previous attempts to transfect K562 cells using electroporation were also unsuccessful 
(M. Kakar, dissertation).  In this method, over 75% cell death occurred, even in negative 
control groups, presumably as a direct result that the high voltage necessary for cell 
permeabilization was too toxic (M. Kakar, dissertation). 
As a result, a different type of electroporation was attempted on K562 cells, 
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known as nucleofection™.  This technology, developed by the Lonza Group, uses a 
proprietary blend of cell-specific reagents and electrical parameters to enhance cellular 
transfection (177).  Specifically, this method is suggested to not only permeabilize the 
cell membranes but also to facilitate efficient DNA delivery directly into the nucleus 
(177).  Unlike the previous attempts using polycationic and common electroporation 
methods, nucleofection™ was shown to be a successful method for transfection of K562 
cells (M. Kakar, dissertation).   
Throughout this work, most of the DNA transfections were carried out using this 
nucleofection™ method.  For our purposes, delivery of plasmid DNA to K562 (human, 
BCR-ABL+ leukemia) and Ba/F3 (murine, pro-B) cells was optimized prior to 
experimentation (Appendix).  On average, transfection efficiencies for K562 and Ba/F3 
cells were approximately 40% and 35%, respectively (Appendix). 
 
Biological method: viral transduction 
 Finally, one of the most prolific methods used to introduce exogenous DNA into 
cells utilizes viral vectors.  A method translatable to in vivo gene therapy, the three most 
commonly used viral vectors are adenovirus (178), adeno-associated virus (AAV) (179), 
and lentivirus (180).  Adenoviral vectors do not integrate their packaged DNA into the 
host genome, but instead allow it to be expressed transiently (178).  The DNA is not 
replicated during cell division, thus repeated injections of virus would be necessary for 
successful in vivo therapy.  The only approved gene therapy product, Gendicine, which 
expresses the wild-type tumor suppressor p53, is delivered via adenovirus (181).  AAV is 
known to deliver DNA to both dividing and nondividing cells while not stably integrating 
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the DNA into the host genome.  Additionally, AAV vectors have shown only mild 
immune responses when delivered in vivo, leading to heightened research for their use in 
gene therapy (179).  Lastly, lentiviral vectors are known to integrate the packaged DNA 
into the genome of nondividing cells.  While this method is very efficient, safety becomes 
an issue because of this integration and due to the problems that arise if the DNA 
becomes integrated at random locations (182).  In the case of proof-of-principle 
experiments for CML therapy, lentivirus (used specifically to result in high expression) 
that contained DNA expressing a modified CC inhibitor of BCR-ABL has been shown to 
successfully inhibit proliferation of wild-type and mutant BCR-ABL+ primary cells 
obtained from CML patients (D. Woessner, dissertation).   
Overall, in vivo viral use for gene therapy is promising due to the efficiency at 
which the gene is delivered into cells, however, many issues still exist including safety, 
toxicity, and evasion of the host immune system (182, 183).  In the case of our work, we 
expect delivery as a peptide to be a better option, able to overcome many of the issues 
that would arise with gene delivery. 
 
Introduction to peptide delivery 
Peptides have great potential for therapeutics due to their improved selectivity and 
specificity over small molecules, and their increased number of contact points with their 
targets (184).  The market for peptides and proteins continues to grow, and now holds 
around a 10% share, or roughly US$40B, of the overall pharmaceutical market (185).  
However, despite showing a high level of target affinity and specificity, peptides, when 
used as therapeutics, face a number of obstacles before they can even reach their target. 
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Oral delivery of therapeutics is certainly a preferred method due to the simplicity 
and convenience associated with ingesting pills.  This method works very well for many 
small molecules; however, with peptide and protein drugs, a number of barriers must be 
overcome before even entering systemic circulation (184).  Should a peptide drug be 
administered orally, it would first have to avoid degradation by acidic hydrolysis and 
cleavage by peptidases and proteases present in the stomach and GI tract.  Next, the 
peptide or protein drug would need to find a way to be absorbed into circulation by 
crossing the intestinal epithelial layer.  Due to the hydrophilic nature of many peptides 
and the large size of many proteins, this process is extremely inefficient without the 
assistance of any kind of absorption enhancers.  Finally, the small amount of peptide that 
may evade gastrointestinal degradation and permeate through the epithelial layer now 
approaches the problem involving efflux pumps (MDR1) that may actively pump the 
drug back into the GI.  The amount of unaltered peptide following these three steps often 
remains too low to exert a beneficial therapeutic effect.  Though still not perfect, 
enhancement methods for oral delivery and absorption of peptides have been studied to 
improve this system.  These enhancements include structural modification, PEGylation, 
co-administration with enzyme inhibitors and absorption enhancers, and encapsulating 
the peptide drug into carrier systems such as liposomes, nanoparticles, and hydrogels 
(184). 
 Because of the many issues and barriers involved with oral delivery of peptide 
and protein therapeutics, other delivery methods are often more commonly explored.  
Delivery of peptide drugs transdermally has garnered interest recently due to the ease and 
noninvasive nature for introducing peptides into circulation.  By delivering a drug via a 
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transdermal route, both GI degradation and hepatic first-pass metabolism are avoided, 
especially important for short half-life drugs (184).  This method can overall lead to 
greater patient compliance (due to the ease of use) and less frequent dosing, especially 
when using a transdermal controlled release system (186, 187).  Importantly, traditional 
transdermal patches are used solely to deliver small, hydrophobic drugs with high logP 
values, not peptides.  Thus, specific technologies have been developed to aid in the 
transdermal delivery of peptides, many of these showing success in moving delivery into 
clinical trials.  Precisely, these technologies include microneedles (188-190), thermal 
ablation (191, 192), electroporation (166), sonophoresis (192, 193), iontophoresis (190, 
194), and biochemical enhancement to increase permeability of the skin (112, 195, 196).  
More in depth analysis about each of these delivery methods can be found in the 
Transdermal Delivery section of Bruno, Miller and Lim, Ther. Deliv., 2013 (184). 
Other alternative delivery methods for peptide drugs include intranasal, buccal, 
rectal, and pulmonary delivery.  Intranasal delivery provides the benefits of convenience 
and comfort to the patient, and in the past has shown success in delivering the small 
peptides desmopressin and calcitonin as well as seasonal flu vaccines (197, 198).  Buccal 
delivery is also a convenient method for patients in which drugs are administered thru the 
cheek on the inside of the mouth.  Successful drugs delivered through the buccal route 
include oxytocin, insulin, sulfacetamide (sCT), and glucagon-like peptide 1 (GLP-1) 
(184, 199).  Rectal delivery, though not as convenient for patients, is beneficial in 
avoiding hepatic first-pass effect and widespread presence of proteases.  Used generally 
when other routes of administration are not possible, insulin is an example of a drug 
delivered via this method (200).  A final method also used to successfully deliver 
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peptides utilizes the pulmonary system.  Though slightly more challenging due to low 
absorption of larger hydrophilic peptides, success was found in 2006 with Exubera 
(Pfizer, Inc.), an FDA approved inhalable insulin product (201).  Despite being removed 
from the market in 2007 due to poor sales (202), a different inhalable insulin has returned 
in 2014, marketed now by MannKind Corporation™ under the trade name Afrezza® 
(203).  Aside from insulin, calcitonin, growth hormone, and desmopressin have also been 
successfully delivered via the pulmonary route (204-206). 
 While much work has been done studying noninvasive and convenient methods to 
deliver peptide and protein drugs, the injectable route remains as the most successful and 
most widely used method (intravenous (IV), intramuscular (IM), and subcutaneous (SC) 
routes).  First and foremost, injecting peptides or protein therapeutics intravenously 
allows for 100% bioavailability immediately following injection into systemic 
circulation.  Therefore, many of the previously discussed barriers (GI proteases and 
absorption barriers, for example) do not exist when using this delivery method.  
However, other obstacles still do remain.  These obstacles include avoiding degradation 
by systemic proteases, avoiding detection by the host immune (RES) system, ensuring 
proper solubility, locating the site of action, and in some cases, entering cells when 
targeting intracellular molecules.  To overcome these obstacles, a few strategies have 
been designed and studied with the intent of improving the efficiency of delivery, 
increasing the circulation time (half-life), and increasing the overall systemic stability of 
peptide and protein drugs.   
One of these strategies involves PEGylating, or adding polyethylene glycol (PEG) 
chains to the exterior, as a way to improve peptide drug delivery.  PEG is a strongly 
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hydrophilic molecule, which often leads to improved solubility of the peptide drug in 
question (207).  When the PEG chains are interacting with a hydrophilic medium, they 
often undertake an extended conformation, providing in a way steric hindrance from 
peptide recognition by proteolytic enzymes and antibodies (207-209).  Finally, depending 
on the size of the PEG chains used, their presence can also increase the size of the peptide 
enough to increase the overall circulation time of the drug, avoiding rapid clearance in 
the kidney (210).  Some drugs that have utilized PEG chains to improve delivery and 
activity include PEG-asparaginase (Oncaspar®, for acute lymphoblastic leukemia) (211) 
and PEG-interferon α2a (Pegasys®, for hepatitis C) (212), among others.  Addition of 
PEG can have some disadvantages, however.  If the chains that are added are not of 
optimal size, steric hindrance may prevent interaction between the modified drug and its 
target.  Additionally, the density at which PEG is added to the drug may allow protein 
aggregation to occur, decreasing availability of the drug (184).  Optimal loading density 
and length of PEG chains is something that may differ amongst drugs and must be 
optimized on a drug-by-drug basis. 
While PEGylating peptides can allow longer circulation time and more efficient 
delivery, a major barrier that exists when inhibiting an intracellular target with a peptide 
drug is the difficulty of permeating the cell membrane.  One way to circumvent this issue 
is to fuse a peptide drug to a cell penetrating peptide, or CPP (213).  Briefly, CPPs are 
short, water-soluble peptides comprised mainly of positively-charged amino acids (214).  
Examples of CPPs that have previously been used for successful drug and cargo delivery 
include HIV-TAT (215), penetratin (216), and polyarginine (217).  While the mechanism 
of internalization remains controversial (213), CPPs fused to proteins have shown success 
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in permeating cells for cargo delivery while not causing damage to the cellular membrane 
(218).  Additionally, some CPPs have been designed to target specific types of cells for 
more efficient delivery and less off-target toxicity.  An example of this includes a 
leukemia-specific CPP discovered by Nishimura et al. via phage display (219).  This 
short, 9-amino acid peptide includes both a lymph node homing motif and a cell-
penetrating domain (219), and, when fused N-terminally, has shown successful leukemia-
specific delivery of a peptide targeted against BCR-ABL (unpublished data, Lim Lab). 
Fusing CPPs to peptide drugs provides an internalization method for targeting 
intracellular molecules.  Also, adding PEG chains to the exterior of peptides is expected 
to increase solubility and the circulation time of these drugs.  However, one major 
problem that still remains when dealing with peptide drugs is the maintenance of the 
biologically relevant shape of the peptide in solution (220).  A drug can circulate for an 
extended period of time and enter into a cell to come into close proximity with its target, 
but because protein-protein interactions are highly dependent on the shapes and structures 
of peptide domains, if the peptide drug loses its biologically relevant shape, it is less 
likely to effectively interact with its target.  To overcome all of the aforementioned 
issues, a new class of α-helical peptides, termed stapled peptides, has been designed. 
 
Stapled Peptides 
A recently developed method for the stabilization of α-helical peptides is referred 
to as hydrocarbon stapling (221).  This method involves replacing traditional amino acids 
at two (for a singly-stapled peptide) or four locations (for a doubly-stapled peptide) in an 
α-helical sequence with nonnatural, α,α-disubstituted amino acids.  More precisely, in 
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these α,α-disubstituted amino acids, the α-hydrogen and the amino acid-specific side 
chain are replaced with a methyl group and a hydrocarbon chain of arbitrary length, 
respectively (222).  Following solid phase synthesis of the peptide backbone, the 
hydrocarbon staple is formed by fusing the hydrocarbon chains from the α,α-disubstituted 
amino acids using ruthenium-catalyzed olefin metathesis, discussed in more detail below 
(222, 223).  Adding a hydrocarbon staple to the backbone of the α-helix overcomes many 
of the drawbacks commonly seen when using peptide drugs, including structural 
unfolding (which leads to loss of biologic activity), in vivo proteolysis, and lack of 
cellular penetrance when attempting to target intracellular domains (224). 
Historically, stabilizing α-helical peptides has been shown to provide great 
enhancements in the deliverability and overall therapeutic efficacy of these drugs (225-
230).  First and foremost, when targeting an intracellular protein-protein interaction with 
a peptide drug, the drug must display significant cellular penetrance to reach its target.  In 
the case of hydrocarbon-stapled peptides, the α-helical structure is stabilized, or locked in 
shape (225).  This in turn buries the polar amide backbone of the α-helix, concealing the 
hydrophilicity and increasing the hydrophobic exposure of the peptide.  This concealment 
of hydrophilicity and exposure of hydrophobicity enhances the cellular uptake of the α-
helical peptides (224).  In some constructs, for instance those that display a low amount 
α-helical stability, sequence modifications may be required to optimize cellular uptake 
(222). Sequence modifications may include substituting negatively charged residues for 
closely related positively charged residues (for example, changing aspartate to asparagine 
or changing glutamate to glutamine), or simply placing positively charged residues at 
either terminus to enhance cell permeability (221).  Overall, however, α-helical peptides 
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equipped with a hydrocarbon staple show vastly superior cell internalization than similar 
peptides that lack the stabilizing feature (224, 226).  
Another advantage to adding a hydrocarbon staple to α-helical peptides is the 
increase in proteolytic resistance (225, 228).  Like the increase in cellular penetrance, this 
is due to locking the peptide in an α-helical shape and concealing the hydrophilic amide 
bond. An increase in proteolytic resistance is seen because proteases are known to bind 
and degrade their substrates in an extended, nonhelical conformation (220, 231).  
Because the amide backbone is buried, the α-helix now becomes a poor substrate for 
enzymatic hydrolysis (225).  Knowing which amino acid sequences are more susceptible 
to proteolytic degradation, staples can be strategically designed to encompass those areas 
and even further prevent access to proteases, this time by forming a steric shield (224).  
Previous work with stapled peptides has shown greater in vitro stability of stapled 
peptides via incubation in both purified proteases and isolated serum.  On top of that, 
during in vivo studies, stapled peptides have shown up to a four-fold increase in overall 
half-life, most notably due to the decrease in proteolytic susceptibility (222, 224).  
 After avoiding much proteolytic degradation in circulation and internalizing into a 
target cell, it is important that the peptide drug now be able to bind to its intracellular 
target with high affinity.  Like the previous two advantages discussed, locking the peptide 
in an α-helical state has also been described to increase its target affinity, in some cases 
anywhere from a 5 to 5000-fold increase in affinity, when compared to similar, 
unmodified peptides (224).  Simply put, due to the restraint placed on the peptide by the 
hydrocarbon staple, the peptide is prohibited from sampling and attaining other 
conformations while in solution.  Therefore, an increase in target affinity results due to 
! 41!
the vast reduction in the entropic cost of target binding caused by the pre-organized 
locked peptide state (224).  After all, the stapled peptide is ideally synthesized in its 
biologically relevant structure, thereby readying it for protein-protein interaction.  
Overall, the increases in cell internalization, proteolytic resistance, and enhanced target 
affinity result in drastic improvements of the in vitro and in vivo efficacy of the peptide 
therapeutic.  These enhancements can also be multiplied even further by adding a second 
hydrocarbon staple to the backbone of larger peptides, resulting in double-stapled 
peptides (229). 
 
Choosing the staple location 
Prior to synthesis of the peptide, amino acid residues must be chosen based on 
their location in the secondary structure of the peptide for replacement with α,α-
disubstituted amino acids; these α,α-disubstituted amino acids will eventually be used to 
form the hydrocarbon staple.  Choosing the proper location for incorporation of these 
α,α-disubstituted amino acids must follow certain criteria.  First, the residues must exist 
on the same face of the α-helix.  In order accomplish this, residues must be spaced in one 
of the following arrangements, representative of approximately 1 or 2 full helical turns in 
the peptide: i, i+3; i, i+4; or i, i+7 (225, 232).  Alignment on the same helical face 
prevents skewing of the hydrocarbon staple, which could potentially distort the shape and 
structure of the α-helical peptide.  Next, the residues chosen for substitution should not be 
involved in interaction with the target.  As at many protein-protein interfaces, interactions 
are often facilitated by intrinsic characteristics of specific amino acids (charge-charge 
interactions, hydrophobic interactions, etc).  Therefore, these amino acid residues that 
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facilitate target specificity should not be hindered or changed, thus the staple should be 
built on the side of the α-helix opposite the target interface.  Generally speaking, an 
efficient way to determine this location (opposite the target interface) is by examining the 
three-dimensional structure of the protein-protein interaction in question.  Many of these 
interaction structures are available via the Protein Data Bank and can be accessed using 
Pymol or another similar program.  Additionally, as briefly mentioned above, residues for 
substitution can also be chosen to protect against sequences known to be susceptible to 
degradation by common serum proteases.  Finally, it can be inferred that engineering a 
hydrocarbon staple onto a peptide will decrease the overall solubility in hydrophilic 
solvents.  Thus, if possible, replacing highly hydrophilic amino acids should be avoided 
in an attempt to reduce the impact on solubility.  
Another way in which locations for hydrocarbon staple incorporation can be 
identified is through the use of computational modeling and molecular dynamics (MD) 
simulations.  Here, modeling is predicted to provide the “best location” for the staple 
from a maximal amount of starting combinations.  Thus, the “best location” is calculated 
using MD simulations looking for: 1) energetically favorable binding between the 
designed peptide and BCR-ABL, and 2) enhancements in structural stability as a result of 
hydrocarbon staple addition.  Analysis of this sort has the potential to save time by 
quickly analyzing a large amount of staple possibilities and to save money by not 





Synthesis of stapled peptides 
The synthesis of these stapled α-helical peptides occurs in two steps: 1) solid 
phase synthesis of the peptide, which includes incorporation of the nonnatural α-methyl, 
α-alkenyl amino acids, and 2) closure of the alkenyl chains using ruthenium-catalyzed 
olefin methathesis, or ring-closing metathesis (RCM), thus creating the hydrocarbon 
staple or staples (Figure 1.8) (223).  The desired size (and spacing) of the hydrocarbon 
staple(s) must be predetermined in order to incorporate α-methyl, α-alkenyl amino acids 
with the correct alkene chain length and stereospecificity, as efficiency of RCM is 
dependent on these two parameters.  For example, to effectively join a hydrocarbon 
staple in an i, i+7 spacing arrangement, the disubstituted amino acid at position i must  
 
        
Figure 1.8.  Schematic of ring-closing metathesis during synthesis of stapled peptides.  
α,α-disubstituted amino acids with alkene hydrocarbon chains of arbitrary length are 
inserted into the peptides during solid-phase synthesis.  Following the synthesis process, 
the terminal alkenes are joined using ruthenium-catalyzed olefin (or ring-closing) 




contain a C8 chain with R stereospecificity, while the disubstituted amino acid at position 
i+7 must contain a C5 chain with S stereospecificity (223, 232).  These parameters bring 
the two olefin ends within close proximity for the RCM reaction.  During synthesis, the 
α-methyl, α-alkenyl amino acids simply take the place of the replaced natural amino acids 
from the parent sequence.  In other words, there are no postsynthesis steps that remove 
amino acids from peptides and replace them with α-methyl, α-alkenyl amino acids. 
Once the automated synthesis is complete, the α-methyl, α-alkenyl amino acids in 
the peptide chain still contain free olefin ends.  Thus, the next step includes joining the 
two free olefin ends (and thus creating the hydrocarbon staple) using RCM chemistry, an 
organic synthesis method whose discovery and development by Chauvin, Grubbs, and 
Schrock earned them the Nobel Prize in Chemistry in 2005 (223, 233).   
 
Ring-closing olefin metathesis 
In general, RCM involves the creation and redistribution of alkene bonds utilizing 
metal complexes as catalysts (234-236).  The first widely accepted mechanism of RCM 
was proposed by Herisson and Chauvin in 1971.  Since then, improvements have been 
made to different transition metal-based catalysts that cater to different situations.  In the 
case of creating stapled peptides, the specific catalyst commonly used is known as the 
Grubbs’ catalyst, a ruthenium (II) carbenoid complex (233-236).  Briefly, the Grubbs’ 
catalyst, when added, promotes formation of a metallocyclobutane intermediate with one 
of the two free olefin ends from one of the α-methyl, α-alkenyl amino acids.  Following 
intermediate formation, the reaction is energetically favored to release the ruthenium 
species and proceed to creating a new alkene.  This newly created alkene is the double 
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bonded product that connects the original two free olefins, forming the hydrocarbon 
staple.  Kim et al. has described the specific protocol and the important techniques to be 
employed for efficient RCM in stapled peptide synthesis (223). 
 
Methods used to characterize stapled peptides 
During preliminary testing, the biophysical characteristics of the stapled peptides 
are studied to determine whether or not the design enhancements actually improve the 
properties of the peptide.  To ensure the amino acid substitutions made to incorporate the 
staple do not alter the structure of the peptide, circular dichroism (CD) is often used for 
validation.  Based on CD theory, α-helical peptides absorb differentially polarized light in 
a characteristic manner, providing two minimum absorption peaks at 208 and 222 nm in 
the instrument readout (237).  The percentage of the peptide remaining in a helical state is 
often calculated based on these absorption peaks and is used to determine the efficiency 
of the added staple.  This strategic enhancement in helicity alone is expected to improve 
many of the biophysical and biochemical properties of the molecule, discussed further in 
the next paragraphs. 
 Increases in the percent helicity of stapled peptides are expected to also facilitate 
greater proteolytic resistance in both circulating serum and inside the target cell.  When 
degrading proteins, proteases such as trypsin require the substrate (protein) to bind in an 
extended conformation (224).  By binding in this manner, the protease now has available 
access to amide peptide bond, further resulting in hydrolysis and degradation.  Because 
the addition of the hydrocarbon staple allows the peptide to maintain a helical (non-
linear) structure, the amide bond is shielded from the protease, which leads to proteolytic 
! 46!
resistance.  This claim is often verified when studying stapled peptides using both in vitro 
and ex vivo methods, involving incubation with either purified proteases or serum from 
mice or human.  The amount of peptide remaining fully intact following incubation can 
be quantified using mass spectrometry. 
 In addition to stronger protease resistance, stapled peptides have also been shown 
to display cell permeability characteristics.  Simply put, permeability or cell 
internalization capability can be analyzed by treating cells with fluorescently labeled 
(FITC, for example) stapled peptides for a short period of time.  Following treatment, 
cells can be analyzed using FACS flow cytometry to determine the percentage of cells 
into which the peptide internalized.  For further analysis, these same cells can be imaged 
using confocal microscopy (and staining of certain intracellular organelles) to further 
understand the subcellular localization of the peptides. 
 Lastly, stapled peptides are expected to show greater affinity for their target than 
similar nonstapled peptides.  This improvement is expected due to a reduced entropic cost 
in target binding that results from the stapled peptide existing in a pre-organized and 
locked state (224, 225, 229).  Though tough to measure in a living cell, target affinity can 
be quantified in vitro using purified stapled peptide and target constructs and utilizing 
either isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR) 
techniques (238).  Depending on the peptides and targets being studied, increases in 





Stapled peptides in the Lim Lab 
To this end, we have begun a collaborative, multidepartmental, and multi-
institutional effort to design a stapled peptide inhibitor of BCR-ABL using the previously 
described CCmut3 construct as a launch point for design.  Original locations for 
incorporations of hydrocarbon single and double staples were determined by hand using 
the CCmut3 helical wheel diagram and the three-dimensional Pymol structure.  Further 
validation of these staple locations is underway using MD simulations by world-
renowned computational chemist Tom Cheatham, Ph.D. at the University of Utah.  
Following validation of the top three stapled candidates, these peptides will be 
synthesized by stapled peptide expert Greg Bird, Ph.D. in the laboratory of stapled 
peptide pioneer Loren Walensky, MD, Ph.D. at the Dana-Farber Cancer Institute at 
Harvard University.  More detailed information on this project is provided in Chapter 6. 
 
Current status of stapled peptides 
Since the first publication regarding the idea of stabilizing α-helical peptides 
using hydrocarbon staples in 2000, dozens of stapled peptides have been designed for 
both extracellular and intracellular targets (221).  However, few of them, possibly in part 
to the field being relatively new, have advanced past the developmental stages and into 
preparation for clinical trials. 
 
ALRN-5281 
The first (and currently, only) stapled peptide to enter into clinical trials was 
ALRN-5281, a 29-amino acid growth hormone releasing hormone (GHRH) agonist for 
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treating endocrine disorders (239).  ALRN-5281 binds to and activates the GHRH 
receptor, a G-protein coupled receptor expressed on somatotrophs in the anterior pituitary 
(240).  Upon activation, these cells release growth hormone (GH) in a normal physiologic 
(pulsatile) pattern (241).  
Because this GHRH agonist is a stapled peptide, its concentration in the 
bloodstream remains within the tolerated therapeutic window for a longer period of time 
when compared to other currently available GHRH agonists.  This in turn both lowers the 
number of administrations needed to achieve a similar therapeutic effect (as a non-
stabilized GHRH agonist) and additionally prevents the concentration from reaching or 
surpassing the MTC.  Preclinical data showed rises in peak serum GH and biomarker 
IGF-1 following only once or twice weekly subcutaneous (SC) injections in dogs.  The 
Phase I dose-escalation safety and tolerability study of ALRN-5281 (Clinical Trial 
Identifier NCT01775358), which utilized 0.015 mg/kg, 0.05 mg/kg, and 0.015 mg/kg 
doses, was completed in May, 2013 (239).  Exact pharmacokinetic data have not yet been 
released publicly, although no serious adverse events, dose-limiting safety findings, or 
tolerability issues leading to withdrawal were reported. 
 
ALRN-6924 
A second stapled peptide that is primed to move into clinical trials in 2014 is 
known as ALRN-6924 (formerly ATSP-7041), a p53 re-activator with dual targeting of 
the p53-interacting domains of MDM2 and MDMX (230).  As negative regulators of p53, 
MDM2 and MDMX, when bound to p53, impair p53’s function as a tumor suppressor via 
multiple mechanisms (242-245).  In order to prevent binding of MDM2 and MDMX to 
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p53, ALRN-6924, a 14 amino acid peptide containing an i, i+7 staple connecting residues 
4 and 11, was created. 
Prior to creation of ALRN-6924, other small molecules designed to target these 
interaction domains were studied.  However, “poor pharmacological characteristics” 
made these therapeutics unsuitable for further use (246).  Because a protein-protein 
interaction was being targeted, it was thought that isolating the p53 α-helix that binds 
both MDM2 and MDMX and using that as a therapeutic could be successful.  Following 
study of the α-helical structure, sequence enhancements were made to improve the 
binding affinity to the targets and a hydrocarbon staple was added to improve the 
pharmacologic characteristics.  Furthermore, the addition of the hydrocarbon staple 
actually improved binding to the targets as the hydrocarbon staple was shown to bind into 
the hydrophobic cleft of the binding active site.  The final product was shown to bind to 
MDM2 and MDMX with nanomolar affinities (preventing MDM2 and MDMX from 
binding to and inactivating p53) and to re-activate the p53 tumor suppressor pathway 
with submicromolar cellular activity in the presence of serum (230).  While a clinical trial 
has yet to begin for ALRN-6924, Aileron Therapeutics Inc. claims to have secured 
enough funding necessary to launch this process, with the hopes of a 100 patient phase I 
trial beginning in 2014 (247). 
 
Statement of Objectives 
Current therapy for CML involves the use of tyrosine kinase inhibitors (TKIs) 
targeted against the kinase domain of BCR-ABL.  Despite their success in treating this 
disease, their continued use often causes problems due to acquisition and surfacing of 
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mutations in the tyrosine kinase domain (thus rendering the TKIs inactive) and non-
specific kinase inhibition causing toxic off-target effects.  The overall objective of this 
project is to avoid the problems described above by designing and developing a 
deliverable coiled-coil inhibitor of BCR-ABL oligomerization for use as a therapeutic for 
CML.  Original design and optimization of the CC inhibitor (CCmut3) itself is described in 
the study.  Further, a therapeutic combination of CCmut3 and the TKI ponatinib is 
explored with the idea of lowering the administration dose of ponatinib for prevention of 
toxic off-target effects.  Finally, the design of a deliverable method of CCmut3 is 
discussed, including presentation of preliminary data that validate the original design of 
the peptide. 
Because the peptide we have designed is highly specific for BCR-ABL, it is 
believed that off-target effects would be minimal to nonexistent.  When administering 
TKIs, the BCR-ABL kinase domain can mutate to evade TKI binding.  As for mutations 
against our designed CCmut3, it is believed that should BCR-ABL mutate to prevent 
binding our construct, it would impair its own ability to dimerize, resulting in auto-
inactivation.  Therefore, the strategy of targeting the BCR-ABL CC domain with a 
therapeutic peptide could provide a means of greater long-term success in the treatment 
of CML.  
 
Research hypotheses 
Research aim 1  
The hypothesis for research aim 1 states that the insertion of a K39E mutation into 
the previously characterized CCmut2 construct (BCR-ABL CC with C38A, S41R, L45D, 
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E48R, and Q60E mutations) would further destabilize mutant homo-dimerization and 
enhance the therapeutic efficacy against BCR-ABL.  Adding the K39E mutation, and 
thus creating a new construct called CCmut3, is expected to create an additional charge-
charge repulsion between the BCR-ABL CC and our newly improved CC inhibitor. 
 
Research aim 2 
 It is expected that concurrently targeting two separate domains of BCR-ABL, the 
CC domain and the tyrosine kinase domain, through co-administration of CCmut3 and 
ponatinib will result in more potent inhibition of BCR-ABL.  We also aim to determine 
whether or not the dose of ponatinib required to successfully inhibit BCR-ABL can be 
lowered due to co-administration with CCmut3.  A dose-lowering potential of ponatinib 
could lead to limiting some of the dose-dependent toxic off-target effects in vivo.  
 
Research aim 3 
It is hypothesized that truncating the CCmut3 construct to contain only the α-helix2 
domain will inhibit BCR-ABL to a similar extent as the full-length CCmut3.  Since the 
majority of BCR-ABL CC interactions occur at the α-helix2 interface, this region alone 
should be sufficient to inhibit BCR-ABL oligomerization.  Further, adding α-helix 
stabilizing capping residues should allow further truncation of CCmut3 and enhance the 





Research aim 4 
Lastly, it is believed that a stapled, truncated CC peptide inhibitor can potently 
inhibit native and tyrosine kinase mutant BCR-ABL.  Building off of the previous CCmut3 
design, a deliverable form of this peptide is being created by adding a hydrocarbon staple 
to the peptide backbone.  This hydrocarbon staple is expected to stabilize the peptide in 
solution, allow penetration into leukemia cells, and bind to BCR-ABL with high affinity, 
inhibiting cell proliferation and inducing apoptosis.   
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IMPROVED COILED-COIL DESIGN ENHANCES INTERACTION 
 






The oncoprotein BCR-ABL drives aberrant downstream activity through trans-
autophosphorylation of homo-oligomers in chronic myelogenous leukemia (CML) (1, 2). 
The formation of BCR-ABL oligomers is achieved through the coiled-coil domain at the 
N-terminus of Bcr (3, 4).  We have previously reported a modified version of this coiled-
coil domain, CCmut2, which exhibits disruption of BCR-ABL oligomeric complexes and 
results in decreased proliferation of CML cells and induction of apoptosis (5).  A major 
contributing factor to these enhanced capabilities is the destabilization of the CCmut2 
homodimers, increasing the availability to interact with and inhibit BCR-ABL. Here, we 
included an additional mutation (K39E) that could in turn further destabilize the mutant 
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homodimer. Incorporation of this modification into CCmut2 (C38A, S41R, L45D, E48R, 
Q60E) generated what we termed CCmut3, and resulted in further improvements in the 
binding properties with the wild-type coiled-coil domain representative of BCR-ABL. A 
separate construct containing one revert mutation, CCmut4, did not demonstrate improved 
oligomeric properties and indicated the importance of the L45D mutation. CCmut3 
demonstrated improved oligomerization via a two-hybrid assay as well as through 
colocalization studies, in addition to showing similar biologic activity as CCmut2. The 
improved binding between CCmut3 and the BCR-ABL coiled-coil may be used to redirect 
BCR-ABL to alternative subcellular locations with interesting therapeutic implications. 
 
Introduction 
Chronic myelogenous leukemia (CML) has been transformed from a deadly 
cancer into a manageable disease through the development of tyrosine kinase inhibitors 
(TKIs) (6, 7).  Currently, there are three approved TKIs for the treatment of CML: 
imatinib, nilotinib, and dasatinib.  All three are now FDA approved for newly diagnosed 
chronic phase CML, with the second-generation TKIs (nilotinib and dasatinib) more 
effective against mutant BCR-ABL variants (8). While TKI therapy has proven effective 
for the management of CML, one particular resistant form, harboring an isoleucine 
mutation in the T315 “gatekeeper” residue, is uninhibited by all of the currently approved 
TKIs (9-12).  Ponatinib (13, 14) and DCC-2036 (15) are third-generation TKIs currently 
in clinical trials that have shown to be effective against the T315I form. Nevertheless, 
TKIs are not without problems and are in fact not a cure for CML (8, 16-18), as patients 
will need to chronically manage the disease with TKIs. Thus, alternative approaches are 
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still of scientific and therapeutic interest. 
In the majority of CML cases, the Abl protein is fused onto the C-terminus of the 
breakpoint cluster region protein (Bcr), a fusion protein expressed from the Philadelphia 
chromosome (19-22). This expression leads to unregulated Y-kinase activity that 
phosphorylates and activates signaling pathways such as RAS, PI3K/AKT, and Src 
family kinases such as STAT5 (23-25).  The net result is inhibition of apoptosis, 
activation of cell proliferation, and an altered cell adhesion and motility, all engendering 
growth advantages and cancer. The trans-autophosphorylation of BCR-ABL stems from 
the oligomeric state achieved through a coiled-coil (or oligomerization) domain at the N-
terminus of the Bcr portion of the fusion protein (1, 26, 27).  BCR-ABL constructs 
lacking the coiled-coil domain have diminished transformation potential (1), validating 
oligomerization as a pivotal role in oncogenicity through BCR-ABL (27-29).  Formation 
of hetero-oligomeric structures between BCR-ABL and an isolated coiled-coil domain 
prevents the trans-autophosphorylation necessary for constitutive activity leading to 
cancer, and is an interesting alternative to TKIs that bind at the Y-kinase domain. 
The 72-amino acid BCR-ABL coiled-coil domain forms two parallel α-helices 
connected through a short linker region (3).  The dimerization interface is composed 
primarily from the second helix (α-2), residues 28–67. The first helix (α-1) functions as a 
swap domain and folds onto the backside of the opposing α-2 helix after dimerization. 
This dimer subsequently dimerizes to form a tetrameric dimer-of-dimers. While the 
tetrameric interface consists primarily of aromatic and hydrophobic interactions and is 
challenging for rational design, both hydrophobic and ionic interactions additionally 
contribute to formation of the dimer interface (3, 4).  Given that formation of dimers is a 
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preceding step to formation of the tetramer, coupled with the fact that modifications to 
charged interactions in α-helices are more readily identified, analysis of the dimer 
interface permits logical modifications for improved oligomerization. 
While it is possible to use the wild-type coiled-coil domain to interfere with BCR-
ABL homo-oligomerization, problems may arise in that there is no preference for 
interacting with BCR-ABL over another isolated coiled-coil domain. As BCR-ABL in the 
cell will already be found in the tetrameric state, the feasibility of using the wild-type 
domain relies heavily on pushing the equilibrium toward formation of hetero-oligomers 
through increased concentration of the isolated coiled-coil domain. The ideal coiled-coil 
domain would exhibit minimal homo-oligomerization and form hetero-oligomers that are 
more stable than the BCR-ABL oligomeric structures. In an attempt to generate a coiled-
coil domain that more closely resembles the properties of the ideal coiled-coil, we have 
deliberately mutated residues in the BCR-ABL coiled-coil domain. We previously 
demonstrated that modifications can be made to the BCR-ABL coiled-coil domain to 
improve the oligomeric capabilities (5). The design approach was two-fold: decrease 
homodimer interaction through incorporation of charge–charge repulsion, and increase 
heterodimer interaction through formation of additional salt bridges. The resulting 
product, termed CCmut2, not only was found to have improved oligomeric properties but 
further resulted in improved inhibition of BCR-ABL and enhanced effects in preventing 
proliferation of CML cells. Regardless of this design approach, there is much evidence 
supporting that the improved oligomeric properties stem primarily from decreased 
interaction between the mutant homodimer coupled with the retention of the ability to 
oligomerize with BCR-ABL, not necessarily the formation of a higher affinity 
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heterodimer. This indicates the importance of reducing the formation of mutant 
homodimers to allow for interaction with BCR-ABL. 
In an attempt to increase the heterodimer interaction, Q60 was mutated to 
glutamate in CCmut2 for the formation of an additional salt bridge with K39 of the BCR-
ABL coiled-coil domain. Notwithstanding, in the CCmut2 homodimer where both domains 
contain the Q60E mutation, an unintentional result is the possibility to form two sets of 
K39:E60 salt bridges (Figure 2.1B,C). In order to turn these undesired salt bridges (that 
may stabilize the mutant homodimer) into charge–charge repulsions (that can decrease 
the mutant homodimer stability), K39 was mutated to glutamate. The incorporation of 
K39E into the previously described CCmut2 set of mutations was termed CCmut3 (Figure 
2.1D,E). 
In analyzing possible mutations that led to CCmut2, it was discovered that 
incorporation of both L45D and V49D mutations, aimed at decreasing homodimer 
interaction through charge–charge repulsions, introduced a kink in the α-2 helix and was 
unfavorable. However, making either L45D or V49D mutations alone contributed to 
specific interactions between the mutant and wild-type coiled-coils. Thus, L45D was 
chosen for incorporation into CCmut2. Residues 45 and 49 are unique among the set of 
possible mutations analyzed due to the fact that they are not located at “g” or “e” helical 
positions, but instead are located at the typical hydrophobic “d” and “a” positions. 
Although the L45D mutation was demonstrated to contribute to a decreased homodimer 
interaction (due to the D45:D45 charge–charge repulsion formed between the two mutant 
domains), it may have the drawback of decreased hydrophobic interactions in the 
heterodimer. The additional charge–charge repulsion designed through the K39E  
! 79!
 
Figure 2.1. Ribbon diagrams of the coiled-coil domains.  White ribbons indicate wild- 
type (WT) coiled-coil, grey ribbons indicate mutant coiled-coils, and each homo-dimer 
(A, B, D, and F) or hetero-dimer (C, E, and G) is labeled above.  Blue numbering/spheres 
indicates positively charged amino acid residue; red numbering/spheres indicates 
negatively charged amino acid residue.  For the WT, white = C38, blue (+ chg) = K39, 
purple = S41, cyan (hf) = L45, red (- chg) = E48, green = Q60.   Underlined residue is 
colored in the figure.  For CC mutants, gray = C38A, red (- chg) = K39E, blue (+ chg) = 
S41R, red (- chg) = L45D, blue (+ chg) = E48R, red (- chg) = Q60E.  Underlined residue 
is colored in the figure.  A)  WT:WT homo-dimer.  Only the top strand is numbered.  B) 
CCmut2:CCmut2 homo-dimer (CCmut2 contains C38A, S41R, L45D, E48R, Q60E 
mutations). The two R41:R48, and one D45:D45 charge-charge repulsion are shown, as 
well as the two sets of K39:E60 salt bridges. C) WT:CCmut2 hetero-dimer.  The E48:R41 
and K39:E60 salt bridges are indicated. D) CCmut3:CCmut3 homo-dimer (CCmut3 contains 
C38A, K39E, S41R, L45D, E48R, Q60E mutations).  The two sets of K39:E60 salt 
bridges are now replaced with two sets of E39:E60 charge-charge repulsions.  The two 
R41:R48 and one D45:D45 charge-charge repulsions are retained.  E) WT:CCmut3 hetero-
dimers.  CCmut3 may form E48:R41 and K39:E60 salt bridges with WT as illustrated.  F) 
CCmut4 homo-dimers (CCmut4 contains C38A, K39E, S41R, E48R, Q60E mutations).  
Similar to CCmut3 homo-dimer, the two sets of E39:E60, and two R41:R48 charge-charge 
repulsions are again illustrated.  D45:D45 charge-charge repulsion is now replaced with a 
L45:L45 hydrophobic interaction in the middle.  G) WT:CCmut4 hetero-dimers.  The 
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mutation may obfuscate the need for charge–charge repulsion through the L45D 
mutation, and reverting the L45D mutation back to the original leucine may provide the 
benefit of better hydrophobic interactions with the BCR-ABL coiled-coil domain (Figure 
2.1F,G). Thus, CCmut3 with the revert mutation D45L, was termed CCmut4. 
For Figure 2.1, molecular graphics are shown displaying the average structures 
from 20 to 25 ns for the various “AB” “std” models of each class with the exception of 
the CCmut3:WT model, which was from 15 to 20 ns. In some of the mutated homodimers, 
such as CCmut2:CCmut2 and CCmut3:CCmut3, buckling at the center of the coiled coil is 
evidenced by bulging of the helices. MM-PBSA analysis (30) proved inconclusive, even 
with inclusion of neutralizing salt and/or truncation of the noncoiled-coil regions. Further 
free energy investigation using thermodynamic integration, consistent with our previous 
work, is underway. 
As a second iteration of a rationally designed coiled-coil domain for improved 
binding to BCR-ABL, we demonstrate here that CCmut3, but not CCmut4, provides further 
enhancements of the oligomerization properties. CCmut3 produced similar effects as 
CCmut2 in inhibiting BCR-ABL activity, decreasing CML cell proliferation, and inducing 
apoptosis in CML cells. In addition to an alternative inhibitor of BCR-ABL, the enhanced 
binding may further prove beneficial for other interests currently underway in our 






Materials and Methods 
Model building from molecular dynamics simulations 
Snapshots were taken from molecular dynamics simulation using AMBER11 (31) 
initiated from crystal structure models from the 1K1F (3) PDB structure for Figure 2.1. 
 
Model building 
The four distinct coiled-coils in the unit cell were broken into four models of 67 
residues each using chains A and B, C and D, E and F, and G and H. Missing terminal 
residues (chain D residue 67, chain E residues 1–2, chain G residues 66–67, and chain H 
residues 1–3 and 67) were grafted onto their respective structures based on the 
corresponding coordinates from model AB. Selenomethionine was altered back to 
methionine, and residue 38 was reverted back to cysteine in the wild-type structures. 
Mutated coiled coils (WT:CCmut2, WT:CCmut3, WT:CCmut4, CCmut2:CCmut2, CCmut3:CCmut3, 
and CCmut4:CCmut4) were built using the “swapaa” utility in Chimera (32) to swap amino 
acids with reasonable rotamers for the mutated residues. The models were built using the 
ff99SB force field (33) and solvated with TIP3P (34) solvent extending a minimum of 8 
Å from the protein into a truncated octahedral box. Net-neutralizing Na+/Cl- (35) was 
added, followed by the addition of 45 extra Na+/Cl- ions for an excess salt concentration 
of ∼200 mM. The initial ion positions were based on favorable electrostatic fits as per 
AMBER’s LEaP adding single ions (for net-neutralization) or pairs of oppositely charged 
ions at a time (denoted “std”). Two additional simulations for each model separately 




An initial minimization with electrostatics turned off was applied to all atoms to 
relax the added ions and remove large clashes, followed by 1000 steps of minimization 
(500 steepest descent and 500 conjugate gradient) and then 100 ps of heating (100 K to 
300 K over the first 10 ps) with 25.0 kcal/mol-Å2 restraints on the protein atoms. 
Following the initial heating, five cycles of 1000 step minimization (as before) and 50 ps 
of MD were performed with restraint weights on the protein reduced sequentially from 
5.0 to 1.0 kcal/mol-Å2 at each step in the cycle. Constant temperature and pressure were 
controlled by a Berendsen thermostat (36) with a 0.2 coupling time. 
 
Production 
Production simulations used a 5.0 coupling time without any positional restraints. 
All simulations, unless otherwise noted, applied a 9 Å cutoff to the direct space 
interactions with a homogeneous long-range correction and automated 10 Å pairlist 
building if atoms moved more than 0.5 Å, particle mesh Ewald (37) with default 
parameters, SHAKE (38) on hydrogens, removal of center of mass motion every 5000 
steps, and a 2 fs time step for molecular dynamics integration. During the three 
independent simulations for each pair on the ∼25+ ns time scale, all of the coiled coil 






Construction of Plasmids and Mutagenesis 
The plasmids pEGFP-CC, pEGFP-CCmut2, pM1-CC, pM1-CCmut2, pEFVP16-CC, 
and pEFVP16-CCmut2 were constructed as previously described (5). pM1-CCmut3 and 
pEFVP16-CCmut3 were created through site-directed mutagenesis using pM1-CCmut2 and 
pEFVP16-CCmut2 as the templates, respectively. The mutagenic primers were 5′-
GCTGGAGCGCGCCGAGGCCCGCATTCGG-3′ and 5′-CCGAATGCGGGCCT 
CGGCGCGCTCCAGC-3′. pM1-CCmut4 and pEFVP16-CCmut4 were created through site-
directed mutagenesis using pM1-CCmut3 and pEFVP16-CCmut3 as the templates, 
respectively. The mutagenic primers were 5′-CCGCATTCGGCGCCTGGAG 
CAGCGGGTGAAC-3′ and 5′-GTTCACCCGCTGCTC CAGGCGCCGAATGCGG-3′. 
The genes encoding CCmut3 and CCmut4 were then amplified through PCR using pM1-
CCmut3 and pM1-CCmut4 as the templates, respectively, and the primers 5′-
TGTAACTCGAGTTATGGTGGACCCGGTG-3′ and 5′-ATGCTCTCGAGACCGGTC 
ATAGCTCTTC-3′. The PCR products were then inserted into pEGFP-C1 (Clontech, 
Mountain View, CA, USA) at the XhoI restriction site. To create pmCherry-BCR-ABL, 
the gene encoding BCR-ABL was digested out of pEGFP-BCR-ABL (39) with EcoRI 
(New England Biolabs, Ipswich, MA, USA), and inserted into pmCherry-C1 (Clontech). 
 
Cell Lines and Transient Transfection 
Cells were maintained at 37 °C in a 5% CO2 incubator. K562, Ph+ leukemia cells 
(gifted from Kojo Elenitoba-Johnson, Univ. of Michigan), and Cos-7 cells, African 
monkey kidney cells (ATCC), were grown in RPMI (Invitrogen, Carlsbad, CA, USA) 
media with 10% fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT, USA), 1% 
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penicillin–streptomycin–glutamine (Invitrogen), and 0.1% gentamicin (Hyclone). K562 
cells were passaged every 2 to 3 days and seeded at a density of 5.0 × 104 cells/mL. Two 
days after passaging, 2.0 × 106 cells per treatment group were transfected with 5–8 µg of 
DNA according to the Cell Line Nucleofector Kit V protocol (program T-013) using the 
Amaxa Nucleofector II (Lonza Group, Basel, Switzerland). Cos-7 cells were passaged 
every 2–3 days and transfected 24 h after seeding the cells using Lipofectamine LTX 
(Invitrogen) as recommended by the supplier. Both K562 and Cos-7 cells were 
transfected consistently between cell passages 3 and 10, as the most optimal transfection 
efficiencies are seen in that range. 
 
Mammalian Two-Hybrid Assay 
An in depth description of how the mammalian two-hybrid assay was carried out 
is described elsewhere (5). In short, pM1-CC (or mutant), pEFVP16-CC (or mutant), 
pG5-Fluc (Promega, Madison, WI, USA), and pRL-CMV (Promega) plasmids were 
cotransfected into Cos-7 cells in a 10:10:10:1 ratio. pAD-SV40 and pBD-p53 
(Stratagene, Agilent Technologies Inc., Santa Clara, CA, USA) plasmids were used for 
the positive control, and pM1 lacking the coiled-coil gene was used as the negative 
control. Forty-eight h after transfection both firefly and renilla luminescence were 
measured using the Dual-Glo Luciferase Assay (Promega) reagents per the 
manufacturer’s recommendations. The mean from duplicate transfections were taken 
from five separate experiments. A relative response ratio was calculated using the 
following equation on the firefly values normalized to the renilla values: (experiment – 
ctrl-)/(ctrl+ – ctrl-). For ease of comparing to the wild-type coiled-coil interaction, the 
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results were then normalized to the wild-type interaction (n = 4 or 5). 
 
Confocal Microscopy and Colocalization 
K562 cells were cotransfected with mCherry-BCR-ABL and coiled-coil domains 
of interest 24 h after seeding into 2-well live cell chambers (Lab-Tek chamber slide 
system, Nalge NUNC International, Naperville, IL, USA). At least 24 h after transfection, 
the cells were imaged. All images of cells were acquired on an Olympus IX81 FV1000-
XY confocal microscope equipped with 405 diode, 488 argon, and 543 HeNe lasers using 
a 60× PlanApo oil immersion objective (NA 1.45) using Olympus FluoView software. 
Excitation and emission filters were as follows: EGFP, 488 nm excitation, emission filter 
500–530 nm; mCherry, 543 nm excitation, emission filter 555–655 nm. Images were 
collected in sequential line mode. The exposure settings and gain of laser were kept 
constant and below detected pixel saturation for each group of cells. No crosstalk was 
observed between channels as determined by excitation with either the 488 or 543 nm 
laser lines, independently, while collecting fluorescence in both channels. Pixel 
resolution was kept at 1024 × 1024 with maximum of 2.5× digital zoom. Prior to 
statistical colocalization analysis, all images were corrected for background noise (i.e., 
mean background intensity outside of cells). All experiments were completed in triplicate 
(n ≥ 3). Regions of interest (ROIs) were created around whole cells. Image and statistical 
analysis was performed with JACoP in ImageJ (http://rsb.info.nih.gov. 
ezproxy.lib.utah.edu/ij) (40). Costes’s automatic threshold was used to generate the 




Forty-eight h following transfection of K562 cells with pEGFP-C1, pEGFP-CC, 
pEGFP-CCmut2, or pEGFP-CCmut3, 5 mL of cells were pelleted and resuspended in 0.5 
mL of 1× annexin binding buffer (Invitrogen). Immediately before flow cytometry 
analysis, 0.5 µL of 7-aminoactinomycin D (7AAD, Invitrogen, 1 mg/mL) and 5 µL of 
annexin V conjugated with allophycocyanin (annexin-APC, Invitrogen) were added to 
the cells. Flow cytometric analysis was performed on a FACSCantoII analyzer (Becton 
Dickinson, Franklin Lakes, NJ, USA) using BD FACSDiva v6.1.3 (BD) software. Both 
EGFP and 7AAD were excited with a blue laser with 488 nm wavelength, while APC 
was excited with a red laser with 635 nm wavelength. The fluorescence detector used for 
EGFP was 530/30 nm, the detector for 7AAD was 660/20 nm, and the detector for APC 
was 660/20 nm. The untransfected cells were excluded from analysis through gating on 
the EGFP fluorescence, and the percentage of transfected, apoptotic cells was quantified 
through combining the number of cells that stained positively for annexin-APC only (Q2) 
with the number of cells that stained positively for annexin-APC and 7AAD (Q4). Each 
of the four plasmids was transfected three separate times for separate analysis (n = 3). 
 
Cell Proliferation and Western Blotting 
Cell proliferation analysis and Western blotting were carried out as previously 
described (5). Briefly, for proliferation analysis, 48 h following transfection into 2.5 × 
106 K562 cells, trypan blue exclusion was used to determine the number of viable cells. 
For Western blots, cell pellets were resuspended in 200 µL of lysis buffer/106 cells and 
freeze thawed at −80 °C. After protein gel electrophoresis and transfer to a PVDF 
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membrane, the membrane was probed with primary antibodies (anti-pAbl(Y245), 73E5, 
Cell Signaling Technology; anti-pSTAT5(Y694), E208, Abcam; anti-pCrkl(Y207), 
#3181, Cell Signaling Technology; anti-actin, mAbcam 8226, Abcam), followed by 
HRP-conjugated secondary antibodies (Ab6814, Abcam) or antirabbit (#7074, Cell 
Signaling Technology) before the addition of ChemiGlo (Alpha Innotech, Cell 
Biosciences, Santa Clara, CA, USA) chemiluminescent substrate and detection with a 
FluorChem FC2 imager (AlphaInnotech). Plasmids were transfected three separate times, 
and a Western blot was performed on each lysate for analysis (n = 3). 
 
Colony Forming Assay 
The colony forming assay was carried out as previously described (5).  In short, 
24 h following transfection into K562 cells, 1000 cells in Iscove’s modified Dulbecco’s 
media (Stem Cell Technologies, Vancouver, BC, Canada) with 2% FBS were seeded in 
Methocult H4230 methylcellulose medium (Stem Cell Technologies) in the absence of 
cytokines. Each group of treated cells was seeded in duplicate, and colony formation was 
assessed 7 days after seeding cells by counting colonies in two 200 µm2 areas of the plate. 
Experiments were repeated at least three times and compared to control (cells transfected 
with pEGFP-C1) (n = 3). 
 
Caspase-3/7 Assay 
Caspase-3/7 assays were performed as previously described (5).  Briefly, 48 h 
following transfection into K562 cells, cell counts were performed and 3 × 106 cells were 
resuspended in 50 µL of EnzChek Caspase-3/7 lysis buffer (kit #2, Invitrogen). Cells 
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were frozen at −80 °C and thawed, and the cell debris was removed by centrifugation at 
5000g for 5 min. Lysates were mixed with 50 µL of 2× AMC-DEVD substrate in a black 
96-well plate (Cellstar, Greiner Bio-One, Monroe, NC, USA) and incubated at room 
temperature for 30 min before measuring the fluorescence with excitation 342 nm and 
emission 441 nm on a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, 
USA). Lysates from three separate transfections for each plasmid were assayed for 
caspase-3/7 activity (n = 3). 
 
Fluorescence Microscopy and DNA Segmentation 
A detailed description of the fluorescence microscopy and DNA segmentation can 
be found elsewhere (5).  In short, 48 h following transfection K562 cells were transferred 
to 2-well live cell chambers.  Cells were incubated at 37 °C for 15 min following addition 
of 0.3 µL of H33342 (nuclear dye, Invitrogen). Cells were then analyzed with an inverted 
fluorescence microscope (Olympus IX701F, Scientific Instrument Co., Sunnyvale, CA, 
USA) with high-quality narrow band GFP filter (excitation HQ480/20 nm, emission 
HQ510/20 nm, beam splitter Q4951p, Chroma Technology Corp., Brattleboro, VT, USA) 
equipped with an F-view Monochrome CCD camera. Fields of view for imaging were 
selected based on EGFP fluorescence (blinded to nuclei) and were imaged with a 40× oil 
immersion objective. The nuclei of at least 50 transfected cells (EGFP fluorescence) per 
group were classified as either healthy (round or kidney shaped) or segmented (punctate) 





All experiments were analyzed using one-way ANOVA with Tukey’s posttest (as 
previously) (5).  
 
Results 
Mammalian two-hybrid assays, to determine interactions between coiled-coil and 
coiled-coil mutants, were carried out in Cos-7 cells. For the heterodimer interactions, 
both possible fusion constructs were assayed (i.e., pM1-CC/pEFVP16-CCmutX and pM1-
CCmutX/pEFVP16-CC). While the same trend was observed regardless of which fusion 
construct was the wild-type, slightly higher values were obtained when the wild-type was 
fused to the DNA binding domain (pM1). As illustrated in Figure 2.2A, the greatest 
interaction resulted from the heterodimer between CCmut3 and the wild-type coiled-coil 
domain (CC) (Figure 2.2A, third column). Equally important, the CCmut3:CCmut3 
interaction (homodimer) resulted in negligible binding (Figure 2.2A, fourth column). 
Although it is difficult, if not impossible, in this assay to separate out the binding 
contributions from increased availability versus increased affinity, the design to decrease 
the interaction of the mutant homodimer did correlate to an increased ability to bind wild-
type as predicted. The result from the CCmut3 heterodimer and homodimer together 
indicate the improved interaction exhibited by CCmut3. Although the CCmut4 heterodimer 
did result in a slightly greater interaction than wild-type (all results are normalized to the 
wild-type CC:CC interaction, Figure 2.2A, fifth column), the CCmut4 homodimer 
produced an almost equivalent result (Figure 2.2A, sixth column). This finding indicates 
the importance of the L45D mutation in generating a preferential binding toward wild-  
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Figure 2.2. Mammalian two-hybrid assay. (A) Relative response ratios determined for 
each interaction and normalized to the wild-type homo-oligomerization (CC:CC) to 
indicate the relative binding efficiency. Values indicated are means ± SD. Statistics were 
performed on the values prior to normalizing to CC so as to include the wild-type 
interaction in the statistics (n = 4 or 5). *p < 0.05, ***p < 0.01 versus CC:CC interaction; 
one-way ANOVA, Tukey’s posttest. (B) The quotient of the heterodimer and homodimer 
interaction (absolute value) is graphed for all three mutants, indicating the preferential 
binding to CC over the formation of a homodimer. 
 
type. Whereas the other mutations designed for charge–charge repulsion are found on the 
helix at “g” and “e” positions and may more readily adopt rotamer conformations that 
position the like charges away from each other, the L45D mutation is in the hydrophobic 
core where such rotamer flexibility may be more limited. As demonstrated from the 
dramatic differences between CCmut3 and CCmut4, the L45D mutation is critical. 
 As both the heterodimer and homodimer formations are critical in evaluating the 
improvements made through the mutations, the quotient of the heterodimer and 
homodimer can be used to more easily compare the overall effect. Figure 2.2B reports 






































































































it is a favorable domain for interacting with BCR-ABL (at least the wild-type coiled-coil 
domain of BCR-ABL), the best set of mutations are those comprising CCmut3. While 
CCmut4 may interact favorably with wild-type (Figure 2.2A, fifth column), it does not 
exhibit any preferential binding (Figure 2.2B, third column) and did not result in any 
improvement as compared to the wild-type domain. Following these results, CCmut4 was 
dropped from further analysis due to the lack of improvement in oligomerization 
properties. 
While the mammalian two-hybrid assays are a quantitative method of studying 
the effects of the mutations, these assays were carried out with the isolated coiled-coil 
domains and not full-length BCR-ABL. To validate the modifications corresponding to 
the binding to BCR-ABL, colocalization experiments were performed in K562 cells. A 
rigorous analysis for determining colocalization, one utilizing the Costes’s colocalization 
coefficient, was employed (41).  Given that CC, CCmut2, and CCmut3 should all bind BCR-
ABL, the colocalization was aimed at simply confirming the interaction with the full-
length protein, and not necessarily at distinguishing their binding affinities. Nevertheless, 
Figure 2.3 shows that CCmut3 was found to exhibit a much higher degree of colocalization 
with BCR-ABL (colocalization coefficient of 0.716 ± 0.04) than CC (colocalization 
coefficient of 0.442 ± 0.13) or CCmut2 (colocalization coefficient of 0.478 ± 0.11), and 
further validated the improved oligomeric properties. Not entirely surprising, there was 
no difference between CC and CCmut2 (Figure 2.3). These colocalization results confirm 
the CCmut3 set of mutations have improved the ability to bind BCR-ABL inside a live cell. 
 Analysis of the oligomeric disruption of BCR-ABL was further explored to 





Figure 2.3. Colocalization with BCR-ABL. Representative images of either EGFP or 
coiled-coil domain seen in left column (false colored cyan for visualization) with 
representative images of Bcr-Abl distribution in middle column (false colored magenta 
for visualization). Heat maps indicating the colocalization of the two fluorophores seen in 
the right column with colocalization scale at the bottom (red highest), followed by the 
colocalization coefficient. The mean colocalization coefficient was determined from at 
least three cells per transfection (n = 4), with values reported as means ± SEM. *p < 0.05, 




































is dependent on the coiled-coil domain, the formation of hetero-oligomers between a 
coiled-coil domain and full-length BCR-ABL should reduce the phosphorylation of BCR-
ABL. As a measure of the phosphorylation state of BCR-ABL, Western blotting was 
carried out probing K562 lysates with an antibody that recognizes the phosphorylated 
form of BCR-ABL. As seen in Figure 2.4A, the phosphorylation of BCR-ABL was the 
least after transfection of CCmut3. A secondary measure of the phosphorylation of BCR- 
 
 
Figure 2.4. Effects of CCs on BCR-ABL and proliferation of K562 cells. (A) Western 
blot indicating the phosphorylation of Bcr-Abl (top, p-Bcr-Abl) and STAT5 (middle, p-
STAT5). (B) Viable K562 cells were counted 48 h following transfection, with the 
number of proliferating cells normalized to the number resulting from the EGFP 
transfection (n = 4). Values reported as means ± SD. *p < 0.05 control; one-way 
ANOVA, Tukey’s posttest. (C) Colony forming units counted 7 days after seeding 10
3
 
transfected K562 cells into methylcellulose medium, normalized to colony growth from 
EGFP control (n = 3). Values reported as means ± SD. *p < 0.05 control; one-way 
ANOVA, Tukey’s posttest. 
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ABL, and its corresponding kinase activity, is the phosphorylation of BCR-ABL 
substrates such as STAT5. The phosphorylation of STAT5 was also the least after 
transfection of CCmut3 (Figure 2.4A). The Western blot results corroborate the 
mammalian two-hybrid and colocalization data. 
Next, the improved BCR-ABL binding of CCmut3 was analyzed for its effect on 
CML cells.  As CML cells are dependent on BCR-ABL signaling for growth, inhibition 
of BCR-ABL will affect the proliferation rate of the cells, which can be monitored simply 
by performing cell counts after treatment. Forty-eight h following transfections of either 
EGFP, CC, CCmut2, or CCmut3 into a CML model cell line (K562), cell counts were 
performed using trypan blue exclusion. As seen in Figure 2.4B, the proliferation of the 
cells decreased in the order of CC, CCmut2, and CCmut3. Although indirect, this provides 
evidence of the disruption of BCR-ABL oligomerization resulting in inhibition of its 
signaling. 
As an alternative method of measuring the proliferation of the cells, a colony 
forming assay was performed. Twenty-four h following transfection of the plasmids into 
K562 cells, 1000 cells were seeded into methylcellulose medium and incubated at  37 °C 
for 7 days before counting the colony forming units in a 200 µm2 area. Both CCmut2 and 
CCmut3 were found to produce the fewest number of colonies, indicative of the decrease in 
cell proliferation (Figure 2.4C). Notwithstanding, there was no difference in the number 
of colonies after transfection of CCmut2 or CCmut3. The results achieved by CCmut2 and 
CCmut3 were comparable to the result after treating K562 cells with 0.5 µM imatinib (5), 
demonstrating the therapeutic potential. 
Further exploration of the effects on CML cells was carried out through analysis  
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of the induction of apoptosis. First, flow cytometry was used to analyze the number of 
cells with externalized phosphatidylserine, an established marker of apoptosis. As seen in 
Figure 2.5A, the level of cell death incrementally increased in the order of CC, CCmut2, 
and CCmut3.  Although the statistical significance compared to the EGFP control was 
greater for CCmut3 than for CCmut2, there was no statistically significant difference 
between CCmut2 and CCmut3. To further validate the induction of apoptosis, the activity of  
 
 
Figure 2.5. Apoptosis assays. (A) Forty-eight h following transfection into K562 cells 
phosphatidylserine externalization was assessed through flow cytometry. After gating on 
EGFP fluorescence to select only the transfected cells, the number of 7AAD-/Annexin+ 
cells (Q2, early apoptosis) was combined with the 7AAD+/Annexin+ cells (Q4, late 
apoptosis) and used to determine the percentage of apoptotic cells (n = 3). Values 
reported as means ± SD. *p < 0.05, **p < 0.01 control; one-way ANOVA, Tukey’s post- 
test. (B) Forty-eight h following transfection into K562 cells the activation of caspase-3/7 
was analyzed in the cell lysates through a fluorescence-based assay (n = 3). Values 





























































caspase-3/7 was also measured. A substantial increase in caspase-3/7 activity was 
observed after transfection of either CCmut2 or CCmut3 compared to both EGFP and CC 
(Figure 2.5B), but no statistical difference was observed between CCmut2 and CCmut3. 
 Analysis of the cell morphology is an alternative method of studying the induction 
of apoptosis. Healthy K562 cells are relatively large, round cells with kidney shaped (or 
round) nuclei (Figure 2.6A, top row). Apoptotic cells, however, exhibit very distinct 
morphological signs readily detectable through microscopy. Some morphological signs of 
apoptosis include cell shrinkage (as opposed to necrotic cells that may expand), 
cytoplasmic blebbing, echnoid spikes, and nuclear segmentation (42, 43).  Of these signs, 
nuclear segmentation is one indication that can be quantified (each individual cell 
determined to have either a normal or segmented nucleus) as a measurement of the 
induction of apoptosis. Forty-eight h after the transfection of the plasmids into K562 
cells, the nuclei were stained with H33342 and photographed on a fluorescence 
microscope. The fields of view photographed were selected based on the EGFP 
fluorescence, while being blinded to the nuclear stain, which reduces biased selection of 
nuclei. Representative images are illustrated in Figure 2.6A. The percentage of 
transfected cells with segmented nuclei is graphed in Figure 2.6B. Similar to the cell 
proliferation, and flow cytometry, an incremental effect was observed on nuclear 
segmentation with CC, CCmut2, and CCmut3. Nevertheless, CCmut2 and CCmut3 produced 
statistically significant differences versus control, but were indistinguishable from each 
other. Thus, the flow cytometry, caspase assay, and nuclear segmentation together 
demonstrate the ability of the modified coiled-coils (both CCmut2 and CCmut3) to inhibit 
BCR-ABL, decrease cell proliferation, and induce apoptosis in CML cells. 
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Figure 2.6. Nuclear segmentation of K562 cells. (A) Representative images of K562 
cells 48 h after transfection of EGFP (top row) or CCmut3 (bottom row). Left column = 
phase contrast images with black arrow indicating example of cell shrinkage; middle 
column = fluorescence from EGFP; right column = stained nuclei with white arrow 
indicating example of nuclear segmentation. (B) Quantitative results of nuclear 
segmentation. Percentage of transfected cells with segmented nuclei was determined 
from three or four fields of view, and repeated with three separate transfections (n = 3). 
Values reported as means ± SD. *p < 0.05; one-way ANOVA, Tukey’s posttest. 
 
Conclusions 
Analysis of the structure of the BCR-ABL coiled-coil domain, and the previously 
designed CCmut2, guided the identification of residues 39 and 45 as interesting locations 
for possible mutations. Incorporation of a K39E mutation into CCmut2 produced CCmut3. 
Subsequently, reverting the CCmut3 L45D mutation back to leucine produced CCmut4. The 
effects of these modifications on the oligomerization properties were studied through a 
mammalian two-hybrid assay in Cos-7 cells and compared to the effects observed from 
CCmut2 as well as the wild-type coiled-coil domain. While CCmut3 yielded impressive 
improvements in the binding capabilities, CCmut4 was found to bind almost equivalently 
to another CCmut4 as it binds CC. The binding results from CCmut4 indicate the importance 
of the L45D mutation in preventing homo-oligomerization. These binding results, 











































interaction is a major driving force in the improved oligomerization capability with BCR-
ABL. The mammalian two-hybrid assay using isolated coiled-coil domains was then 
followed by colocalization with full-length BCR-ABL. CC, CCmut2, and CCmut3 were all 
found to colocalize with BCR-ABL, with CCmut3 resulting in the greatest degree of 
colocalization. The improved binding of CCmut3 to BCR-ABL also decreased the 
phosphorylation of BCR-ABL, a parameter indicative of the oligomeric state and activity 
of BCR-ABL. These binding studies validated the additional mutation used in CCmut3 led 
to enhanced oligomeric properties and demonstrated its usefulness as a BCR-ABL 
binding domain. 
The improved binding by CCmut3 was then tested for its effect on CML cells. Cell 
proliferation was first measured through cell counts and colony forming assays following 
transfection of the coiled-coil domains. Both CCmut2 and CCmut3 decreased the cell 
proliferation, but there was no statistical difference between the two compounds. 
CCmut3 was also demonstrated to induce apoptosis in K562 cells as measured through 
7AAD staining, activation of caspase-3/7, and hallmark morphological signs of 
apoptosis. Both the decreased cell proliferation and the induction of apoptosis are indirect 
evidence of the ability of CCmut3 to interfere with the homo-oligomerization of BCR-
ABL, as oligomerization is essential for BCR-ABL activity. Due to the fact that CCmut3 
does not contain the Y-kinase domain necessary for activation through trans-
autophosphorylation, the binding between CCmut3 and BCR-ABL results in inactivation 
of BCR-ABL and induction of apoptosis in CML cells. 
These results can be divided into two distinct categories of experiments: testing 
the binding, and testing the effect the compound has on CML cells. The analysis of the 
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binding revealed a marked improvement in CCmut3, even over the proven CCmut2. 
Nevertheless, this improved binding did not correlate to enhancements over CCmut2 in 
effects on CML cells. This may be explained by insufficient assay sensitivity to 
distinguish a modest difference, indicating the improvement is only marginal. An 
alternative explanation lies in the idea that the disruption of BCR-ABL oligomerization is 
already maximized with the binding capabilities of CCmut2. If this is the case, any 
improvements in binding with an alternative coiled-coil domain would not instigate 
enhancements in the effect on CML cells. This theory is supported by the inability to 
increase the effect of CCmut2 on CML cells through combinatorial treatment with CCmut2 
and a TKI (unpublished data). 
Although use of CCmut3 for interfering with the oligomeric state of BCR-ABL is 
an interesting alternative to the standard TKIs, a further application currently in pursuit in 
our laboratory is the use as a capture motif for escort of BCR-ABL to alternative 
subcellular locations. As opposed to a passive induction of apoptosis when BCR-ABL is 
inhibited, we are seeking an active induction of apoptosis that may lead to a more potent 
therapeutic strategy. With this goal in mind, the improved binding properties are of 
utmost interest. This work establishes CCmut3 as an efficient binding partner to BCR-ABL 
with implications in inhibiting BCR-ABL as well as other interesting therapeutic 
strategies that require tight binding to BCR-ABL. 
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RESISTANT MUTATIONS IN CML AND PH+ALL –  
 






In 2012, ponatinib (Iclusig®), an orally available pan-BCR-ABL tyrosine kinase 
inhibitor (TKI) developed by ARIAD Pharmaceuticals, was FDA-approved for use in 
resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-
positive acute lymphoblastic leukemia (Ph+ALL).  Ponatinib is the only approved TKI 
capable of inhibiting BCR-ABL with the gatekeeper T315I kinase domain mutation, 
known to be the cause for 20% of resistant or relapsed CML cases.  In 2013, ponatinib 
sales were temporarily suspended due to serious side effects seen in nearly 12% of 
patients.  These side effects are thought to stem from the potent nature and pan-activity of 
this TKI.  ARIAD has since been permitted to resume sales and marketing of ponatinib to 
a limited patient population with an expanded black box warning.  In the following 
review, the use of ponatinib in CML and Ph+ALL will be discussed.  Mechanisms of 
! 105!
resistance in CML are discussed, which provide insight and background into the need for 
this third generation TKI, followed by the molecular design and pharmacology of 
ponatinib, which led to its success as a therapeutic.  Finally, the efficacy, safety, and 
tolerability of ponatinib will be highlighted, including summaries of the important 
clinical trials involving ponatinib as well as its current place in therapy.  
 
Management Issues in the Treatment of CML and ALL 
Chronic myeloid leukemia, or CML, is characterized by the presence of the 
Philadelphia (Ph) chromosome, which results from a chromosomal translocation between 
chromosomes 9 and 22.  This genetic aberration in turn forms the fusion oncoprotein 
tyrosine kinase BCR-ABL, whose kinase activity is responsible for the constitutive 
activation of growth, survival, and proliferation signaling pathways seen in CML cells (1-
3).  The end result is an expansion of functionally normal cells of the myeloid lineage, 
causing a leukemia phenotype.  Inhibition of the BCR-ABL kinase domain results in 
leukemic cell death and often-successful management of the disease (4).  
The Philadelphia chromosome (and, thus, BCR-ABL) is also present in some 
cases of acute lymphoblastic leukemia, referred to as Ph+ALL, which is a subset of 
leukemia characterized by an expansion of immature cells from the lymphocyte lineage.  
Unlike CML, only 20% - 30% of adult cases and 3% - 5% of childhood cases contain the 
Ph chromosome and subsequent BCR-ABL protein (5).  Specifically, the presence of the 
Ph chromosome in ALL correlates with a less favorable prognosis (6).  Whereas in CML 
the leukemic cells are normally dependent on BCR-ABL signaling for growth and 
survival, solely inhibiting the BCR-ABL tyrosine kinase is not sufficient to inhibit 
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leukemic cell growth in Ph+ALL (7).  Thus, more broad, intense therapies are needed to 
eradicate Ph+ALL. 
 
Current Treatment of CML and Ph+ALL 
In 2001, imatinib mesylate (Gleevec®), a small molecule targeting the ATP-
binding region of the BCR-ABL tyrosine kinase domain, was approved for first-line 
treatment of CML (8, 9).  While the introduction of this drug aided in improving 10-year 
survival rates to 80-90% (10), not all patients responded to imatinib therapy (9).  In many 
of these cases, resistance was due to the presence or acquisition of mutations in the kinase 
domain that prevented imatinib binding and activity. Thus, second and third generation 
tyrosine kinase inhibitors were designed and developed to overcome this resistance or 
intolerance. In 2006, dasatinib (Sprycel®), a dual-Src family kinase inhibitor, and in 
2007, nilotinib (Tasigna®), a more potent BCR-ABL inhibitor, were approved for CML 
therapy in patients who were intolerant or nonresponsive to imatinib.  Each of these 
inhibitors was designed to inhibit a broader range of kinases, thereby exhibiting greater 
activity against a number of kinase domain mutations that could not be inhibited by 
imatinib (4). 
Presently, newly diagnosed CML patients in the chronic phase have the option of 
beginning treatment on imatinib, dasatinib, or nilotinib.  A majority of patients will 
initially respond to treatment.  However, in nearly one-third of patients, first-line TKI 
treatment will eventually become ineffective, forcing patients to start on another TKI 
(11).  Most patients will convert to either nilotinib or dasatinib; however for some, 
especially those possessing the T315I kinase domain mutation, ponatinib (Iclusig®) will 
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be the TKI of choice.  Additionally, omacetaxine, a protein synthesis inhibitor, has 
recently been approved for relapsed CML patients.  While this drug shows a marginal 
success rate, significant side effects (including myelosuppression, bleeding, and 
hyperglycemia, among others) are seen in 99% of patients, likely due to the non-
specificity of the molecule, making it undesirable for many with CML; hence, it will not 
be further discussed (12).  Table 3.1 shows some of the approved therapies for CML, 
including their mode of action, usage indications, and common side effects. 
While the treatment of Ph+ALL includes the use of the aforementioned TKIs, the 
overall treatment strategy differs from CML.  Current frontline treatment of childhood 
Ph+ALL includes a rigorous induction phase chemotherapy regime, often 
cyclophosphamide, vincristine, adriamycin, and dexamethasone (known as hyper-CVAD) 
in combination with a tyrosine kinase inhibitor, namely imatinib or dasatinib.  Once 
remission is reached, the standard of care and only possibility of a cure remains 
hematopoietic stem cell transplantation (HSCT).  Most patients who do not undergo 
HSCT eventually relapse (13).  Depending on the molecular status of BCR-ABL 
transcripts during follow-up, patients may be administered a TKI for maintenance therapy 
purposes. 
In the following sections, the mechanism of resistance to TKIs will be discussed, 
as well as the role of ponatinib in these scenarios.  Additionally, the pharmacology and 
mode of action of ponatinib will be discussed to describe how and why ponatinib is often 
effective against both native and mutant BCR-ABL.  Finally, the efficacy and safety of 
ponatinib will be discussed, including a summary of various clinical trials, and the 




Table 3.1. Select approved drugs for CML therapy, kinase specificity, and notable 








The majority of this review will focus on the potential of ponatinib in the treatment of 
CML.  Although CML and Ph+ALL involve different treatment strategies, the same 
issues that arise in TKI-resistant CML are also present with BCR-ABL inhibition in 
Ph+ALL.   
 
Mechanisms of Mutational Resistance in CML and Ph+ALL 
It is well documented how the introduction of imatinib (and other TKIs) has 
profoundly changed the management of CML and Ph+ALL (21-23).  Despite these 
successes, it is estimated that one-third of CML patients on first-line imatinib therapy will 
require other therapy due either to imatinib intolerance or resistance (11).  BCR-ABL 
independent resistance represents another mechanism of TKI resistance, which will not 
be discussed in this review.  For excellent reviews on this topic, see the following papers 
(24, 25). 
Resistance to TKIs can be classified into two types: primary resistance and 
secondary resistance.  Primary resistance refers to the lack of initial response, presumably 
due to the presence of baseline mutations in the kinase domain.  On the other hand, 
secondary resistance refers to the loss of an established response, often due to the 
prolonged exposure to the TKI (26).  Whether primary or secondary, the most common 
and well understood mechanism of resistance against all TKIs is the appearance or 
development of point mutations in the BCR-ABL kinase domain (25).  In patients with 
primary resistance, cells harboring mutations normally make up a sizeable fraction of the 
leukemic cells from the onset.  Conversely, a clonal model of resistance is often used to 
describe secondary resistance from a molecular standpoint.  Here, nonresistant cells are 
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first eliminated by TKI therapy, giving surviving resistant clones a selective advantage 
for future outgrowth.  Supporting this theory is the observation that sequential treatment 
with TKIs often leads to enhanced TKI resistance (27, 28).  In a subset of patients who 
were treated sequentially with and failed both imatinib and dasatinib, all of the patients 
showed new BCR-ABL mutations after dasatinib failure that had not been recognized 
following failure on imatinib.  These double mutants, described below, can confer 
resistance to multiple drugs and enhance BCR-ABL oncogenicity (27). 
Importantly, the kinase domain mutations responsible for resistance occur at 
strategic locations, which prevent TKI activity.  When these residues are mutated, they 
inhibit TKI binding but still allow ATP binding and kinase activity (17).  Imatinib, 
dasatinib, and nilotinib each bind the BCR-ABL kinase in a characteristic manner (Table 
3.1).  Due to these binding specifics, resistance profiles specific to each TKI will exist.  
In some cases, mutations will occur directly in the kinase active site, sterically hindering 
TKI binding.  In other cases, mutations will occur at residues that affect the overall three-
dimensional structure of the kinase.  Because imatinib and nilotinib bind BCR-ABL in its 
inactive conformation (Table 3.1), mutations may occur in resistant patients that 
destabilize or prevent adoption of the inactive conformation of the kinase.  Failure to 
adopt this conformation prevents imatinib and nilotinib binding and activity (24, 27).  
Most importantly, clinically relevant mutations in the BCR-ABL kinase domain all occur 
on residues such that the integrity of the tyrosine kinase itself is not eliminated.  
Specifically, more than 55 residues showing varying levels of resistance to imatinib have 
been identified (24).  It should be noted that while many of the studied kinase domain 




Emergence of Compound Mutations 
In a 2013 study, 1700 patient samples with BCR-ABL kinase domain mutations 
were analyzed using direct sequencing.  In this set of samples, 11.4% showed two or 
more mutations in the kinase domain (29).  Double mutants in the BCR-ABL kinase 
domain can exist in two forms: compound or polyclonal.  Compound mutations, which 
account for 70.2% of double mutations in the BCR-ABL kinase domain, refer to multiple 
mutations in the same BCR-ABL molecule (29).  The other 29.8% of double mutations 
are represented as polyclonal mutants, where mutations occur in multiple BCR-ABL 
molecules within a single cell.  As mentioned above, sequential treatment with TKIs can 
lead to the emergence of multiple mutations in a single patient.  Not surprisingly, the 
composition of the compound mutations noted in this study reflected the TKI treatment 
history, where one or more mutational components was associated with a typical clinical 
or in vitro resistance profile to the specific TKIs (29).  Altogether, 30 different compound 
mutations were observed, with the T315I mutation being the most frequently observed 
mutation amongst all compound mutants.  It has been suggested that the best way to 
prevent the onset of compound mutations is to initially treat with a molecule that can 
“collectively suppress” all single point mutations.  A molecule such as ponatinib, which 
during preclinical evaluation inhibited all clinically important kinase domain mutations 
including T315I, has the potential to achieve this feat, although will unlikely be used for 
first-line therapy at its current dosing regimen (27, 30).  
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Pharmacology of Ponatinib 
Although dasatinib and nilotinib have shown efficacy against many of the 
clinically relevant mutations for which imatinib is ineffective, neither has the ability to 
inhibit BCR-ABL with the T315I mutation (BCR-ABLT315I) (31).  Thus, the need arose 
for a new TKI that not only inhibited BCR-ABLT315I but also native BCR-ABL and other 
commonly seen BCR-ABL mutations.  In order to design a molecule that could meet 
these criteria, it is important to understand the structural features of the BCR-ABL kinase 
domain containing the T315I mutation.   
 
Effects of the T315I mutation 
Despite maintaining the overall structure of the BCR-ABL protein, the presence 
of the T315I mutation does indeed affect the topology of the ATP binding region (32).  
Current TKIs are unable to inhibit this mutant form of the enzyme for two main reasons.  
The T315I mutant form of BCR-ABL lacks a threonine residue, which provides a 
hydroxyl group critical for hydrogen bonding with first and second generation TKIs.  
This hydrogen bond has been described to drive both the potency and specificity of these 
ABL inhibitors (32, 33).  This hydrogen bond disappears when the threonine is replaced 
with an isoleucine (Ile) residue.  Additionally, residue 315 is located directly in front of 
the hydrophobic pocket, which is why it is referred to as the “gatekeeper” residue.  When 
mutated to an isoleucine, the more bulky Ile side chain further protrudes into the enzyme 
active site, initiating a steric clash and subsequently blocking entrance of a TKI into the 
hydrophobic pocket but still allowing access to ATP.  For these reasons, first and second 
generation TKIs fail to inhibit BCR-ABLT315I (30, 32, 34).   
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Design of ponatinib 
Overcoming both the loss of an active-site hydrogen bond and the steric hindrance 
caused by the T315I mutation was the main focus during the design process of ponatinib 
(35). While still binding to the kinase active site of BCR-ABL, the overall design of the 
ponatinib molecule would still be based on the ATP-mimetic template provided by the 
previous TKIs imatinib, nilotinib, and dasatinib.  The structure of ponatinib is shown in 
Figure 3.1.  The five critical regions of the molecule and the structure-activity 
relationships of each region are described below. 
 
Hinge region 
The hinge region (Figure 3.1A) was optimized to improve binding affinity, 
lipophilicity, and overall oral bioavailability.  The final product resulted in a 6-5 fused 
ring system with an imidazole[1,2]pyridazine chemical moiety that occupies the adenine-
binding pocket of the kinase domain (35).  Chemically, the imidazole moiety forms H-
bonds with the hinge of the enzyme pocket (Figure 3.2) while the pyridazine ring 
interacts hydrophobically with F382 of the DFG region and Y253 in the P-loop of BCR-
ABL (Figure 3.2).  Finally, the lack of atomic substitutions and substituents in this fused 
ring system has led to optimal lipophilicity and oral bioavailability (34). 
 
Ethynyl linker 
Ponatinib differs from previous BCR-ABL TKIs with the presence of a triple 
bond-ethynyl linker (Figure 3.1B), which connects the hinge region and A ring.  Most 




Figure 3.1.  Chemical structure of ponatinib.  Chemical structure of ponatinib with labels 
for the A) Hinge region, B) Ethynyl linker, C) A ring, D) Linker 2, and E) B ring.  The 
trifluoromethyl and 4-methylpiperazine groups, added during the optimization process for 
maximal BCR-ABL inhibition, also shown. 
 
 
present in BCR-ABLT315I (Figure 3.2).  Structurally, this Ile side chain protrudes into the 
active site in front of the hydrophobic pocket.  Previous TKIs could not span this side 
chain and thus could not dock into the hydrophobic pocket.  Structure-activity studies 
revealed that the presence of the triple bond allows a greater than 10-fold potency when 
compared to similar molecular designs containing single or double-bonded systems (34).  
Vinyl and acetylene linkages were also attempted during the design process.  While also 




The A ring of ponatinib (Figure 3.1C) binds in the hydrophobic pocket of the 











Figure 3.2. Hydrogen bonding pattern between ponatinib and BCR-ABLT315I.  Pymol 
figure showing ponatinib (pink) binding in the ATP-binding region of BCR-ABLT315I.  
Hydrogen bonds involving the residues E286, M318, I360, and D381 of BCR-ABLT315I 
are represented by yellow dashed lines.  Oxygen atoms are shown in red, nitrogen atoms 
in blue, sulfur in gold, and fluorine in cyan.  PDB ID 3IK3. 
 
 
methylphenyl moiety, the A ring appeared very sensitive to any substitutions or chemical 
modifications, thus was not changed (34, 35). 
 
Linker 2 
Linker 2 (Figure 3.1D) chemically exists as an amide linkage with the purpose of 
connecting the A and B rings, spatially aligning the molecule with the structure of the 
BCR-ABL (34).  Hydrogen bonds are formed between the linker carbonyl group and 




The B ring (Figure 3.1E) contains both a trifluoromethyl substituent and a 4-
methylpiperazine moiety.  This B ring binds into the DFG-out pocket of the enzyme 
active site.  The addition of these particular substituents has allowed for optimization of 
maximal BCR-ABLT315I inhibition due to the formation of critical hydrogen bonds 
between the piperazine group and the enzyme backbone, notably at residue I360 (Figure 
3.2) (33).  Specifically, methylpiperazine increases potency and molecular recognition, 
while piperazine itself is a solubilizing group, and improves permeability and decreases 
lipophilicity and protein binding.  
Taken together, the optimization process of the five regions listed above led to the 
final design of ponatinib.  Although the overall structure remains similar in many ways to 
other approved tyrosine kinase inhibitors, the ability to potently inhibit native BCR-ABL, 
BCR-ABLT315I, and many other kinase mutant forms of BCR-ABL made ponatinib a 
highly versatile drug with great potential heading into clinical trials. 
 
Efficacy, Safety, and Tolerability of Ponatinib 
Preclinical testing of ponatinib 
The design and preclinical testing of ponatinib began in 2006 as the need for a 
CML therapy capable of inhibiting many resistant forms of BCR-ABL arose (Figure 3.3).  
Initial preclinical testing involved demonstrating that ponatinib could both decrease auto-
phosphorylation of the BCR-ABL kinase as well as inhibit the proliferation of cells 
dependent on BCR-ABL.  Namely, these in vitro experiments utilized K562 cells 
(human, BCR-ABL+) and Ba/F3 cells (mouse, pro-B) stably transduced to express BCR-
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Figure 3.3. Timeline of ponatinib events from discovery to present day.  This figure 
highlights the dates of the discovery of ponatinib (formerly AP24534), including 
preliminary studies, clinical trials, and events involving the approval, suspension, and 
resumption of sales (36-43).  
 
 
ABL with a wild-type or mutant tyrosine kinase domain.  From these studies, it was 
found that ponatinib inhibits both wild-type and mutant BCR-ABL kinase with IC50 
values between 0.37 and 2.0 nM (30).  Further, cell proliferation assays demonstrated 
inhibition at IC50 values ranging from 0.3 to 0.5 nM for unmutated and up to 36 nM for 
mutant BCR-ABL. It was also found that a dose of 40 nM was able to completely 
suppress the emergence of BCR-ABL resistant mutants in vitro; although, efficacy may 
be limited, particularly in examples with the E255V point mutation (IC50 of 36 nM).  
Finally, ponatinib also inhibited the activity of members of the VEGFR, FGFR, and 
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PDFR families at similar doses, but showed IC50 values >1000-fold higher for inhibition 
of insulin receptor and members of the cyclin kinase and aurora kinase families (30).  
Armed with this information, researchers proceeded to an in vivo xenograft mouse 
model (Figure 3.3) as is standard for in vivo CML studies.  Cells harboring native BCR-
ABL and BCR-ABLT315I were subcutaneously injected into the right flank in female 
mice, and these mice were given ponatinib at 10, 30 and 50 mg/kg doses.  The 10 and 30 
mg/kg doses were able to suppress tumor growth, while the 50 mg/kg dose was able to 
cause 96% reduction in mean tumor volume (30).  Pharmacokinetic studies of the 30 
mg/kg dose revealed mean plasma levels of 782, 561, and 8 nM at 2, 6, and 24 h 
postdose, respectively.  No PK data for the 50 mg/kg dose were reported.  This 
demonstrated that plasma concentrations of ponatinib effective against mutated forms of 
BCR-ABL could be sustained for 24 h using the 30 mg/kg dose. 
 
Moving ponatinib into clinical trials 
The first phase I trial involving ponatinib enrolled CML and Ph+ALL patients 
who were resistant or had relapsed while on standard of care therapy.  The goal of the 
study was to determine the maximum tolerated or recommended daily dose of ponatinib, 
while also investigating the safety, antileukemic activity, and PK/PD profile of the drug 
(44).  Eighty-one patients were enrolled, 65 of whom had Ph+ disease.  Daily doses of 2-
60 mg were tested.  No dose-limiting toxic effects were observed up to the 30 mg/day 
dose, while the 60 mg/day dose led to toxicity in 6/19 patients.  Adverse effects included 
elevation of pancreatic enzymes, clinical pancreatitis, fatigue, and increases in liver 
enzymes AST and ALT (Table 3.1).  Pharmacokinetic studies demonstrated a linear 
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relationship between dose and peak blood concentration.  For the 30 mg/day dose, the 
half-life was 22 h, and the trough blood concentration was above 40 nM, which is the 
concentration thought to be required to prevent the emergence of BCR-ABL mutants 
resistant to ponatinib.  The antileukemic activity of the drug was also promising; 42/43 
(98%) of patients with CP-CML (chronic phase CML, Table 3.2) had a complete 
hematologic response (CHR, see Table 3.3 for clinical terms); 31/43 (72%) had a major 
cytogenetic response (MCyR), 27/43 (63%) had a complete cytogenetic response 
(CCyR), and 19 patients had a major molecular response (MMR).  Further, all 12 patients 
with CP-CML and the T315I mutation had a complete hematologic response, and 8/12 
(67%) had a MMR.  With these results, despite a dose of 30 mg/day showing excellent 
results in the phase I trial, researchers proceeded to a phase II study using the 45 mg/day 
dose to ensure coverage of any and all BCR-ABL TKI resistant clones (44-46).  
The phase II PACE (Ponatinib Ph+ALL and CML Evaluation) trial enrolled 449 
patients: 267 with CP-CML, 83 with AP-CML, and 94 with BC-CML or Ph+ALL (Table 
3.2) (45).  Patients were eligible for the study if they were resistant or had unacceptable 
side effects to dasatinib or nilotinib, or harbored the T315I mutation.  Thirty-seven 
percent of patients had received two TKIs, and 55% had received 3 or more.  Of those 
who had received dasatinib or nilotinib, 88% were resistant.  At 12 months after the 
initiation of ponatinib therapy, 56% of patients with CP-CML had a MCyR, 46% had 
CCyR, and 34% had MMR (Table 3.3).  Interestingly, higher response rates were reached 
for those with the T315I mutation, but presence of this mutation was determined not to be 
a significant prognostic factor (53).  Six patients had an unsustained MCyR, but no 
change in mutation status was seen in those with unsustained responses.  In patients with 
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Table 3.2. World Health Organization (WHO) definitions and descriptions of CML 





Table 3.3. Clinical terminology describing patient response in CML (52). 
 
Chronic Phase Accelerated Phase Blast Crisis 
≤ 10% blast cells in blood 
and bone marrow 
10% - 19% blast cells in blood 
and bone marrow 
 
≥ 20% blast cells in blood and 
bone marrow 
•  WBCs still capable of 
fighting infection 
•  High basophil count            
(≥ 20% of WBC differential)  
•  Persistent thrombocytopenia 
unrelated to therapy 
•  Persistent thrombocytosis 
unresponsive to therapy 
•  Increasing WBC and spleen 
size unresponsive to therapy 
•  Cytogenic evidence of clonal 
evolution  
•  Large clusters of blasts in 
bone marrow 
•  Extramedullary blast 
proliferation 
Mild symptoms, if any Fever, poor appetite, weight 
loss, fatigue 
Fever, loss of appetite, weight 
loss, fatigue, bleeding, 
infections common, stomach 
pain, bone pain 
Clinical Terminology Abbreviation Description 
Hematologic response HR Decrease in the number of WBCs from the 
time of diagnosis 
Complete hematologic 
response 
CHR WBC count returns to normal level and no 
immature cells seen in the blood 
Cytogenetic response CyR Any reduction in Ph chromosome levels 
from baseline established at diagnosis 
Major cytogenetic 
response 
MCyR 0%-35% of cells are Ph+ 
Complete cytogenetic 
response 
CCyR 0% Ph+ cells measured by cytogenetic testing  
Molecular response MR Any reduction in BCR-ABL transcript levels 
as measured by PCR 
Major molecular 
response 




CMR Undetectable BCR-ABL transcript levels 
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AP-CML and BC-CML (Table 3.2) or Ph+ALL, rates of major hematologic response at 6 
months were 39% and 31%, respectively. Importantly, no single mutation conferring 
resistance was seen.   
Responses were observed for each of 15 mutations present at baseline for CP-
CML patients, and 26 unique mutations in total were counted (54).  Response rates were 
similar for those with and without mutant BCR-ABL, with MCyR occurring in 56% of all 
patients, 49% of patients with native BCR-ABL, 64% for those with 1 mutation, 62% for 
those with 2 or more mutations, and 74% for those with the T315I mutant (54).  Though 
no single point mutation has shown resistance against ponatinib, compound mutations 
developed in 21 patients, mainly those in BC-CML or Ph+ALL.  While ponatinib is 
expected to inhibit a number of compound mutants based on their in vitro cell 
proliferation IC50 values, a select few clinically reported compound mutants, including 
G250E/T315I, E255K/T315I, and E255V/T315I (IC50 values of 49 nM, 106 nM, and 425 
nM, respectively (28)), have shown increased resistance.  Because these compound 
mutants appear only infrequently, and based on these results from the clinical trials 
described above, ponatinib was granted accelerated FDA approval in December 2012 for 
use in resistant or intolerant CML or Ph+ALL or in patients harboring BCR-ABLT315I 
(Figure 3.3) (36). 
 
Safety profile of ponatinib 
Minimal safety concerns were initially reported. Sixty-seven percent of patients 
had dose interruptions, with 55% having at least one dose reduction.  Serious 
nonhematologic adverse drug events (ADEs) included pancreatitis, abdominal pain, and 
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myocardial infarction (MI).  Serious hematologic ADEs included thrombocytopenia, 
anemia, neutropenia, and pancytopenia.  Cardiovascular, cerebrovascular, and peripheral 
vascular events were observed in 7.1%, 3.6%, and 4.9% of the population, respectively; 
although it was speculated these were minimally related to the treatment.  Serious arterial 
thrombotic events were seen in 8.9% of patients on ponatinib, predominantly in patients 
with either documented ischemic conditions or with one or more risk factors at baseline. 
An analysis of the cardiovascular risk profile of ponatinib was performed with the 
results of the PACE trial (55).  There were 14 cases of myocardial infarction (MI), 5 of 
coronary artery disease, and 2 of angina (21 in total).  At the start of the study, 10/21 had 
active cardiovascular disease, and 5 had valvular or pericardial disease.  Further, 81% of 
these patients had at least two cardiovascular risk factors, while 95% had at least 1.  At 
the time of the drug’s approval, the label noted that 8% of patients had cardiovascular, 
cerebrovascular, and peripheral vascular thrombosis including fatal MIs and strokes (56).  
However, at a 2.7-year follow-up of the phase I study, 48% of patients reported adverse 
vascular events.  At a follow-up of the phase II study (median time of 1.3 years), 24% of 
patients had an MI, stroke, limb ischemia, or stenosis of the vessels of the heart, 
extremities or brain requiring revascularization (56).  It is unlikely that these events can 
be fully explained by underlying cardiovascular risk, as numbers this high were not seen 
in late phase trials of other TKIs.  Further, adverse events occurred as soon as 2 weeks 
into therapy and even in patients with no cardiovascular risk factors (56).   
As the increased cardiovascular risks associated with ponatinib were uncovered, 
ponatinib was removed from the market in October 2013 (37).  Additionally, the EPIC 
trial (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia), a phase III 
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trial investigating the use of ponatinib versus imatinib for first-line use, was halted 
following this decision.  The FDA and ARIAD “mutually agreed the trial should be 
terminated” due to the now understood increased cardiovascular risks associated with 
ponatinib (57).  Ponatinib has since been put back on the market for a narrowed patient 
population: treatment of adults with T315I-positive CML (any phase) and Ph+ALL, and 
treatment of adult patients for whom no other TKI therapy is indicated (56).  A timeline 
highlighting important events in the discovery and approval process of ponatinib is 
provided in Figure 3.3. 
One question that still remains concerning TKI therapy is whether or not the 
therapy can ever be discontinued without resulting in disease recurrence.  The STIM trial 
(Evaluation of the Persistence of the Complete Molecular Remission After Stopping 
Imatinib Chronic Myeloid Leukemia) was undertaken to determine if those with the 
deepest level of disease suppression could successfully be taken off of imatinib therapy 
without disease recurrence (58).  Briefly, patients on imatinib for at least 3 years and had 
been in CMR (deepest response) for at least 2 years were eligible for the study.  They 
were taken off imatinib therapy and monitored for a median follow-up time of 17 months.  
Fifty-four out of 100 patients had a molecular relapse, and 46 were relapse-free at a 
median follow up time of 14 months.  The majority of relapses (35/54) occurred in the 
first 3 months, and only 1 patient relapsed after 7 months.  Males, those with a good 
prognosis (based on the Sokal scale for CML prognosis (59)), and those with imatinib 
therapy duration of >50 months were more likely to remain in CMR.  Encouragingly, all 
of the patients who relapsed remained sensitive to imatinib therapy, and the median time 
to CMR return was 3 months.  Imatinib therapy infrequently leads to sustained CMR for 
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the 2 years required for acceptance into this study.  The cumulative incidence of CMR on 
imatinib therapy was 0.5% at 1 year and 8.3% at 5 years in newly diagnosed CP-CML 
patients (60). Studies with the second-generation TKI nilotinib showed that patients on 
nilotinib were more likely to be in CMR at 24 months than those on imatinib (22.1% vs 
8.7%) (61).  The PACE trial results indicated that 15% of patients who entered treatment 
with CP-CML and 23% of patients with the T315I mutation were in CMR at 12 months 
(45). 
Therefore, patients on ponatinib may be more likely to successfully discontinue 
treatment than those taking imatinib. 
 
Conclusions and Place in Therapy for Ponatinib 
Ponatinib is currently FDA-approved for T315I-positive CML (in any phase) and 
T315I-positive Ph+ALL, or any phase of CML or Ph+ALL for which no other TKIs are 
indicated (14).  As it has only been available on the market since December 2012, more 
time is required to sufficiently analyze the effect that ponatinib will have on long-term 
CML and Ph+ALL therapy.  It is speculated that more potent inhibition of BCR-ABL 
earlier in therapy with drugs like ponatinib may lead to decreased development of 
resistance (11, 45).  Regardless of the time of therapy, detection and quantitative 
monitoring of patients on ponatinib for potentially resistant (poly)mutant subclones could 
be performed using newer methods including ligase-dependent PCR (62) or long-range 
next generation sequencing (63).  The toxicity profile of ponatinib, however, precludes its 
use alone as a frontline agent (64).  To circumvent this unwanted toxicity, one possibility 
may include using ponatinib in combination with other therapeutic agents to allow for 
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dose-lowering of ponatinib.  Our lab has taken a multidomain targeting approach of 
concurrently inhibiting both the tyrosine kinase domain (with ponatinib) and the N-
terminal coiled-coil domain of BCR-ABL with a rationally designed peptidomimetic 
(65). Using this therapeutic strategy, we have shown the ability to lower the dose of 
ponatinib necessary for BCR-ABL inhibition (66), which would likely result in a safer 
toxicity profile (46).  This coiled-coil dimerization inhibitor has in fact shown activity by 
itself against the BCR-ABLT315I (66), as well as the BCR-ABL E255V/T315I compound 
mutant (unpublished data), which is not targetable by any current TKI, and could be used 
as an alternative to ponatinib.  Other strategies include concurrently targeting BCR-ABL 
along with proteins and signaling pathways important to leukemia progression including 
MUC-1 (67), Alox5 (67), STAT3 (68), and Hedgehog (69), to name a few.  It is also 
expected that combination targeting with ponatinib may result in reducing the emergence 
of resistance in cells, which could lead to greater long-term success (25, 70).  Lastly, it 
has also been reported that dosing of potent drugs such as ponatinib with a high risk of 
ADEs should be lowered to the minimum effective dose rather than the maximum 
tolerable dose, which in this case turned out to be toxic in clinical trials (46). 
While ponatinib is the only approved TKI that targets BCR-ABLT315I, other drugs 
in development capable of targeting this resistant form of BCR-ABL in either CML or 
Ph+ALL include: rebastinib (formerly DCC-2036), an ABL switch control inhibitor (71, 
72); HG-7-85-01, a multitargeted kinase inhibitor (73); and AT9283, a multitargeted 
kinase inhibitor (74, 75).  For more comprehensive lists and discussions of ATP-
competitive, allosteric, and other inhibitors of BCR-ABL, see the following papers (4, 
16).  Additionally, drugs are being developed to target CML stem cells by attacking other 
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signaling pathways (24, 76).  One example includes SL-401, a therapeutic targeting the 
IL-3 receptor that is overexpressed on CML stem cells (77, 78).  
Due to the broad-spectrum activity of ponatinib for tyrosine and other kinase 
families (Table 3.1) (79-83), the drug is also being examined for use in other cancers and 
malignancies.  As of March 2014, ponatinib was either being used in or currently 
suspended from six clinical trials for cancers and malignancies other than CML or Ph+ 
ALL via inhibition of FGFR, EGFR, ALK, and RET (84-89).  Ultimately, ponatinib may 
prove to be useful in combination with other agents that robustly target BCR-ABL 
(multidomain targeting) (66), or other pathways involved in cancer progression besides 
BCR-ABL (for example, in combination with STAT3 inhibitors (68)) for a synthetically 
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MULTIDOMAIN TARGETING OF BCR-ABL BY DISRUPTION  
 
OF OLIGOMERIZATION AND TYROSINE KINASE  
 





The oncoprotein BCR-ABL, the causative agent of chronic myeloid leukemia 
(CML), requires homo-oligomerization via a coiled-coil domain to function (1-4).  While 
tyrosine kinase inhibitors (TKIs) have shown great efficacy as treatment options for 
CML, their use may cause an acquisition of mutations in the tyrosine kinase domain 
which prevent TKI binding and lead to a loss in activity (5).  Previously, we have shown 
that a rationally modified coiled-coil domain (CCmut3) can disrupt this oligomerization, 
inhibit proliferation, and induce apoptosis in CML cells (6). Here, we show that using the 
most recently approved TKI, ponatinib (IclusigTM), in combination with CCmut3 allows a 
dose reduction of ponatinib and increased therapeutic efficacy in vitro measured by 
reduction in kinase activity, induction of apoptosis via caspase-3/7 and 7AAD/Annexin V 





combination was effective not only in cells containing wild-type BCR-ABL (K562, 
Ba/F3-p210) but also cells with BCR-ABL containing the T315I mutation (Ba/F3-p210-
T315I).  In addition, we report for the first time the ability of CCmut3 alone to inhibit the 
T315I mutant form of BCR-ABL.  This novel combination may prove to be more potent 
than single agent therapies and should be further explored for clinical use. 
 
Introduction 
 CML is characterized by the presence of the Philadelphia (Ph) chromosome, 
created from a reciprocal translocation between the long arm of chromosome 9 and the 
short arm of chromosome 22.  This unique genetic abnormality produces the cytosolic 
fusion protein, BCR-ABL (1, 2).  Signaling through survival and proliferation pathways 
including RAS, PI3K/AKT, and Src family kinases, BCR-ABL is the driving force for 
the development and persistence of CML (7, 8).  Activation of this protein occurs via 
homo-oligomerization at the coiled-coil (CC) domain, located on the N-terminus of the 
Bcr portion (Figure 4.1).  Upon homo-dimer and homo-tetramer formation, trans-
autophosphorylation can occur most notably at the tyrosine kinase domain, among other 
locations (3, 4).  This autophosphorylation is responsible for the constitutive tyrosine 
kinase activity present in the cell, the primary oncogenic driver responsible for CML 
disease manifestation (9).   
 Currently, most clinically available drugs for CML treatment are designed to 
block this tyrosine kinase activity by binding to and inhibiting the tyrosine kinase domain 
(5).  Although often effective, these drugs are noncurative and may result in the 






Figure 4.1. Targeting two distinct domains of BCR-ABL.  CCmut3 (left) targets the 
coiled-coil oligomerization domain of BCR-ABL while ponatinib (right) targets the 
tyrosine kinase domain of BCR-ABL.  BCR-ABL domains labeled as follows: CC = 
Coiled-Coil (Oligomerization Domain) (4); S/T Kinase = Serine/Threonine Kinase (10); 
DH/PH = Dbl Homology / Pleckstrin Homology (11, 12); Y-Kinase = Tyrosine Kinase; 
DB = DNA-Binding (13); AB = Actin-Binding (14-16); SH3 = Src Homology 3 ; SH2 = 
Src Homology 2; NLS = Nuclear Localization Signal; NES = Nuclear Export Signal; G-
actin = Globular Subunit of Actin; F-actin = Fibrous Subunit of Actin.  Numbers above 
domains represent approximate amino acid residues.  
 
Such mutations prevent the binding and activity of TKIs (17, 18).  One such mutation in 
BCR-ABL, T315I, evades binding to first generation (imatinib) and second generation 
(dasatinib and nilotinib) TKIs (19).  The recent development of ponatinib (Iclusig® –
45mg, daily), a third generation TKI, has now provided a means by which to combat 
many resistant forms of BCR-ABL, including those with the T315I mutation (20, 21).  
However, compound mutations (defined as two or more mutations in a single molecule), 
such as E255V/T315I, confer high-level resistance to all currently available TKIs (22).  
Indeed, patients whose molecular profile identifies compound mutations in BCR-ABL 
(e.g., G250E/T315I, E255V/T315I) would also be expected to be resistant to ponatinib 
(23).  It is thought that BCR-ABL inhibitors with “broader mutational coverage … may 





progression” (24).  In addition, because ponatinib shows some nonspecificity of kinase 
inhibition, side effects include thrombocytopenia, rash, and arthralgia; ponatinib’s dose-
limiting toxicity is pancreatitis, indicating a need for strategies that would reduce its dose 
(25, 26).  With this in mind, the use of two BCR-ABL-targeted drugs with distinct 
mechanisms of action may provide this broader mutational coverage and increase 
potency against BCR-ABL. 
 We recently demonstrated that disruption of oligomerization of BCR-ABL is an 
effective means of inhibiting its activity (6, 27).  A mutant coiled-coil was designed to 
bind to and inhibit the BCR-ABL coiled-coil domain (responsible for oligomerization).  
This mutated coiled-coil, termed CCmut3, contains six mutated residues from the wild-
type BCR-ABL coiled-coil domain (C38A, K39E, S41R, L45D, E48R, Q60E) designed 
to both favor hetero-dimerization between CCmut3 and endogenous BCR-ABL 
(CCmut3:BCR-ABL) and to disfavor homo-dimerzation between two CCmut3 molecules 
(CCmut3:CCmut3).  Previous work has validated CCmut3 as a potential therapeutic for CML 
(6).  To devise a more potent therapy, combining CCmut3 with ponatinib was attempted as 
a “dual-hit” strategy (Figure 4.1).  Using this strategy, both the oligomerization domain 
and the tyrosine kinase domain of BCR-ABL can be targeted concurrently to provide an 
enhanced therapeutic effect. 
In the following studies, the “dual-hit” hypothesis was tested by treating CML 
cells with both CCmut3 and ponatinib (or each agent alone).  Experiments were performed 
in cells containing the wild-type, unmutated form of BCR-ABL (K562; Ba/F3-p210), as 
well as cells containing the T315I mutation in BCR-ABL (Ba/F3-p210-T315I).  Western 





downstream targets.  Colony forming assays were used to measure the inhibition of both 
transformative ability and proliferation of CML cells.  Finally, the induction of apoptosis 
was studied by measuring the activation of intracellular caspases and by 7AAD and 
Annexin V staining.  In most cases, CCmut3 in combination with ponatinib resulted in 
more potent inhibition of BCR-ABL than either agent alone.  We also report, for the first 
time, effective use of our CCmut3 inhibitor in T315I mutant cells. 
 
Materials and Methods 
Construct Design 
The constructs pEGFP-CCmut3 and pmCherry-CCmut3 were subcloned as 
previously described (6, 28). 
 
Ponatinib 
Ponatinib HCl salt (AP24534) was obtained from ChemieTek (Indianapolis, IN, 
USA) and stored at -20°C as a 10 mM stock solution.  Serial dilutions (100 µM and 10 
nM) of stock solution were made prior to cell experiments.  
Cell Lines, Transfection Method, and Ponatinib Treatment 
Cells were maintained at 37°C and 5% CO2 in a humidity-controlled incubator.   
 
K562 cells 
K562 cells, human leukemia BCR-ABL+ cells (gifted from Kojo Elenitoba-
Johnson, University of Michigan), were grown in RPMI 1640 media supplemented with 





medium).  The cells were passaged every 2 to 3 days, and seeded at a density of 5.0 x 104 
cells/mL.  Transfections were carried out 2 days following cell passaging.  Cells (2.0 x 
106) were collected and transfected with 6 µg of either pEGFP, pEGFP-CCmut3, 
pmCherry, or pmCherry-CCmut3 according to the Cell Line Nucleofector Kit V protocol, 
program T-013, using the Amaxa Nucleofector II (Lonza Group, Basel, Switzerland).  
Immediately following transfection, cells were added to 10 mL RPMI complete medium 
and treated with ponatinib at 100 pM, 1 nM, or 10 nM doses.  
 
Ba/F3 cells 
Ba/F3 cells, mouse pro-B cells (gifted from Michael Deininger, University of 
Utah) transduced to express either p210-BCR-ABL (Ba/F3-p210) or p210-BCR-ABL and 
containing the T315I mutation (Ba/F3-p210-T315I) were maintained in RPMI complete 
medium.  Parental Ba/F3 cells without BCR-ABL (also from Deininger), used as control, 
were grown in RPMI 1640 complete medium supplemented with IL-3 produced in 
WEHI-3 cells (29).  All groups of cells were passaged every 2 to 3 days, and seeded at a 
density of 1.0 x 105 cells/mL.  Transfection method (Amaxa, Kit V) included program X-
001, 3.0x106 cells, and 4!μg DNA per transfection.  In addition, immediately following 
transfection, transfected cells were incubated in plain RPMI 1640 for 20 min, as per 
optimized conditions.  Cells were then added to 10 mL RPMI complete medium and 








Kinase Activity (Western Blot) 
Western blot was done as previously described (6).  In short, 48 h following 
transfection and treatment with ponatinib, 2.0 x 106 cells were collected from each 
transfection and treatment group, and subjected to at least one freeze-thaw cycle at -80°C.  
Next, cells were lysed using radioimmunoprecipitation (RIPA) buffer with protease 
inhibitor (1:200) added and sonicated at 70% amplitude for two pulses of 5 s each. After 
electrophoresis and transfer, the membrane was probed using a combination of primary 
antibodies against phospho-c-Abl (Cell Signaling, #2861), phospho-STAT5 (Abcam, 
ab32364), phospho-CrkL (Cell Signaling, #3181) and GAPDH (Cell Signaling, #5174) as 
a loading control, followed by incubation with secondary HRP-conjugated antibody (Cell 
Signaling, #7074).  Finally, blots were imaged using a FluorChem FC2 imager 
(AplhaInnotech) after addition of chemiluminescent substrate (WesternBright™ 
Quantum Western blotting detection kit, Advansta).  Assay was performed three separate 
times (n=3). 
 
Colony Forming Assay 
Both EGFP and EGFP-CCmut3 were transfected into separate groups of cells on 
day 0.  One day following transfection, 1.0 x 106 cells per treatment group were collected 
and resuspended in 1.0 mL PBS.  Through serial dilutions, 1.0 x 103 cells in Isocove’s 
modified Dulbecco’s media (IMDM) with 2% FBS were seeded into methylcellulose 
medium in the absence of cytokines (MethoCult H4230 for K562 cells, MethoCult 
M3234 for p210 and p210-T315I cells) or in the presence of cytokines (MethoCult GF 





(0, 100 pM, 1 nM, or 10 nM) to the methylcellulose medium.  Colonies formed were 
counted after 7 days of incubation.  All reagents were purchased from Stem Cell 
Technologies, Vancouver, BC, Canada.  Assay was run three separate times (n=3) in 
duplicate.    
 
7AAD and Annexin V Staining 
Seventy-two h following transfection and treatment with ponatinib, 5 mL of cells 
from each treatment were pelleted and resuspended in 0.5 mL of 1X Annexin Binding 
Buffer (Invitrogen).  Next, 0.5 μL of 1 mM 7-aminoactinomycin D (Invitrogen) was 
added to each sample and allowed to incubate for 45 min.  Five minutes before flow 
cytometric analysis, 1.0 μL of Annexin V (APC) (Invitrogen) was added to each sample.  
Analysis was performed using the FACSCantoII analyzer with BD FACSDiva software.  
Fluorophores were excited/emitted at the following wavelengths: EGFP, 488/530nm; 
mCherry, 587/610nm; 7AAD, 488/660nm; and APC, 635/660nm.  Untransfected cells 
were eliminated from analysis by gating for cells only showing EGFP or mCherry 
fluorescence.  Percentage of apoptosis / necrosis was calculated by combining the 
transfected cells (EGFP-positive or mCherry-positive) that stained positively for 7AAD 
and those that stained positively for APC.  Assays were run in triplicate (n=3).    
 
Caspase-3/7 Assay 
Caspase-3/7 Assay was performed as previously described (6).  In short, 48 h 
following transfection and treatment with ponatinib, 3.0x106 cells were pelleted and 





lysis buffer (Invitrogen).  Lysates were then mixed with 50µL of 2X AMC-DEVD 
substrate in a 96-well plate and allowed to incubate in the dark at room temperature for 
30 min.  Following incubation, fluorescence was measured on a SpectraMax M2 plate 
reader (Molecular Devices, Sunnyvale, CA, USA).  Lysates from three separate 
transfections were analyzed on the same plate for caspase-3/7 activity (n=3).   
 
Cell Proliferation 
Seventy-two and 96 h following transfection of either pmCherry or pmCherry-
CCmut3, trypan blue exclusion was used to determine proliferation/viability of cells (6).  
Cell counts were performed using a standard light microscope.  
 
Statistical Analysis 
Experiments were analyzed using one-way ANOVA with Tukey’s posttest, or a 
Student’s t-test, as mentioned in figure legends. 
 
Results 
Kinase activity following CCmut3 and ponatinib treatment 
Western blots measuring kinase activity were performed using CCmut3 and 
ponatinib to examine the potential oligomeric disruption and signaling inhibition of 
endogenous BCR-ABL.  A range of ponatinib between 1 nM and 100 nM was originally 
tested based on previous in vitro studies (20) in order to determine the lowest dose of 
ponatinib that could be used in combination with CCmut3 (data not shown).  The current 





 Because BCR-ABL undergoes trans-autophosphorylation upon dimerization at 
the coiled-coil domain (3), oligomeric disruption in this case was measured according to 
the phosphorylation state of BCR-ABL (Figure 4.2A).  In addition, inhibition of BCR-
ABL signaling, thus inhibition of kinase activity, was measured by examining the 
phosphorylation states of BCR-ABL downstream target STAT5 (Figure 4.2A) and direct 
substrate CrkL (Figure 4.2B).  When comparing equal doses of ponatinib with or without 
CCmut3, BCR-ABL phosphorylation appears to most significantly decline when adding 1 
nM of ponatinib in combination with CCmut3 (Figure 4.2A, lane 5 vs. lane 2).  At this 
same dose, the phosphorylation of both STAT5 (Figure 4.2A, lane 5) and CrkL (Figure 
4.2B, lane 6) is greatly diminished.  Complete eradication of phosphorylation of STAT5 
and CrkL appears at 10 nM ponatinib (Figure 4.2A, lane 3; Figure 4.2B, lane 7).  One 
further lower dose of ponatinib, 100 pM, was also tested (Figure 4.2B, lanes 3 and 4); no 
significant difference in CrkL phosphorylation with the combination was observed at this 
dose.  Because p-BCR-ABL activity is obliterated when 10 nM ponatinib is used in 
combination with CCmut3 (Figure 4.2A, lane 6 vs. lane 3), we chose to reduce ponatinib to 
a subsaturating dose of 1 nM in subsequent experiments.    
 
CCmut3 plus 1 nM Ponatinib Treatment Activates Caspase-3/7 
Following analysis of the phosphorylation state of the signaling pathways, 
apoptotic induction following treatment was measured.  Here, the activity of the effector 
caspase-3/7 upon treatment was analyzed as a measure of apoptosis.  In order to suggest 
that a combination of CCmut3 and ponatinib provides an enhanced effect over each 








                 
                 
Figure 4.2.  Western blots: Oligomeric disruption and decrease in BCR-ABL 
downstream signaling in K562 cells. Upon 48 hour treatment of K562 cells with CCmut3 
and ponatinib or EGFP (transfection control) and ponatinib, phosphorylation states of (A) 
BCR-ABL and downstream target STAT5, or (B) direct BCR-ABL substrate CrkL 
(including 100 pM dose of ponatinib) were assessed (n=3 for both (A) and (B), 









and (ii) EGFP with the corresponding ponatinib dose.    Figure 4.3 shows that the 
combination consisting of CCmut3 and 1 nM ponatinib (last bar) results in significant 
induction of apoptosis compared to all other groups.  Importantly, the enhanced apoptosis 
seen with this combination (last bar) is significantly greater than both CCmut3 alone 
(second bar) and EGFP with 1 nM ponatinib (fifth bar).   
 
Induction of Apoptosis and Necrosis in K562 Cells. 
Flow cytometry was utilized to measure apoptosis and necrosis of cells treated 
with our combination.  7-Aminoactinomycin D (7AAD), which binds the DNA of dead 
and dying cells no longer possessing an intact membrane, and Annexin V, which binds to 
the externalized apoptotic marker, phosphatidylserine, were used to determine apoptosis.  
To ensure that we tested the effects of the combination treatment, only cells showing 
EGFP fluorescence (thus, CCmut3-positive or positive for control) were selected for and 




Figure 4.3.  Induction of apoptosis by measuring intracellular activation of caspase-3/7.  
Forty-eight h following transfection and treatment of K562 cells, activity of caspase-3/7 
was analyzed via fluorescence (n=3). Values reported as overall means ± SD; one-way 








Figure 4.4.  Induction of apoptosis and necrosis in K562 cells using CCmut3 and/or 
ponatinib measured by Annexin V (apoptotic) and 7AAD (necrotic) staining.  Seventy-
two h following transfection and treatment, K562 cells were gated for EGFP fluorescence 
and cellular apoptosis was assessed using Annexin V and 7AAD dyes. A-F) 
Representative individual contour plots from each transfection and treatment group 
showing only EGFP-gated cells. Q1 = 7AAD+/AnnexinV- (necrotic); Q2 = 
7AAD+/AnnexinV+ (apoptotic); Q3 = 7AAD-/AnnexinV- (healthy); Q4 = 7AAD-
/AnnexinV+ (apoptotic) G) Percentage of apoptosis and necrosis induced by each 
transfection and treatment group (plots A-F), n=3.  Values reported as overall mean ± 









combination of CCmut3 and 1 nM ponatinib (Figure 4.4F) induces the highest percent of 
apoptosis and necrosis.  Notably, this combination is higher than each of its individual 
components (Figure 4.4F vs Figures 4.4B and 4.E).  These results are summarized in 
Figure 4.4G.   
 
Apoptotic and Necrotic Effect Is Not K562 Cell Specific 
To ensure that the combination induces apoptosis and necrosis in other cells 
harboring BCR-ABL (besides human K562 cells), experiments were conducted in mouse 
Ba/F3 cells expressing the 210 kDa BCR-ABL fusion protein (Ba/F3-p210).  The full 
length p210 form of BCR-ABL, the product of the BCR-ABL hybrid gene, causes 
leukemic cell growth in hematopoetic cell lines, and is known to induce leukemia in 
animal models (31).  Ba/F3-p210 cells have been engineered to depend on BCR-ABL for 
growth, and stably express EGFP along with BCR-ABL (32, 33).  Therefore, in these 
experiments, mCherry was used as a negative control and as the CCmut3 tag (instead of 
EGFP).  Flow cytometry was again utilized to study apoptosis and necrosis, where the 
cell population that contained both EGFP (BCR-ABL positive) and mCherry 
(transfection positive) was analyzed. Figure 4.5 shows the induction of apoptosis in 
Ba/F3-p210 cells, where the data agree with the results also seen in K562 cells (Figure 
4.4).  Again, the combination including 1 nM ponatinib (Figure 4.5F) shows the highest 
induction of apoptosis and necrosis, higher than 1 nM ponatinib alone (Figure 4.5E) and 
also higher than CCmut3 alone (Figure 4.5B).  These results are summarized in Figure 










Figure 4.5.  Induction of apoptosis and necrosis measured by Annexin V and 7AAD 
staining in Ba/F3-p210 cells.  Seventy-two h following transfection and treatment with 
ponatinib, Ba/F3-p210 cells were gated on EGFP (internal presence of BCR-ABL) and 
mCherry (presence of control or CCmut3) fluorescence, and the percentage of cells 
undergoing apoptosis and necrosis was assessed via flow cytometry. A-F) Representative 
individual scatterplots (as opposed to contour plots with K562 cells to distinguish cell 
type) from each transfection and treatment group showing only EGFP and mCherry-gated 
cells. Q1 = 7AAD+/AnnexinV- (necrotic); Q2 = 7AAD+/AnnexinV+ (apoptotic); Q3 = 
7AAD-/AnnexinV- (healthy); Q4 = 7AAD-/AnnexinV+ (apoptotic) G) Percentage of 
apoptosis and necrosis induced by each transfection and treatment group (plots A-F), 
n=3.  Values reported as overall mean ± SD; one-way ANOVA with Tukey’s posttest, 








Decrease in the Transformative Ability of K562 Cells 
Transformative ability of K562 cells following treatment with our combination 
was tested using a colony forming assay, where outgrowth of colonies were a direct 
measure of oncogenic potential.  Results are shown in Figure 4.6.  With CCmut3 alone, it 
should be noted that this construct causes a three-fold decrease in the amount of colonies 
formed compared to EGFP (Figure 4.6, second bar vs. first bar).  With CCmut3 plus 1 nM 
ponatinib (Figure 4.6, last bar), the combination therapy shows a significant effect with a 
near six-fold decrease in the amount of colonies formed compared to EGFP (Figure 4.6, 
last bar vs. first bar), an over five-fold decrease compared to EGFP plus 1 nM ponatinib 
(last bar vs. fifth bar) and a two-fold decrease compared to the number of colonies 
formed when treated with CCmut3 alone (last bar vs. second bar).  This highlights 
specifically the benefit of CCmut3 + Pon 1 nM compared to CCmut3 alone or EGFP + Pon 1 
nM, indicated by asterisks in Figure 4.6. In Ba/F3-p210 cells, however, the reduction in 
transformative ability seemed to be mainly mediated by treatment with CCmut3.  In Figure 
4.7, CCmut3 was significantly lower than the EGFP control (second bar vs. first bar).  
Likewise, CCmut3 + Pon 100 pM or CCmut3 + Pon 1 nM were both significantly lower than 
ponatinib alone at either dose (fourth bar vs. third bar, sixth bar vs. fifth bar).  
Importantly, CCmut3 + Pon 100 pM and CCmut3 + Pon 1 nM were not significantly lower 
than CCmut3 alone.  In other words, the combination did not enhance the reduction in 








Figure 4.6.  Colony forming assay: transformative ability of K562 cells with different 
treatment groups.  Colony forming units counted 7 days after seeding transfected cells 
into methylcellulose media supplemented with corresponding dose of ponatinib.  Data 
presented as percentage of growth from EGFP control with no ponatinib added (n=3 in 
duplicate).  Values reported as overall mean ± SEM; one-way ANOVA with Tukey’s 





Figure 4.7. Colony forming assay: transformative ability of Ba/F3-p210 cells with 
different treatment groups.  Colony forming units counted 7 days after seeding 
transfected cells into methylcellulose media supplemented with corresponding dose of 
ponatinib.  Data presented as percentage of growth from EGFP control with no ponatinib 
added (n=3 in duplicate).  Values reported as overall mean ± SEM; one-way ANOVA 






Induction of Apoptosis in Cells Containing the T315I Mutation 
BCR-ABL cells containing the T315I tyrosine kinase domain mutation are known 
to be resistant to most TKIs.  Ponatinib is known to be effective against these cells, albeit 
with a higher in vitro IC50 (20).  Because ponatinib is a pan-inhibitor of BCR-ABL, 
higher dosing may lead to unintended inhibition of other receptor tyrosine kinases, 
potentially leading to increased side effects (in vivo) (26, 34).   Therefore, the 
combination was tested in BCR-ABL-containing Ba/F3 cells which harbor the T315I 
mutation (Ba/F3-p210-T315I cells).  Notably, the combinations of CCmut3 with both 1 nM 
and 10 nM ponatinib showed significantly higher induction of apoptosis/necrosis than 
corresponding ponatinib doses alone (Figure 4.8F vs. 4.8E, and 4.8H vs. 4.8G).  Overall, 
CCmut3 with 10 nM ponatinib works more effectively than all other treatments (Figure 
4.8H vs. 4.8A-G).  All results are summarized in Figure 4.8I.  
 
Transformative Ability and Proliferation of Cells 
Containing the T315I Mutation 
Transformative ability of Ba/F3-p210-T315I cells treated with the CCmut3 and 
ponatinib combination was also tested (Figure 4.9).  Again, CCmut3 alone reduced 
transformative ability, this time by ~40% compared to EGFP control (Figure 4.9, second 
bar vs. first bar).  However, as seen in the Ba/F3-p210 experiment, the combination did 
not provide additional benefit over either agent alone.  Therefore, to support the evidence 
of anti-proliferative activity caused by CCmut3 alone, a cell proliferation assay was also 
performed.  CCmut3 alone was also found to inhibit Ba/F3-p210-T315I cell proliferation 









Figure 4.8. Induction of apoptosis and necrosis measured by Annexin V and 7AAD 
staining in Ba/F3-p210-T315I cells.  Seventy-two h following transfection and treatment 
with ponatinib, Ba/F3-T315I cells were gated on EGFP and mCherry fluorescence and 
the percentage apoptotic/necrotic cells was assessed as before.  A-H) Representative 
individual scatterplots from each transfection and treatment group showing EGFP and 
mCherry-gated cells. Q1 = 7AAD+/AnnexinV- (necrotic); Q2 = 7AAD+/AnnexinV+ 
(apoptotic); Q3 = 7AAD-/AnnexinV- (healthy); Q4 = 7AAD-/AnnexinV+ (apoptotic).  I) 
Percentage of apoptosis and necrosis induced by each transfection and treatment group 
(plots A-H), n=3. Values reported as overall mean ± SD; one-way ANOVA with Tukey’s 








Figure 4.9. Colony forming assay: transformative ability of Ba/F3-p210 cells harboring 
the T315I mutation (Ba/F3-p210-T315I cells) with different treatment groups.  Colony 
forming units counted 7 days after seeding transfected cells into methylcellulose media 
supplemented with corresponding dose of ponatinib.  Data presented as percentage of 
growth from EGFP control with no ponatinib added (n=3 in duplicate).  Values reported 
as overall mean ± SEM; one-way ANOVA with Tukey’s posttest, ** p < 0.01, *** p < 
0.005.  Notable significance shown.  
 
!
Figure 4.10. Cell proliferation of Ba/F3-p210-T315I cells as measured by trypan blue 
exclusion.  Cells were transfected with either mCherry or CCmut3.  The amount of live 
cells from each transfection group were counted after 72 and 96 h (n=3). Values reported 






points.   
Lastly, the CCmut3 and ponatinib combination did not have activity in the Ba/F3- 
parent cells (BCR-ABL negative, IL-3 dependent cells, data not shown) as expected, 
which suggests that the effects seen were only due to the presence of BCR-ABL. 
 
Discussion 
 We previously demonstrated the inhibitory effect of coiled-coil mutants on BCR-
ABL activity (6, 27, 35).  In this study, we sought to determine whether BCR-ABL 
inhibition could be enhanced by a “dual-hit” strategy.  Using this strategy, both the 
oligomerization domain and the tyrosine kinase domain of BCR-ABL were targeted 
concomitantly.  Both a novel coiled-coil therapeutic (CCmut3) and a recently approved 
TKI (ponatinib) were used.  BCR-ABL was further inhibited when these two agents were 
administered in combination, leading to decreased oncogenic potential and enhanced 
apoptosis in both BCR-ABL-positive myeloid K562 cells and Ba/F3-p210 lymphoid 
cells, including the T315I mutant Ba/F3-p210 cell line.  
 Kinase activity of BCR-ABL, including autophosphorylation and phosphorylation 
of downstream targets (STAT5, CrkL), was reduced to an extent by each agent alone and 
further reduced in combination.  The combination of CCmut3 and 10 nM ponatinib 
resulted in complete elimination of phosphorylation; therefore, a subsaturating dose of 1 
nM ponatinib was used for further studies.  With the goal of reducing the IC50 of 
ponatinib (3.9 nM in K562 cells (20)), a “dose-lowering capability” provided by CCmut3 
may be important in managing adverse drug events caused by off-target kinase inhibition 





 In both K562 and Ba/F3-p210 cells, induction of apoptosis (activation of caspase-
3/7, 7AAD/Annexin V binding) was enhanced using the combination of CCmut3 and 1 nM 
ponatinib.  Likewise, transformative ability (oncogenic potential) was diminished using 
the combination at the same ponatinib concentration in K562 cells.  However, in the 
Ba/F3-p210 cells, the diminished oncogenic potential seemed to be mediated solely by 
CCmut3, with no enhanced effect upon the addition of ponatinib. 
 To test the effects of the combination against cells containing the T315I mutation 
in BCR-ABL, a higher, 10 nM dose of ponatinib was included to account for the 
increased IC50 seen in the Ba/F3-p210-T315I cell line (reported IC50 of = 11 nM (20), or 
18 nM (22)).  Apoptosis induction, as measured by 7AAD and Annexin V binding, 
showed an increase when treated with the combination at this 10 nM dose of ponatinib.  
 Finally, CCmut3 reduced transformative ability of cells containing the T315I 
mutation by 40% compared to EGFP control.  Importantly, this is the first report of a 
BCR-ABL N-terminally targeted agent that alone is effective against T315I.  In this 
colony forming assay, the combination did not provide additional benefit over either 
agent individually.  Additionally, CCmut3 alone also inhibits Ba/F3-p210-T315I cell 
proliferation (standard trypan blue exclusion assay, Figure 4.10), as measured at 72 h and 
96 h time points.  Ruthardt et al. have shown a benefit of using a truncated wild-type CC 
(α-helix2) in combination with an allosteric inhibitor of BCR-ABL (37).  However, their 
CC by itself was not effective against T315I BCR-ABL, unlike our CCmut3. 
 Because we inhibit BCR-ABL at different domains, we could possibly be 
affecting different intracellular signal transduction pathways.  BCR-ABL, through its 





cell proliferation, differentiation, apoptosis, and other functions (38).  Interestingly, we 
consistently observe a decrease of one of the STAT5 isoforms recognized by this STAT5 
antibody with CCmut3 treatment (Figure 4.2A, lane 4, top p-STAT5 band disappears, 
presumably STAT5a), while a decrease in the lower STAT5 band is seen with ponatinib 
treatment (Figure 4.2A, lane 2, bottom p-STAT5 band reduced, presumably STAT5b) 
(39-41).  In future studies, it would be intriguing to explore other differential pathways 
that are differentially regulated by CCmut3 vs. ponatinib.   
 Resistance to TKIs is a clinical problem that has been recently addressed by the 
development of second- and third-generation inhibitors.  A particular problem that has 
evolved is the appearance of multiple mutations in BCR-ABL that evade binding to any 
one single TKI.  A particular in vitro compound mutation, E255V/T315I, cannot be 
effectively inhibited with current therapies (425 nM cell proliferation IC50 for 
ponatinib(22)) (23).  Recently, Deininger et al. have analyzed double/compound 
mutations in CML patients.  Notably, a G250E/T315I mutation was found in 2 out of 47 
CML patients, neither of which had prior exposure to ponatinib.  The authors further 
suggest that since “certain compound mutations such as G250E/T315I and E255V/T315I 
confer high-level resistance to ponatinib or DCC-2036 in vitro… these mutations may 
emerge as a significant clinical challenge in patients on third-line TKIs” (23).  It should 
be noted that DCC-2036 is not a TKI but instead an allosteric switch control inhibitor of 
BCR-ABL.  Therefore, the use of small molecules as BCR-ABL inhibitors may be 
limited due to the ability of BCR-ABL to mutate to escape their binding.  With CCmut3, 
which uses multiple contact points and interactions with BCR-ABL for binding, we 





BCR-ABL to evolve many mutations in its coiled-coil domain to evade binding to 
CCmut3.  In addition, if BCR-ABL were to mutate sufficiently to evade CCmut3 binding, it 
could also potentially be preventing itself from homo-dimerizing, resulting in a self-
inactivation.  Testing of CCmut3 alone and in combination with ponatinib in cell lines and 
patient samples containing compound BCR-ABL mutations is a focus of our future 
studies. 
 While in these studies CCmut3 has been delivered via plasmid transfection, we are 
currently developing CCmut3 as a peptide therapy using various approaches to enhance 
stability, decrease degradation, and improve delivery.  Our goal is to develop this into a 
peptide drug that can be easily administered to a patient with CML.  If successful, this 
combination could be used after first- or second-generation TKI failure to avoid further 
mutations, or could even be used as a “personalized medicine approach” for CML where 
the BCR-ABL mutational status of a patient is typed prior to, and/or during therapy.  
Finally, one could envision this combination therapy as the optimal frontline therapy for 
newly diagnosed CML patients due to its specificity for BCR-ABL, potency, and reduced 
likelihood of mutational escape. 
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TRUNCATING AND CAPPING THE CCMUT3 α-HELIX FOR  
 






 Oncogenicity in chronic myeloid leukemia (CML) is driven by the fusion protein 
tyrosine kinase BCR-ABL.  In order to aberrantly activate downstream signaling 
characteristic of this disease, BCR-ABL must homo-oligomerize via a coiled-coil domain 
located at its N-terminus.  Removing this domain, or simply disrupting oligomerization, 
eliminates the oncogenic activity of BCR-ABL.  Previously, we have created a modified 
version of this coiled-coil domain, designed to enhance the binding affinity to native 
BCR-ABL while decreasing the likelihood of homo-oligomerization.  This α-helical 
construct, termed CCmut3, delivered as a gene, has shown the ability to inhibit 
oligomerization and thus eradicate the oncogenic function of BCR-ABL.  Here, we 
attempted to improve the deliverability of the CCmut3 construct through truncation and 
helical capping.  Because the majority of interactions between CCmut3 and the BCR-ABL 
coiled-coil domain exist at the α-helix2 interface, we truncated CCmut3 to include only the 
α-helix2 domain (with flanking residues), termed Helix2mut3.  Also, we attempted to 
further truncate Helix2mut3 and include α-helix-stabilizing capping residues (serine on the 
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N-terminus and glycine on the C-terminus), a construct we called cappedHelix2mut3.  
While Helix2mut3 outperformed negative control EGFP in cell proliferation, colony 
forming, and apoptosis, it did not provide any advantage over the full-length CCmut3 
construct.  Additionally, cappedHelix2mut3 failed to out-perform the negative control in 
preliminary cell proliferation and colony forming assays.  These results have prompted us 
to seek additional ways in which the deliverability of CCmut3 can be increased. 
 
Introduction 
 Chronic myeloid leukemia (CML) is caused by the fusion protein BCR-ABL, a 
constitutively active tyrosine kinase responsible for CML progression (1-3).  Current 
CML therapy utilizes ATP-competitive small molecule inhibitors that target the tyrosine 
kinase domain of BCR-ABL (4).  Use of these tyrosine kinase inhibitors (see Chapter 1) 
has allowed sufficient management of CML in most cases (5).  Despite an overall high 
response rate, some patients harbor kinase domain mutations that prevent binding and 
activity of TKIs (6, 7).  With the recent approval of the third generation TKI ponatinib 
(8), all clinically-relevant single point mutations in the kinase domain, including the long-
elusive T315I mutation, can now be overcome by one of the five approved inhibitors 
(imatinib, dasatinib, nilotinib, bosutinib, ponatinib) (9, 10).  Recently, however, 
compound mutations, or multiple point mutations in a single BCR-ABL molecule, have 
begun to surface in some CML patients.  Depending on the mutations involved, some of 
these compound mutants have shown resistance against ponatinib in vitro (9) and in 
patients with clinical resistance (11, 12).  This resistance leaves a gap in CML therapy, 
opening up a door for new therapeutics capable of inhibiting this type of resistant CML. 
! 167!
 Another potential target for CML therapy is the N-terminal oligomerization 
domain.  This 72-amino acid coiled-coil (CC) region is the location responsible for the 
homo-oligomerization of BCR-ABL; a process essential for BCR-ABL function in CML 
(13-15).  We have previously designed a construct targeting this domain, termed CCmut3 
(see Chapter 2), which was shown to inhibit proliferation and transformative ability and 
to induce apoptosis in CML cells (16).  More importantly, recent data from the Lim Lab 
have shown the ability of CCmut3 to inhibit both T315I kinase-mutant BCR-ABL (17) as 
well as BCR-ABL expressing the E255V/T315I compound mutant (Woessner et al., 
unpublished data).  In both cases, however, CCmut3 was delivered as plasmid DNA, a 
method not directly translatable for therapeutic delivery.   
Here, we aim to make further modifications to the CCmut3 construct that may 
improve its deliverability down the road as a peptide.  CCmut3 deliverability may be 
enhanced through helical truncation, as a smaller peptide may result in simplified 
delivery (18, 19).  Structurally, the BCR-ABL oligomerization domain consists of two α-
helices, termed α-helix1 and α-helix2 (14).  Because CCmut3 design was based on this 
structure, it, too, consists of α-helix1 and α-helix2 domains (16).  Figure 5.1 shows a 
representative image of CCmut3 interacting with the BCR-ABL CC domain.  The majority 
of interactions in the CCmut3:BCR-ABL heterodimer occur between the α-helix2 regions 
of each respective molecule (14).  Therefore, and based on results from previous studies 
(20), it is believed that only the α-helix2 region of CCmut3 may be necessary for efficient 
BCR-ABL inhibition.  In our case, all of the mutations incorporated into CCmut3 are 
contained within the α-helix2 domain.  Thus by removing α-helix1, it is not anticipated 















Figure 5.1.  Structural representation of hetero-oligomerization between BCR-ABL CC 
domain (green) and CCmut3 (black).  Blue residues on CCmut3 (black) are representative of 




















construct we chose to create was called Helix2mut3 (Figure 5.2B).  More specifically, it 
contains amino acids 23-72 from the original CCmut3 domain (Figure 5.2A). 
Another approach we explored to simplify delivery and possibly enhance the 
efficacy involved further truncation of CCmut3 and addition of helix-stabilizing capping 
residues to each end of the α-helix2 domain.  Previous work has shown that capping 
helices with specific residues is known to thermodynamically stabilize the α-helices in 
peptides (21).  In an α-helix, the first four N-H groups (from the N-terminal end) and the 
last four C=O groups lack intrahelical hydrogen bonds.  Therefore, adding residues 
adjacent to these N- and C-terminal ends to compensate for these missing hydrogen 
bonds is expected to stabilize the helical shape (21-23).  The following nomenclature for 
capping α-helices appears as follows: Ncap- N1- N2- N3- … -C3- C2- C1- Ccap; where 
N1 is the first residue of the helix, and Ncap is the residue immediately preceding the last 
residue of the helix (and the same is true for the C-terminus as well) (22, 24).  Because 
the α-helix2 in CCmut3 begins at residue 28 and ends at residue 67 (14, 16), we chose to 
use those residues as our N1 and C1 residues, respectively.  Adding to that, we chose to 
incorporate the following two commonly used capping residues: serine (a hydrogen bond 
donor) as Ncap and glycine (a hydrogen bond acceptor) as Ccap.  The final construct, 
consisting of amino acids 28-67 of CCmut3, serine at the Ncap position, and glycine at the 
Ccap position, was termed cappedHelix2mut3 (Figure 5.2C).  Capping and truncations 
were discussed with peptide expert, Michael Kay, MD, Ph.D., (University of Utah, 
department of biochemistry) for verification of design. 
The following proof-of-principle studies were designed to identify whether or not 










Figure 5.2.  Sequences of coiled-coil constructs used for BCR-ABL inhibition.  
Mutations characteristic to CCmut3 appear in blue, both in the above coiled-coil image and 
in all three of the sequences.  A) CCmut3: Full length CCmut3 construct contains both α-
Helix1 and α-Helix2.  B) Helix2mut3: Truncated version of CCmut3 to include only the α-
Helix2 and flanking residues.  C) cappedHelix2mut3: Capped and further truncated version 
of CCmut3; includes only α-Helix2 with N-terminal serine cap at residue 27 (S27, 


















Materials and Methods 
Construction of Plasmids and Mutagenesis 
Construction of Helix2WT and Helix2mut3 
The plasmids pEGFP-CC, pEGFP-CCmut3, and pmCherry-CCmut3 were 
constructed as previously described (15).  pEGFP-Helix2mut3 was created through site-
directed mutagenesis using pEGFP-CCmut3 as a template (16).  The mutagenesis primers 
for construction of pEGFP-Helix2mut3 were as follows: 5’-
AGTTCCCGGACTCAGAGCCCAGATCTATGGAGCTGCGCTCAGTGGG-3’ and 5’-
CCCACTGAGCGCAGCTCCATAGATCTGGGCTCTGAGTCCGGGAACT-3’.  Here, 
the mutagenic primers were designed to include a BglII restriction site before residue 23 
in the CCmut3 domain.  Following insertion, the BglII restriction enzyme (New England 
BioLabs, Ipswich, MA, USA) was used to digest out the region between the vector MCS 
and residue 23, eliminating residues 1-22 in the CC construct. 
 
Construction of CappedHelix2mut3 
 The plasmid pmCherry-CappedHelix2mut3 was constructed using pmCherry-
CCmut3 as a template (25).  Construction occurred in three steps: 1) insertion of BglII 
restriction site prior to residue 27, aiming to create Ser27 as the N-terminal cap; 2) 
insertion of Gly residue and stop codon as C-terminal cap after residue 67; and 3) 
removal of residues 1-26 using BglII digestion, leaving final CappedHelix2mut3 product 
comprising residues 27-68 with Ser27 as N-terminal cap and Gly68 as C-terminal cap.  
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The mutagenesis primers for step 1 were as follows: 5’-
CAGAGCCCCCGCGCATGGAGAGATCTTCAGTGGGCGACATCGAGCA-3’ and 
5’-TGCTCGATGTCGCCCACTGAAGATCTCTCCATGCGCGGGGGCTCTG-3’.  For 
step 2, the mutagenesis primers were as follows: 5’GCTGGCCAAGGAAAAGGGGTAG 
TATGACCGGTCTCG-3’ and 5’-CGAGACCGGTCATACTACCCCTTTTCCTTG 
GCCAGC-3’. 
 
Cell Lines and Transient Transfection 
K562 and Ba/F3-p210 cells were maintained and passaged as previously 
described (17). 
 
Transfection of K562 Cells 
Two days following cell passaging, 2.0 x 106 cells were collected by 
centrifugation at 500 x g for 10 min for each transfection group.  Following cell 
collection, 6 µg DNA (pEGFP, pEGFP-CC, pEGFP-CCmut3, pEGFP-Helix2WT, pEGFP-
Helix2mut3, pmCherry, pmCherry-CCmut3, or pmCherry-CappedHelix2mut3) was 
transfected into cells according to the Cell Line Nucleofector® Kit V protocol (program 
T-013) using the Amaxa Nucleofector II (Lonza Group, Basel, Switzerland).  Following 
transfection, the DNA/cell mixture was added to 10 mL Complete RPMI 1640 media and 





Transfection of Ba/F3-p210 Cells 
Two days following cell passaging, 3.0 x 106 cells were collected by 
centrifugation at 750 x g for 10 min for each transfection group.  Following collection, 4 
µg DNA was transfected into cells according to the Cell Line Nucleofector® Kit V 
protocol (program X-001) using the Amaxa Nuelcofector II.  Following nucleofection, 
the DNA/cell mixture was added to 500 µL plain RPMI and incubated for 20 min.  After 
incubation, the 500 µL cell/DNA/RPMI mixture was added to complete RPMI 1640 
media and allowed to incubate at 37 °C for 72 h until analysis. 
 
Fluorescence Microscopy and DNA Segmentation 
Nuclear segmentation analysis was performed as previously described (16).  
Briefly, immediately prior to cellular analysis, 2-well live cell chambers were treated for 
15 min with poly-L-lysine (Sigma-Aldrich, St. Louis, MO, USA), which would allow cell 
adhesion in the wells.  Forty-eight h following transfection, the transfected K562 cells 
were transferred to the pretreated 2-well live cell chambers.  Cells were incubated for 15 
min at 37 °C following addition of 0.3 µL Hoechst H33342 nuclear stain (Life 
Technologies, Carlsbad, CA, USA).  Cells were then imaged using an inverted 
fluorescence microscope (Olympus IX701F, Scientific Instrument Co., Sunnyvale, CA, 
USA) equipped with an F-view Monochrome CCD camera.  Fields of view were selected 
based on EGFP fluorescence when viewing using a 40X oil immersion objective.  Nuclei 
from only cells that were positively transfected (positive for EGFP fluorescence) were 
categorized as either healthy (round or kidney-shaped nuclei) or segmented (punctate 
staining of nuclei) (26, 27), and the percentage of cells with segmented DNA was 
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calculated (n=3 in replicate). 
 
Cell Proliferation 
Forty-eight or 72 h following transfection, 100 µL of treated K562 or Ba/F3-p210 
cells was mixed with 100 µL trypan blue solution (Life Technologies).  The numbers of 
viable cells (those impermeable to the trypan blue dye) from four different quadrants in 
an INCYTO™ C-CHIP™ Neubauer hemacytometer (VWR International, Radnor, PA, 
USA) were counted using a standard light microscope.  Quadrant counts were then 
averaged to obtain the number of viable cells per mL.  For experiments using the 
Helix2mut3 construct, counts were performed on one aliquot per transfection (n=3 in 
replicate).  In experiments involving the CappedHelix2mut3 construct, counts were 
performed three times using separate 100 µL aliquots from one transfection (n=1 in 
triplicate). 
 
Colony Forming Assays 
The colony forming assays were carried out as previously described (17).  Briefly, 
K562 or Ba/F3-p210 cells were transfected according to the protocol above.  One day 
following transfection, 1.0 x 106 cells per transfection group were collected and re-
suspended in sterile PBS.  One hundred µL of this resuspension was then serially diluted 
in Isocove’s Modified Dulbecco’s media (IMDM) to obtain a concentration of 1.0 x 104 
cells/mL.  From this dilution, 300 µL was added into 3.0 mL of methylcellulose medium 
(H4230 medium for K562 cells, M3234 medium for Ba/F3-p210 cells) in the absence of 
cytokines, to obtain a final concentration of 1.0 x 103 cells/mL.  Finally, 1.1 mL of 
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cell/methylcellulose mixture was seeded in duplicate and allowed to grow at 37 °C and 
5% CO2 for 7 days.  Colony formation was assessed by counting colonies in two 200 µm2 
areas on the plate.  Experiments were performed once in duplicate (n=1 in duplicate).  All 
kit reagents and media were purchased from Stem Cell Technologies (Vancouver, BC, 
Canada).   
 
Statistical Analysis 
In instances where three separate transfections were used as replicates for a single 
assay, all data were analyzed using a one-way ANOVA with Tukey’s posttest. 
 
Results 
The goal of these studies was to determine whether or not truncating and/or 
capping CCmut3 would eliminate or interfere with its BCR-ABL inhibitory capacity.  
Therefore, the designed constructs were compared side-by-side to CCmut3 in cell 
proliferation, transformative ability, and apoptosis assays.  Detailed descriptions of the 
constructs that were tested in the following studies appear in Table 5.1. 
 
CCmut3 inhibits transformative ability to a greater degree than Helix2mut3 
As a pilot experiment, we first investigated the ability of Helix2mut3 to inhibit 
transformative ability of K562 cells.  Following transfection of these cells with our 
Helix2mut3, CCmut3, or EGFP control, a colony forming assay was conducted, where 
outgrowth of colonies were a measure of transformative ability of K562 cells.  Results 
from this study, though only performed once in duplicate (n=1 in duplicate), are shown in 
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Table 5.1.  Descriptions of the mutant CC constructs.  *Signifies the amino acid residue 
numbering of the full-length BCR-ABL CC (for example, to create Helix2mut3, the first 




Figure 5.3.  All data were normalized to the EGFP negative control.  Results show that 
CCmut3 reduced colony formation to approximately 20% of control (Figure 5.3, middle 
bar), whereas Helix2mut3 (Figure 5.3 last bar from left) only reduced colony formation to 
approximately 67% of EGFP control.  While not displaying as potent an effect as CCmut3, 
it should still be realized that Helix2mut3 did display some inhibitory activity.  Statistical 
comparisons, however, cannot be made on these data due to the lack of replicates.      
 
Helix2mut3 inhibits proliferation and induces apoptosis to a  
similar extent as CCmut3 
 Next, proliferation of cells treated with Helix2mut3 was studied.  K562 cells were 
transfected with EGFP control, CCmut3, or Helix2mut3, and the viability of cells was then 
analyzed 48 h following treatment via trypan blue exclusion; results are presented in 
Figure 5.4.  As previously (16), treatment with CCmut3 (Figure 5.4, middle bar) resulted in 
a statistically significant decrease in the proliferation of K562 cells.  At the same time, no 
Construct Residues* Description 
CCmut3 1-72 BCR-ABL CC domain with the following mutations: 
C38A, K39E, S41R, L45D, E48R, Q60E 
Helix2mut3 23-72 α-helix2 of wild-type BCR-ABL CC domain plus five 
flanking residues on each end with the following mutations:  
C38A, K39E, S41R, L45D, E48R, Q60E 
cappedHelix2mut3 27-68 α-helix2 of wild-type BCR-ABL CC domain with helical 
capping residues S27 and G68 and the following mutations:  






Figure 5.3.  Colony forming assay: transformative ability of K562 cells.  Colony forming 
units were counted 7 days following seeding into methylcellulose media.  Assay was 
performed one time in duplicate (n=1 in duplicate); data are normalized to EGFP control 




Figure 5.4.  Cell proliferation assay: viability of K562 cells.  Viability was assessed 48 h 
following transfection using trypan blue exclusion; cells not permeated by trypan blue 
dye were considered viable.  Assay was performed using three separate transfections 
(n=3).  Data are normalized to EGFP control and presented as overall mean ± SEM; one-
































































significant decrease was seen in the proliferation of cells treated with Helix2mut3 (Figure 
5.4, far right bar) when compared to EGFP control.  However, importantly, there was no 
significant difference between the growth of cells treated with CCmut3 and those treated 
with Helix2mut3 (Figure 5.4, middle bar and far right bar, respectively).  Because the goal 
of these studies was to determine whether or not a difference in therapeutic potential 
existed between CCmut3 and Helix2mut3, this experiment provided a promising result. 
Finally, induction of apoptosis was studied in K562 cells treated with EGFP 
negative control, CCmut3, and Helix2mut3.  The apoptosis assay we chose, DNA 
segmentation, involved analyzing the morphology of the nucleus of cells treated with our 
constructs.  Commonly, healthy K562 cells contain round or kidney-shaped nuclei, while 
the nuclei apoptotic cells often display a punctate pattern (26, 27).  Percentage of 
apoptotic cells can be determined by calculating the amount of cells with segmented 
nuclei compared to the number of total cells transfected (all three constructs were tagged 
with EGFP, thus EGFP-positive cells were considered positively transfected).  Therefore, 
48 h following transfection, the nuclei of treated cells were analyzed using fluorescence 
microscopy.  Results appear in Figure 5.5.   
As previously (16), an increase in apoptosis was seen in cells treated with CCmut3 
(Figure 5.5, middle bar) compared to the EGFP control (Figure 5.5, leftmost bar).  
Different from the cell proliferation results, a statistically significant increase in apoptosis 
was seen in cells treated with Helix2mut3 (Figure 5.5, rightmost bar) when compared to 
EGFP.  However, as similar to the cell proliferation assay, apoptosis was induced to a 
similar extent between both CCmut3 and Helix2mut3, as no significant difference was 




Figure 5.5.  Nuclear (DNA) segmentation assay: induction of apoptosis in K562 cells.  
Quantitation of apoptosis 48 h following transfection based on the shape of the nucleus of 
K562 cells.  Cells were characterized as healthy if they displayed round or kidney-shaped 
nuclei; apoptotic cells were characterized by punctate staining of the nucleus.  Percentage 
of apoptosis was calculated by analyzing four or five fields of view; each containing 
between 20 and 50 cells each.  Only cells positively transfected (EGFP-positive) were 
analyzed.  Data were normalized to EGFP control and are presented as overall mean ± 
SEM; one-way ANOVA with Tukey’s posttest; * p < 0.05. 
 
 
times using three separate transfections (n=3). 
As previously (16), an increase in apoptosis was seen in cells treated with CCmut3 
(Figure 5.5, middle bar) compared to the EGFP control (Figure 5.5, leftmost bar).  
Different from the cell proliferation results, a statistically significant increase in apoptosis 
was seen in cells treated with Helix2mut3 (Figure 5.5, rightmost bar) when compared to 
EGFP.  However, as similar to the cell proliferation assay, apoptosis was induced to a 
similar extent between both CCmut3 and Helix2mut3, as no significant difference was 
apparent.  Both the cell proliferation and DNA segmentation assays were performed three 















































Further helical truncation and capping provide no therapeutic  
benefit to CCmut3 
 Following the moderate successes seen in truncating CCmut3 to create the 
Helix2mut3 construct, we aimed to further improve this construct by additional truncation 
and through the addition of potentially stabilizing helical capping residues.  These efforts 
resulted in the creation of cappedHelix2mut3, described in Table 5.1.  We first chose to 
analyze the proliferation of both K562 and Ba/F3-p210 treated with cappedHelix2mut3.  
Seventy-two h following transfection, viability of cells was determined via trypan blue 
exclusion.  Based on the cell proliferation results of Helix2mut3, and how no significant 
difference was seen when compared to CCmut3, we chose to compare the effect of 
cappedHelix2mut3 simply to CCmut3 and an mCherry negative control.  Results are 
presented in Figure 5.6.  In K562 cells, CCmut3 (Figure 5.6A, middle bar) again showed 
potent inhibition of cell proliferation compared to mCherry control (Figure 5.6A, leftmost 
bar).  The cappedHelix2mut3 construct (Figure 5.6A, rightmost bar), however, did not 
display inhibition of cell proliferation.  In fact, it appeared that cappedHelix2mut3 did not 
inhibit proliferation to any extent compared to the mCherry negative control.  These 
results were also replicated to a similar extent in Ba/F3-p210 cells, shown in Figure 5.6B.  
Therefore, this effect did not appear to be cell line specific.  In both cases (K562 and 
Ba/F3-p210 cells), constructs were transfected only once, thus statistical analysis is not 
warranted as this does not represent a true n=3.  
 Lastly, a colony forming assay, in both K562 and Ba/F3-p210 cells testing the 
activity of the cappedHelix2mut3 construct was also performed (n=1).  Results showed the 




Figure 5.6.  Cell proliferation assay: viability of K562 cells (A) and Ba/F3-p210 cells 
(B).  Viability was assessed 72 h following transfection using trypan blue exclusion; cells 
not permeated by trypan blue dye were considered viable.  Assay was performed using 
three separate cell counts, but only from one individual transfection (n=1).  Data are 
presented as overall mean ± SEM of the three counts. 
 
can be concluded through these preliminary studies that further truncation of CCmut3 and 
the addition of the chosen capping residues (N-terminal serine and C-terminal glycine) do 
not provide any additional therapeutic benefit to CCmut3. 
 
Discussion 
We have previously demonstrated the capability to inhibit BCR-ABL activity 
using coiled-coil mutants (15, 16).  Additionally, we showed that CCmut3 was the first N-
terminally targeted agent to be active alone against T315I mutant BCR-ABL (17).  In this 
study, we set out to determine whether or not CCmut3 could be truncated to enhance its 
delivery potential without compromising its effect.  We also tested whether or not adding 
helix-stabilizing capping residues to each end of the truncated CCmut3 helix provided any 
benefits (21, 22, 24, 28).  While the 50-amino acid (aa 23-72) truncated CCmut3 construct, 

































































capping the helix, creating cappedHelix2mut3, eradicated this BCR-ABL inhibitory 
activity. 
 The activity of Helix2mut3 compared to both the negative control and to CCmut3 
appeared to be assay-dependent.  In a measure of transformative ability, Helix2mut3 
seemed to prevent outgrowth of colonies to a greater extent than the EGFP control, 
however, not as potently as the full length CCmut3.  In the cell proliferation assay, the 
inhibitory effect provided by Helix2mut3 was not statistically different than the EGFP 
control, but at the same time was not any less potent than the CCmut3 effect (no significant 
difference between the two).  Finally, in the DNA segmentation apoptosis assay, both 
Helix2mut3 and CCmut3 significantly induced apoptosis in K562 cells to a similar extent, 
with no statistical difference in this induction.  Thus, it appears that Helix2mut3 acts with 
similar, if not slightly less, potency as the full length CCmut3.  It is clear, though, that 
truncating CCmut3 does not provide any added effect in terms of actually inhibiting BCR-
ABL.  Added effects by truncation may be more apparent, however, when eventually 
delivering a CCmut3-based peptide.   
The slight decreases in potency seen with truncation can potentially be attributed 
to the removal of the α-helix1 from CCmut3.  While the majority of the contacts between 
CCmut3 and BCR-ABL occur at the α-helix2 dimerization interface, the presence of α-
helix1 may provide a stabilizing effect as it wraps on the backside of α-helix2 of the 
opposite monomer (Figure 5.1) (14).  Removing α-helix1, therefore, removes this 
potential stabilizing effect.  In response, we sought a way to compensate for the stability 
and potency lost by removing α-helix1.  One manner in which α-helices can be stabilized 
involves including helical capping residues on both the N- and C-terminal ends of the 
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helix.  In our case, we chose serine as an N-terminal cap and glycine as a C-terminal cap, 
creating a construct we called cappedHelix2mut3. 
Preliminary data using cappedHelix2mut3 showed no evidence of BCR-ABL 
inhibition in two different CML cell lines, even when compared to negative control.  
Ultimately, it appeared to us that the favorable energy gained by adding the helix caps did 
not overcome the interactions lost by removing the α-helix1.  This lack of inhibition may 
be explained, however, by the identity of the stabilizing residues chosen as the N and C 
caps.  Though N-terminal serine and C-terminal glycine provide stabilizing benefits for 
some α-helices, all helices will behave differently based on their immediate surrounding 
residues.  Additionally, certain residues are better suited for positions directly proximal to 
the helix cap on both sides.  Different combinations of N and C caps and different 
combinations of N1, N2, etc. residues may be tested; however, changing too many 
residues for stabilization purposes may in fact negatively impact the specificity and 
binding capacity of our construct.  After all, specificity for BCR-ABL is the basis of 
CCmut3 design, and compromising this characteristic is not worth minimal gains in helix 
stability.  Thus, due to the lack of promise seen in these results, and because changing 
these capping residues may only provide marginal improvements at best, we decided to 
change direction and explore a truncated CCmut3 peptide that contains a stabilizing all-
hydrocarbon backbone.  Here, we expect that adding a staple will compensate for lost α-
helix1 interactions by intrinsically promoting stability and contributing a lower entropic 






1. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, 
Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, et al. 
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia 
chromosome in chronic myelocytic leukaemia. Nature. 1983;306(5940):277-280. 
 
2. Ren R. The molecular mechanism of chronic myelogenous leukemia and its 
therapeutic implications: studies in a murine model. Oncogene. 
2002;21(56):8629-8642. 
 
3. Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks 
associated with BCR-ABL-dependent transformation. Cancer Control: Journal of 
the Moffitt Cancer Center. 2009;16(2):100-107. 
 
4. Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for 
chronic myelogenous leukemia. Cancer Journal. 2011;17(6):477-486. 
 
5. Shami PJ, Deininger M. Evolving treatment strategies for patients newly 
diagnosed with chronic myeloid leukemia: the role of second-generation BCR-
ABL inhibitors as first-line therapy. Leukemia. 2012;26(2):214-224. 
 
6. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to 
tyrosine kinase targeted therapy. Molecular Cancer. 2010;9:75. 
 
7. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of 
targeted therapy in chronic myeloid leukaemia. Nature Reviews Cancer. 
2012;12(8):513-526. 
 
8. Chustecka Z. FDA Approves Ponatinib for Rare Leukemias. Medscape Medical 
News, 2012. Accessed from:! http://www.fda.gov/NewsEvents/Newsroom/Press 
Announcements/ucm332252.htm. 
 
9. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, 
Zhou T, Huang WS, Xu Q, Metcalf CA, 3rd, Tyner JW, Loriaux MM, Corbin AS, 
Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, 
Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker 
BJ, Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid 
leukemia, potently inhibits the T315I mutant and overcomes mutation-based 
resistance. Cancer Cell. 2009;16(5):401-412. 
 
10. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, 
Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, 
Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-
positive leukemias. The New England Journal of Medicine. 2012;367(22):2075-
2088. 
! 185!
11. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini 
FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, 
Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, 
Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, 
Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, Investigators P. A 
phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The 
New England Journal of Medicine. 2013;369(19):1783-1796. 
 
12. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, 
Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, 
Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-
Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, 
Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman 
R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad 
JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. BCR-ABL1 
compound mutations combining key kinase domain positions confer clinical 
resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 
2014;26(3):428-442. 
 
13. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of 
Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Molecular 
and Cellular Biology. 1993;13(12):7587-7595. 
 
14. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-
Abl oncoprotein oligomerization domain. Nature Structural Biology. 
2002;9(2):117-120. 
 
15. Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimpi AA, Cheatham TE, 3rd, 
Lim CS. Disruption of Bcr-Abl coiled coil oligomerization by design. The 
Journal of Biological Chemistry. 2011;286(31):27751-27760. 
 
16. Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, 
Robertson JC, Cheatham TE, 3rd, Lim CS. Improved coiled-coil design enhances 
interaction with Bcr-Abl and induces apoptosis. Molecular Pharmaceutics. 
2012;9(1):187-195. 
 
17. Miller GD, Woessner DW, Sirch MJ, Lim CS. Multidomain targeting of Bcr-Abl 
by disruption of oligomerization and tyrosine kinase inhibition: toward 
eradication of CML. Molecular Pharmaceutics. 2013;10(9):3475-3483. 
 
18. McInnes C, Andrews MJ, Zheleva DI, Lane DP, Fischer PM. Peptidomimetic 
design of CDK inhibitors targeting the recruitment site of the cyclin subunit. 
Current Medicinal Chemistry Anti-Cancer Agents. 2003;3(1):57-69. 
 
19. Kontopidis G, Andrews MJ, McInnes C, Plater A, Innes L, Renachowski S, 
Cowan A, Fischer PM. Truncation and optimisation of peptide inhibitors of 
! 186!
cyclin-dependent kinase 2-cyclin a through structure-guided design. 
ChemMedChem. 2009;4(7):1120-1128. 
 
20. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, 
Ruthardt M. Targeting of the N-terminal coiled coil oligomerization interface by a 
helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. International 
Journal of Cancer / Journal International du Cancer. 2008;122(12):2744-2752. 
 
21. Aurora R, Rose GD. Helix capping. Protein Science: A Publication of the Protein 
Society. 1998;7(1):21-38. 
 
22. Doig AJ, Baldwin RL. N- and C-capping preferences for all 20 amino acids in 
alpha-helical peptides. Protein Science: A Publication of the Protein Society. 
1995;4:1325-1336. 
 
23. Ermolenko DN, Thomas ST, Aurora R, Gronenborn AM, Makhatadze GI. 
Hydrophobic interactions at the Ccap position of the C-capping motif of alpha-
helices. Journal of Molecular Biology. 2002;322(1):123-135. 
 
24. Harper ET, Rose GD. Helix stop signals in proteins and peptides: the capping 
box. Biochemistry. 1993;32(30):7605-7609. 
 
25. Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS. Changing the 
subcellular location of the oncoprotein Bcr-Abl using rationally designed capture 
motifs. Pharmaceutical Research. 2012;29(4):1098-1109. 
 
26. Barrett KL, Willingham JM, Garvin AJ, Willingham MC. Advances in 
cytochemical methods for detection of apoptosis. The Journal of Histochemistry 
and Cytochemistry. 2001;49(7):821-832. 
27. Willingham MC. Cytochemical methods for the detection of apoptosis. The 
Journal of Histochemistry and Cytochemistry. 1999;47(9):1101-1110. 
 
28. Forood B, Feliciano EJ, Nambiar KP. Stabilization of alpha-helical structures in 




















 This dissertation has focused on the rational design, creation and optimization of a 
BCR-ABL inhibitor for potential use in CML therapy.  While traditional CML 
therapeutics target the BCR-ABL tyrosine kinase domain, we have chosen to explore the 
potential of inhibiting BCR-ABL dimerization at its N-terminal coiled-coil (CC) domain.  
We have designed a selective inhibitor of the BCR-ABL CC domain, termed CCmut3, 
shown to favor binding to BCR-ABL and disfavor binding to itself (Chapter 2).  This 
construct has shown the capability to inhibit proliferation, decrease transformative ability, 
and induce apoptosis in CML cells containing both native and mutant BCR-ABL.  Next, 
the most recently approved BCR-ABL tyrosine kinase inhibitor (TKI), ponatinib, was 
described in detail in terms of its design, mechanism, and place in therapy (Chapter 3).  
Further, combination of CCmut3 with ponatinib resulted in a dose-lowering effect of 
ponatinib (Chapter 4).  Lastly, attempts were made to truncate and stabilize CCmut3 to 
improve its deliverability without compromising its inhibitory activity (Chapter 5).  
While the previous attempts at truncation and stabilization were unsuccessful, new 
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studies are currently underway to overcome these issues.  The design and current status is 
described in detail in the following section: Design of a CCmut3 stapled peptide.  Although 
all of the work described has involved using plasmid delivery as proof-of-principle, the 
foundation has been laid for creating CCmut3 as a deliverable peptide. 
 
Improved Design of a BCR-ABL Coiled-Coil Domain Inhibitor 
Inhibition of the BCR-ABL oligomerization was first explored by Ruthardt et al. 
using a construct mimicking the BCR-ABL CC domain (1).  Showing only marginal 
success, it could be inferred that since the construct being used was identical in sequence 
and structure to the dimerization interface (thus, the construct in itself represented an 
oligomerization domain), this construct would have the same affinity to homo-
oligomerize as it would to bind to the BCR-ABL CC domain.  Homo-oligomerization 
would limit its use as a therapeutic by sequestering the molecules and removing the 
capacity to bind to and inhibit BCR-ABL.  This issue of preventing homo-
oligomerization was later addressed by Dixon et al., using rational design of a 
dimerization inhibitor (2).  Here, in a therapeutic termed CCmut2, five mutations (C38A, 
S41R, L45D, E48R, and Q60E) were made to the BCR-ABL CC domain to improve 
hetero-oligomerization between BCR-ABL and CCmut2 while at the same time 
disfavoring homo-oligomerization between two CCmut2 molecules.  To improve upon that 
concept, we identified one more critical mutation that could be made, K39E.  
Incorporating this mutation along with the other five mutations previously mentioned is 
the basis for CCmut3.  Specifically, by mutating the lysine at position 39 to a glutamate, 
we introduced one additional charge-charge repulsion into the theoretical CCmut3 dimer.  
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This extra repulsion was expected to further disfavor homo-oligomerization between two 
CCmut3 molecules.  Although the biologic activity of CCmut2 and CCmut3 (both delivered as 
plasmid DNA) was found to be similar, the addition of the K39E mutation demonstrated 
improved oligomerization and colocalization with BCR-ABL.  Therefore, CCmut3 was 
used as the starting point to which further improvements would be made.  
 
Role of Ponatinib in CML and Ph+ ALL Therapy 
In 2001, imatinib (Gleevec®), a BCR-ABL tyrosine kinase inhibitor (TKI), was 
approved for first-line use in the treatment of CML (3, 4).  Despite showing a high 
success rate, it is estimated that approximately one-third of the patients using imatinib 
experience intolerance or resistance to this drug within the first 5 years of therapy (5-7).  
This resistance is due in large part to the acquisition of point mutations in the tyrosine 
kinase domain, preventing TKI binding and consequently rendering the TKI inactive (8).  
Thus, alternative therapies have been attempted.  While second generation inhibitors 
(nilotinib and dasatinib) were able to cover the majority of these mutations, no approved 
TKIs could successfully inhibit BCR-ABL with the T315I “gate-keeper” mutation (9).  In 
2012, ponatinib (Iclusig®) became the first TKI to successfully inhibit both native and 
T315I mutant BCR-ABL and was granted accelerated FDA-approval (10).  A year later, 
sales were temporarily discontinued and a phase III trial involving the drug was 
terminated due to the serious side effects seen in nearly 12% of the patient population 
(11-13).  Ponatinib has since been placed back onto the market, intended for a limited 
patient population with an expanded black box warning (14, 15).  Despite this setback, 
ponatinib provides a therapeutic opportunity for many CML and Ph+-ALL patients for 
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whom no previous therapies were successful.  The role of ponatinib in native and 
resistant CML and Ph+-ALL, along with the pharmacology, a summary of clinical trials, 
current place in therapy, and speculations of future use were discussed fully in this 
section.    
 
Targeting the CC and tyrosine kinase domain led to greater therapeutic  
efficacy and dose-lowering effect of ponatinib 
 Multidomain targeting provides an opportunity to inhibit BCR-ABL at two 
separate locations with two different therapeutics.  The effectiveness of CCmut3 at 
inhibiting BCR-ABL has previously been described (16).  Likewise, the role of ponatinib 
and its therapeutic advantages as a tyrosine kinase inhibitor has also been discussed 
(Chapter 3).  However, despite these successes, ponatinib has been found to cause 
significant dose-dependent side effects (including life-threatening blood clots and blood 
vessel narrowing) in nearly 12% of patients on the drug (11, 12).  In this study, we found 
that combining CCmut3 (as plasmid DNA) and ponatinib resulted in a dose-lowering effect 
of ponatinib and provided increased therapeutic efficacy in vitro.  Analyzing kinase 
activity, oncogenic potential, and induction of apoptosis, we found that the combination 
had a greater impact than treatment with either agent alone.  Additionally, we reported for 
the first time the effectiveness of an N-terminally targeted agent (CCmut3) against cells 
containing T315I mutant BCR-ABL.  This combination approach may be used in the 
future to lower the dose of ponatinib necessary for BCR-ABL inhibition in an attempt to 
avoid serious off-target effects.   
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Truncating and capping the helix did not provide a therapeutic advantage  
compared to the full-length CCmut3 
 Strategic truncation of the CCmut3 α-helix is expected to make the construct more 
deliverable as a peptide by decreasing the overall size.  Because the majority of 
interactions between CCmut3 and the BCR-ABL CC domain exist at the α-helix2 interface, 
we did not expect to lose any binding affinity by removing α-helix1 from CCmut3.  The 
first construct we created using this logic was termed Helix2mut3, a 50-amino acid domain 
consisting of residues 23-72 of the original CCmut3.  Delivered as plasmid DNA, 
Helix2mut3 outperformed the negative control EGFP in cell proliferation, colony forming, 
and apoptosis assays.  However, the therapeutic efficacy was not as potent as that seen 
using the full CCmut3 construct.  Thus, further truncation of Helix2mut3 and addition of 
helix-stabilizing capping residues was also attempted.  The construct used in these 
studies, also delivered as plasmid DNA, consisted of amino acid residues 27-68 of the 
original CCmut3 domain.  On top of that, a serine residue was added at position 27 and a 
glycine residue added at position 68 for the purposes of stabilizing the α-helix (17-21).  
This new construct, called cappedHelix2mut3, failed to out-perform the negative control in 
preliminary cell proliferation and colony forming assays.  These negative results 
prompted us to determine other manners in which CCmut3 could be better improved as a 
therapeutic.  The final decision resulted in designing a hydrocarbon stapled and truncated 






Design of a CCmut3 Stapled Peptide 
Abstract 
Investigation into delivery methods for the CCmut3 peptide has commenced in the 
Lim Lab.  Currently, full-length CCmut3 fused to a leukemia-specific cell penetrating 
peptide (LS-CPP) has shown promising results for both cell penetration and inducing cell 
death in CML cell lines (unpublished data, Ben Bruno).  Recently, we have sought to 
further this process by designing a CCmut3 peptide containing an all-hydrocarbon staple 
expected to improve delivery.  Optimally spaced residues suitable for addition of the 
hydrocarbon staple have been identified.  The design process and results are described 
fully in this section.  Following design validation by molecular simulation dynamics, the 
top three peptides will be synthesized and further characterized and analyzed for activity 
in CML cells. 
 
Introduction 
Biologic protein-protein interactions are highly specific, often requiring multiple 
contact points for optimal selectivity (22).  Due to this high level of specificity, these 
interactions represent a valid target for specially designed therapeutics (23).  Thus, using 
a peptide to target this interaction provides an opportunity to maintain the interaction 
specificity, which may limit off-target effects, representing an ideal case for drug 
development.  In the case of chronic myeloid leukemia, or CML, the constitutively active 
protein BCR-ABL requires homo-oligomerization to fulfill its function as an oncogenic 
driver (24, 25).  This homo-oligomerization occurs via a coiled-coil domain located on 
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the N-terminal portion of the BCR-ABL protein (25, 26).  Disrupting this 
oligomerization, in turn, has been shown to inhibit BCR-ABL activity and thus prevent 
CML activation (1, 2, 16).   
Previously, we have designed a construct capable of interfering with BCR-ABL 
oligomerization that further inhibits its function as an oncoprotein (Figure 6.1) (16).  This 
construct, termed CCmut3, mimics the BCR-ABL coiled-coil domain but contains amino 
acid mutations designed to disfavor homo-oligomerization of CCmut3 and instead favor 
hetero-oligomerization between CCmut3 and BCR-ABL.  The therapeutic efficacy of this 
construct has previously been shown when delivered as a plasmid into in vitro systems 
(16, 27-29) (also D. Woessner, dissertation).  Because this construct shows such a high 
potential for clinical significance, our goal is to fine-tune and formulate it into a practical, 
deliverable peptide capable of eventual BCR-ABL inhibition in vivo.  Delivering the α-
helical CCmut3 as an unmodified peptide is expected to show a lack of stability in 
circulation and inefficient cell internalization due to its overall -3 charge.  Cell 
internalization has been addressed through the addition of a leukemia-specific cell-
penetrating peptide (LS-CPP) to CCmut3 (Bruno & Lim, unpublished data), but this 
strategy does not address the expected lack of stability in circulation (30, 31).  Thus, 
modifying this peptide, including reducing the size and adding a hydrocarbon staple to 
the backbone (and to some peptides with the hydrocarbon staple, adding the LS-CPP as 
well), is expected to overcome the current delivery issues.  
 Using peptides to target protein-protein interactions provides an advantage over 
small molecules in that specificity for the target can be fine-tuned (32).  However, 






Figure 6.1. Disruption of BCR-ABL oligomerization inhibits oncogenic function. A) 
Through homo-oligomerization via the coiled-coil (CC) domain on the N-terminus, BCR-
ABL undergoes trans-autophosphorylation at the tyrosine kinase domain to elicit the 
oncogenic signals for cell proliferation and survival. B) Blocking oligomerization of 
BCR-ABL using CCmut3 inhibits the trans-autophorylation capability and induces 
apoptosis in CML cells. 
 
 
proteolysis (leading to shortened serum half-life), and lack of cell permeability when 
targeting intracellular molecules, often limit peptide therapy (30).  One current approach 
in overcoming barriers of peptide delivery involves stabilizing α-helical peptides thru the 
addition of a hydrocarbon staple on the peptide backbone (33).  The hydrocarbon staple 
locks the α-helical shape of the peptide, increasing its stability, cell permeability, and 














Recently, we have designed deliverable, truncated CCmut3 stapled peptides (further 
termed ST-CCmut3 for Stapled, Truncated-CCmut3) with and without the previously 
mentioned LS-CPP for improved delivery and an enhanced therapeutic effect.  Design 
was first completed by thorough analysis of the three-dimensional structure of CCmut3 
bound with the BCR-ABL oligomerization domain (Figure 6.2).  Because the majority of 
the interactions occur within α-helix2, only this domain (amino acids 28-67 with respect 
to the full length CCmut3) is believed to be necessary for effective inhibition of BCR-ABL 
(1, 25).   
 
 
Figure 6.2.  CCmut3 dimerization with BCR-ABL CC.  Representative image of CCmut3 
(blue) interacting with the BCR-ABL coiled-coil (CC) oligomerization domain (green).  
Residues appearing in red are those characteristic of the CCmut3 mutations (C38A, K39E, 
S41R, L45D, E48R, Q60E).  Below the image is the CCmut3 amino acid sequence, with 
bolded residues representing CCmut3 mutations.  Regions represented by α-helix1 (amino 
acid residues 5-15, labeled) and α-helix2 (residues 28-67, labeled) are highlighted in both 
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Thus, in our design, we will utilize only this 40-amino acid domain, still 
incorporating the same mutations that define CCmut3, for further analysis.  Within α-
helix2, locations unimportant for ST-CCmut3:BCR-ABL interhelical interaction were 
identified for incorporation of the residues necessary to create the hydrocarbon staple.  
Following identification of the staple locations, designs were submitted for computational 
modeling using molecular dynamics simulations to calculate the relative free energy of 
binding between ST-CCmut3 and BCR-ABL.  This work is currently being done 
exclusively in the Cheatham Lab (University of Utah).  The top three ST-CCmut3 
candidates, specifically those that showed the most favorable stability and binding to 
BCR-ABL following computational modeling, will be chosen for synthesis and further 
analysis. 
 
Design of Stapled CCmut3 Peptides 
Use of the Coiled-Coil Helical Wheel Diagram 
The first step of stapled peptide design involved identifying residues suitable for 
attachment of a hydrocarbon staple in an attempt to create a deliverable form of CCmut3. 
α,α-disubstituted amino acids are inserted in the peptide sequence for the hydrocarbon 
staple attachment.  These α,α-disubstituted amino acids  (see Chapter 1) must neither 
hinder the structure of the helix nor the target interface (35).  To avoid these regions, both 
the Pymol (PDB) structure of ST-CCmut3:BCR-ABL interaction (Figure 6.2) and a coiled-
coil helical wheel diagram were examined.  Figure 6.3 shows the helical wheel diagrams 
of (A) CCmut3:BCR-ABL dimerization and (B) CCmut3:CCmut3 dimerization.  As 




Figure 6.3. Helical wheels of CCmut3:BCR-ABL (left) and CCmut3:CCmut3 oligomerization 
(right).  CCmut3 represented with the cyan color; BCR-ABL represented with the gray 
color.  Above and below the helical wheels are individual residues from each domain.  
Side chains of those residues are color-coded, as follows: blue = basic, red = acidic, 
yellow = serine.  Potential ionic interactions are shown with the dotted lines, whereas 
potential charge-charge repulsions are shown with a solid line.  This figure was adapted 
from Dixon et al. (2011). 
 
two full turns that encompass exactly seven amino acids, assigned positions a, b, c, d, e, f 
and g (36-39).  For the purpose of designing locations to incorporate the α-methyl, α-
alkenyl amino acids, we wanted to avoid the interface at which the two coiled-coil 
domains interact.  Specifically, this would include any residues at positions a, d (both 
often involved in protein-protein hydrophobic interaction), e, and g (often involved in 
interhelical electrostatic interactions) (2, 36, 39).  Thus, this leaves positions b, c, and f 
available for modification.  Exact residues and their residue number corresponding to the 
full-length CCmut3 that exist in these positions can be seen in Table 6.1.   
Additionally, hydrocarbon staples must exist in one of the following sequences, 
representative of approximately one or two full helical turns in the peptide: i, i+3; i, i+4; 
or i, i+7 (33, 40).  This provides another restriction to identifying residues suitable to 
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Table 6.1.  Amino acid residue identification and corresponding coiled-coil helical wheel 
position in the α-helix2 of CCmut3.  Highlighted bars (positions b, c, and f) exist on the 
backside of the helix and are not involved in interhelical interaction between CCmut3 and 
BCR-ABL.  These highlighted residues represent possible locations for incorporation of 
α,α-disubstituted amino acids for synthesis of hydrocarbon staples. 
 
Position' Residue'and'number'
a' V28! L35! I42! V49! M56! L63!
b' G29! E36! R43! N50! I57! A64!
c' D30! R37! R44! Q51! Y58! K65!
d' I31! A38! D45! E52! L59! E66!
e' E32! E39! E46! R53! E60! K67!
f' Q33! A40! Q47! F54! T61! ;;;;;!
g' E34! R41! R48! R55! L62! ;;;;;!
 
replace with α-methyl, α-alkenyl amino acids.  For our proposed sequences, we have 
chosen to include residues only spaced with the i, i+7 pattern.  The purpose of this is not 
only for the staple to cover a larger portion of the peptide, but also by spacing seven 
residues apart, we are encompassing exactly two full turns of the helix, which should 
provide greater stability than either of the i, i+3 or i, i+4 options (personal 
communication, Greg Bird, Harvard University). 
 
Use of Molecular Dynamics Simulations to Validate Stapled  
Peptide Design 
   Previous research using stapled peptides has shown that experimental results do 
not always corroborate the intellectual design of peptides (41-43).  In other words, 
incorporating the staple onto the peptide, despite following the design criteria, may 
actually disrupt the three-dimensional structure and distort the binding.  This distortion 
will in turn affect the biophysical characteristics of the peptides, especially interaction 
affinity with the target.  Due to the high cost of synthesis of stapled peptides (between 
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$1500 and $5000 per peptide, depending on the source), it is important to determine 
whether or not a staple connecting certain residues will alter the stability of the monomer 
or dimer prior to synthesis. 
 It is expected that molecular dynamics simulations can be performed to determine 
dimerization stability of stapled peptides.  This work is currently under study by Sean 
Cornillie in the Cheatham Lab (University of Utah, Department of Medicinal Chemistry).  
In brief, free energy of binding between our stapled peptides and the CC of BCR-ABL is 
being determined.  Biomolecular simulation with modern protocols (AMBER, explicit 
solvent, particle mesh Ewald with the new ff12SB protein force field) will be applied (44, 
45).  Model structures based on high resolution structures of Bcr-Abl (PDB ID: 1K1F, 
chains A and B) with our designed peptides will be relaxed through molecular dynamics 
(MD) simulation (~50-100 ns), followed by analysis and further free energy simulations 
to assess the impact of stapling (46-52).  Extensive statistical analysis will be done as 
previously (2, 16).  The information obtained from this computational modeling is 
expected to give us the most energetically favorable peptides, the top three of which will 
be synthesized (for further study).  This process allows us to eliminate the current 
“shotgun approach” of synthesizing many stapled peptides prior to any type of analysis. 
 
Results 
In all, 32 combinations of amino acid residues have been identified for inclusions 
of single i, i+7 staples and i, i+7 double staple variants into the ST-CCmut3 peptide.  
Fourteen unique single i, i+7 staples and 18 unique combinations of i, i+7 double staples 
were designed.  Table 6.2 shows all of the potential staple locations that were identified.   
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Table 6.2.  Residue numbers of the designed locations for single and double i, i+7 




Single'i,#i+7#Staples# Double'i,#i+7'Staples'29/36! 29/36!–!43/50!30/37! 29/36!–!44/51!33/40! 29/36'–'50/57'36/43! 29/36!–!51/58!37/44! 30/37!–!43/50!40/47! 30/37!–!44/51!43/50! 30/37!–!50/57!44/51! 30/37!–!51/58!47/54! 33/40!–!43/50!50/57! 33/40!–!44/51!51/58! 33/40!–!50/57!54/61! 33/40!–!51/58!57/64! 36/43!–!44/51!58/65! 36/43!–!50/57!! 36/43!–!51/58!! 37/44!–!50/57!! 37/44!–!51/58!! 43/50!–!51/58!
 
These staple locations and designs were submitted to the Cheatham Lab, who will 
analyze the structures and sequences using molecular dynamics simulations.  Using only 
the helical wheel and the Pymol structure, our original top design candidate included 
double i, i+7 staples at residues 29/36 and 50/57 (Table 6.2).  Very preliminary data from 
the Cheatham lab appear to corroborate this candidate, though further analysis is 
necessary (unpublished data, Cheatham).  
The top three sequences showing the most favorable binding energy with BCR-
ABL will be chosen as the final stapled peptide designs for synthesis.  These peptides 
will then be synthesized by our collaborator Dr. Greg Bird, a member of the Dr. Loren 
Walensky Lab, at the Dana-Farber Cancer Institute (Harvard University).  
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Discussion 
Maintaining the heterodimeric stability following addition of the hydrocarbon 
staple is critical.  When it comes to binding endogenous BCR-ABL, the coiled-coil 
(helical) structure must be sustained.  After all, as mentioned in detail above, the coiled-
coil that we have designed is specific for BCR-ABL (binding in an antiparallel fashion), 
which means both the sequence and the structure are important (16, 39).  In order to 
interact, the salt bridges must still align in the e to e’ and g to g’ fashion.  “Locking” the 
peptide in a shape that will allow the aforementioned interactions to take place is 
important due to the binding energetics.  It is estimated that because the peptide has now 
preformed a helix, the entropic cost will be vastly reduced, allowing an overall free 
energy gain and favorable binding (35).  As also mentioned, the addition of a staple is 
also important for resistance against proteolytic degradation, as it prevents the peptide 
from adopting an extended conformation.  Preformation of an α-helix in this case is also 
expected to lead to increased cell permeabilization due to the masking of the polar 
backbone within the helix (34).  Finally, we do expect a loss in binding enthalpy due to 
the truncation of the helix.  However, we expect this loss to be overcome by the reduced 
entropic cost of binding due to hydrocarbon stapling, as was the case in recently 
published work involving the design of a stapled peptide to disrupt the cJun-cFos coiled-
coil interaction (53). 
Both single and double staple variants of the truncated CCmut3 were designed.  
Double staples, specifically, were chosen to increase the amount of peptide encompassed 
by the hydrocarbon staples.  Greater coverage in this sense is expected to provide greater 
proteolytic stability by forming an “umbrella” over more sites of potential proteolysis 
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(54; and personal communication with Greg Bird).  Additionally, more efficient cell 
internalization is expected due to a larger amount of exposed hydrophobicity, which 
should aid in crossing the cell membrane (35).  Further, we also expect staples 
incorporated toward the N-terminus to lead to greater α-helical induction.  Based on what 
we know about how α-helices are formed (see Chapter 1), we expect to jump-start this 
process by locking the N-terminus in a helical state before introduction into physiological 
milieu.  Overall, this should lead to improved therapeutic efficacy as maintaining the α-
helical structure is the basis of all improvements provided by stapled peptides (35). 
Overall, the design of our stapled and truncated CCmut3 peptide requires 
knowledge regarding the properties characteristic to α-helices and coiled-coils.  The 
specificity and the ability for rational design (alteration) of these shapes/structures make 
them good candidates for therapeutic design.  While optimal design may not ultimately 
lead to ideal activity (41-43), we hope the use of free energetics computational modeling 
can help us to narrow down the possibilities for locations of a hydrocarbon staple on this 
molecule.  To this end, we have begun collaboration with stapled peptide experts Greg 
Bird and Loren Walensky’s group at Harvard University.  With years of experience in the 
stapled peptide field, their guidance has assisted us throughout the design and decision-
making process.  Once the computational modeling results are analyzed, their group will 
synthesize (55) our top three candidates, both with and without the LS-CPP.  This will 





Future directions in the stapled peptide project 
Characterize the stapled and truncated CCmut3 proteins 
 Methods commonly used to characterize stapled peptides are described fully in 
Chapter 1.  Aside from characterizing the biophysical properties of our designed stapled 
peptides, we also need to test their potential to inhibit BCR-ABL in CML cells.  We 
propose to test the effects of our stapled peptides on four different Bcr-Abl+ cell lines: 
K562 (human, nonmutant), Ba/F3-p210 (murine, nonmutant), Ba/F3-T315I (murine, 
T315I kinase domain mutation), and Ba/F3-E255V/T315I (murine, E255V/T315I kinase 
domain compound mutations).  It is anticipated that our ST-CCmut3 peptide will 
successfully inhibit all forms of mutant BCR-ABL (D. Woessner, dissertation).   
It will also be important to validate the activity of our lead stapled peptide or 
peptides in primary cells obtained from patients.  This method is currently a standard of 
excellence for CML studies.  As with the in vitro testing in BCR-ABL+ Ba/F3 cells, we 
will seek to obtain patient samples containing various BCR-ABL mutational statuses.  
Ideally, patient samples containing both the T315I mutant (as previously obtained) and, if 
available, E255V/T315I mutant, will be studied.  These experiments will provide nearly 
immediately translatable data for future use of our stapled peptide therapeutic in humans.  
Patient samples will be obtained with permission from the Deininger Lab (Huntsman 






Addition of a leukemia-specific cell-penetrating peptide to the  
ST-CCmut3 peptide 
It is important to understand that simply adding a hydrocarbon staple (or two) 
may not necessarily lead to an optimally deliverable and active peptide (41-43).  One area 
of concern is the ability of the peptide to internalize efficiently into cells.  If, during these 
studies, we determine that our lead stapled candidates are not inherently cell permeable, it 
would be necessary to fuse our stapled peptide to a cell-penetrating peptide.  Recent work 
by Ben Bruno in the Lim Lab has delivered the full-length CCmut3 as a recombinant 
peptide fused to a leukemia-specific cell-penetrating peptide (LS-CPP).  This LS-CPP, 
discovered by Nishimura et al. (56) is a short, 9-amino acid peptide with both a lymph 
node homing motif and a poly-arginine protein transduction domain (Figure 6.4).   
Ben Bruno (Lim Lab) has validated its use as a CPP when fused to full-length 
CCmut3, showing successful leukemia cell-specific delivery and therapeutic activity of the 
peptide in multiple CML cell lines (unpublished data, Ben Bruno).  If need be, the CPP 
would be fused to the N-terminus of the ST-CCmut3 peptide.  The staples would remain on 
the CPP-T-CCmut3 peptide for the other characteristic improvements that these 




Figure 6.4.  Leukemia-specific cell-penetrating peptide sequence.  The above sequence 
corresponds to a leukemia-specific cell-penetration peptide, discovered via phage display 
by Nishimura et al. (56).  The beginning portion, cysteine-alanine-tyrosine (CAY), 
represents a lymph node homing motif.  The poly-arginine portion toward the end, 
arginine-leucine-arginine-arginine (RLRR), represents the cell penetrating motif. 
CAYHRLRRC 





Test mutational escape capability of BCR-ABL to CCmut3 
 Chapters 3 and 4 discuss mutations in the tyrosine kinase domain of BCR-ABL 
and how these mutations affect treatment in CML.  Although we are not targeting the 
tyrosine kinase domain with CCmut3, mutation in the BCR-ABL CC to prevent CCmut3 
binding remains a possibility.  We envision, however, that due to the numerous contact 
points inherent to dimerization between two BCR-ABL monomers (or two BCR-ABL 
CC domains), this mutational escape may be unlikely.  CCmut3 was designed to favorably 
and specifically bind to BCR-ABL.  Should BCR-ABL mutate to avoid binding to 
CCmut3, it would also likely compromise its own binding to other BCR-ABL monomers, 
preventing its own dimerization.  Mutation in the CC domain, then, would in a sense lead 
to “self-inactivation” of BCR-ABL oligomerization.  
 This process could be analyzed using an N-ethyl-N-nitrosurea (ENU)-based 
mutagenesis screen (57, 58).  Briefly, BCR-ABL+ Ba/F3 cells would be subjected to 
treatment with the ENU mutagen, which randomly inserts mutations into cellular DNA.  
Following ENU-treatment overnight, cells would be treated with ST-CCmut3.  ST-CCmut3 
exposure would be validated through the use of a fluorescent tag (rhodamine or FITC, for 
example), using fluorescence activated cell sorting (FACS) analysis.  Any cells that 
continued to grow after positive exposure to both ENU and ST-CCmut3 would be isolated 
for their DNA to be amplified and analyzed.  DNA analysis, in this sense, would allow us 






Targeting the BCR-ABL tetramerization domain 
Inhibiting BCR-ABL tetramerization is another avenue that could be explored for 
CML therapy.  Immediately following BCR-ABL translation, the protein exists in the cell 
in a monomeric state.  The next step toward activation includes dimer formation by two 
monomers.  Following this process, two dimers can interact and form a tetramer.  Since 
tetramerization is the final step before BCR-ABL becomes active, it is speculated that 
creating a therapeutic against the tetramerization domain may be a viable option. 
Interactions involved in the BCR-ABL dimerization domain have been 
extensively studied and published (25), and we have used this as the basis for the design 
of our BCR-ABL dimerization inhibitor, CCmut3.  However, interactions involved in 
BCR-ABL tetramerization have not yet been described.  Although the tetrameric 
structure is available (Pymol PDB ID: 1K1F), specific interactions between two BCR-
ABL dimers have not been extensively studied.  Design of a tetramerization inhibitor 
would require comprehensive analysis of these specific dimer-dimer interactions.  
 
Combination of CCmut3 and inhibitors of downstream signaling 
Chapter 4 shows that combination targeting of BCR-ABL with CCmut3 and 
ponatinib can elicit a greater therapeutic effect than targeting with single agents alone 
(59).  This multidomain targeting approach, however, is not expected to provide a 
therapeutic benefit to patients in whom BCR-ABL kinase-independent is predominant.  
In these cases, since the BCR-ABL kinase is not the underlying problem, targeting up-
regulated or activated signaling pathways should provide greater benefit.  One pathway 
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determined to be up-regulated in BCR-ABL kinase-independent CML involves the signal 
transducer and activator of transcription 3, or STAT3 (60).  Recently, Eiring et al. (from 
the Deininger Lab) have shown that combined targeting of BCR-ABL and the STAT3 
pathway induces synthetic lethality in therapy resistant CML (61).  More importantly, 
targeting this STAT3 pathway restored TKI sensitivity of BCR-ABL in previously 
kinase-independent resistant CML.  This major finding has the potential to fill a gap in 
CML resistant therapy, however, will not address the issue if the kinase domain contains 
compound mutations undruggable by any approved TKIs (for example, E255V/T315I 
compound mutant BCR-ABL) (62).  In these cases, combination of STAT3 inhibition and 
treatment with ST-CCmut3 may provide a way to fully close this gap in therapy. 
 
Summary 
 Many different avenues are being explored to improve the original CCmut3 
construct to make it suitable for drug delivery.  Delivering CCmut3 as a peptide using a 
LS-CPP is under study, and on top of the LS-CPP, adding a hydrocarbon staple to the 
CCmut3 peptide backbone is expected to increase deliverability by increasing proteolytic 
resistance, cell internalization capacity, and target affinity.  Once suitable, ST-CCmut3 
(with or without the LS-CPP) treatment alone and other combination treatments will be 
explored to determine its most effective place in therapy against resistant CML.  
Combination treatment may include use with a TKI (ponatinib) or an inhibitor of a 
downstream signaling pathway (STAT3, for example) for use in BCR-ABL independent 
resistant CML.  Finally, it is expected that because CCmut3 does not bind in the tyrosine 
kinase domain, targeting mutant and especially compound mutant BCR-ABL should still 
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be effective, covering a current gap in TKI therapy.  Ideally, final validation of this work 
will provide a translational avenue for the optimized ST-CCmut3 as an option for therapy-
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Background on Ba/F3 cell lines 
 Preliminary studies included testing CCmut3 only in K562 (human, BCR-ABL+ 
leukemia) cells.  As work progressed, the need to test CCmut3 in cells containing mutant 
BCR-ABL arose.  Our lab was kindly gifted (from the Deininger Lab, Hunstman Cancer 
Institute, University of Utah, Salt Lake City, UT, USA) Ba/F3 (murine, pro-B) cells that 
had been virally transduced to express the p210 variant of BCR-ABL (Ba/F3-p210 cells).  
Additional cell lines were created that included mutations in the tyrosine kinase domain 
of BCR-ABL; these were also gifted to us from the Deininger Lab.  Finally, as a negative 
control in some experiments, native (BCR-ABL-negative) Ba/F3 cells were used.  All of 
the Ba/F3 cell lines used experimentally appear in Table A.1.   
 
Viability of transfected cells 
All transfections of Ba/F3 cells were carried out using the Amaxa Nucleofector II 
(Lonza Group, Basel, Switzerland) instrument and Cell Line Nucleofector® Kit V, 
program X-001.  Recommendations by the manufacturer suggested transfecting 2.0 x 106 
Ba/F3 cells with 6 µg DNA.  Early transfections of these cell lines, when following the 
manufacturer’s protocol, showed both inefficiency of DNA uptake and most importantly  
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cellular lethality due to the transfection process.  This was determined due to the 
unusually high amount of dead cells following transfection of EGFP or mCherry negative 
control vectors.  Thus, personal communication with scientific representatives at the 
Lonza Group led to three recommendations for solving this problem: 1) increase the 
amount of cells attempting to transfect, 2) decrease the µg amount of DNA attempting to 
be transfected, and 3) immediately following the nucleofection, incubate the cells in 500 
µL plain RPMI media for 15-30 min.   
All three steps were designed to increase the amount of live cells that have been 
positively transfected, despite steps 1 and 2 potentially decreasing the overall transfection 
efficiency.  Step 3 was recommended as a means to protect the newly transfected cells 
from an over-influx of calcium, contained in the FBS of Complete RPMI 1640 media.  
By incubating in plain RPMI 1640 media, the delicate cells, whose membranes are 
compromised during the electroporation process, are placed in a much lower calcium 
environment that can aid in their survival. 
 Therefore, a quick experiment was designed to determine the best transfection 
Cell Line Description 
Ba/F3 BCR-ABL-negative cell line 
Ba/F3-p210 BCR-ABL p210 variant with no kinase domain 
mutations 
Ba/F3-p210-E255V BCR-ABL p210 variant with E255V point 
mutation in the tyrosine kinase domain 
Ba/F3-p210-T315I BCR-ABL p210 variant with T315I point mutation 
in the tyrosine kinase domain 
Ba/F3-p210-E255V/T315I BCR-ABL p210 variant with the E255V/T315I 
compound mutation in the tyrosine kinase domain 
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method of Ba/F3-p210-T315I cells still using the nucleofection system.  This optimal 
method would then be utilized for all further transfections of Ba/F3 cell lines.  Per Lonza 
scientific representative recommendations, the number of cells, the amount of DNA, and 
the postnucleofection incubation in plain RPMI (or lack of incubation) were varied.  In 
those experimental groups receiving the posttransfection plain RPMI treatment, 
incubation in this media was maintained for 20 min.  Trypan blue exclusion (Chapter 2) 
was used to determine the viability of transfected cells of all experimental groups.  
Results are presented in Figure A.1.  In each treatment group, the pmCherry vector was 
used as the transfected DNA.  Because this vector serves as a negative control, any 
effects seen on the cell can be considered “baseline” in any other experiments.  In other 
words, any cell death that occurred is expected to be due to the transfection process, not 
due to any intrinsic activity by the pmCherry vector.  
In all cases, regardless of the number of cells or amount of DNA transfected, cells 
in the experimental groups incubated in plain RPMI following transfection (Figure A.1., 
black bars) were found to be more viable than those not receiving the plain RPMI post-
transfection treatment (Figure A.1., white bars).  Next, in RPMI-treated groups, 
transfections involving 2 µg DNA (Figure A.1, black bar in leftmost column and black 
bar in third column from left) appeared to cause less nucleofection-mediated lethality 
than those using 6 µg DNA (Figure A.1., black bar second column from left and black 
bar rightmost column).  Finally, again in RPMI-treated cells, the number of starting cells 




Figure A.1.  Cell proliferation assay: viability of Ba/F3-p210-T315I cells.  Viability was 
assessed via trypan blue exclusion 48 h following transfection with mCherry plasmid 
DNA.  Assay was performed once using only one transfection for each treatment group. 
 
Ba/F3 transfection efficiency 
Following optimization to minimize the transfection-mediated lethality, the 
transfection efficiency of Ba/F3-p210 cells was analyzed.  Here, 24 h following 
transfection of pmCherry DNA (per optimized protocol above), the percentage of cells 
expressing mCherry fluorescence was calculated (please refer to Chapter 2 for 
fluorescence microscopy procedure).  Efficiency was determined using the overall total 
number of cells, imaged via phase contrast, and the total number of mCherry-expressing 
cells, imaged via fluorescence microscopy (see Chapter 2).  Results are presented in 
Figure A.2.  Briefly, transfection efficiency was calculated at around 40% and 35% in 
K562 and Ba/F3-p210 cells, respectively. 
In summary, this appendix provides background information on Ba/F3 cells and 
specifically Ba/F3 cells expressing the BCR-ABL protein.  Additionally, optimal 
























































Figure A.2.  Transfection efficiency of K562 and Ba/F3-p210 cells.  Percentage of cells 
positive for mCherry transfection in each cell line was calculated 24 h following 
transfection, with positive transfections identified using fluorescence microscopy.  
Transfection of each cell line was performed once (n=1). 
 
described.  Finally, using this optimized transfection method, transfection efficiency of 
DNA was calculated.  Since all of the cell lines described arise from the Ba/F3 parental 
line, the transfection efficiency and cell lethality (due only to transfection) should not 
depend on the mutational state of the BCR-ABL transduced into the cell lines.  These 
results were used to more effectively make sense of data throughout studies involving 
transfection of Ba/F3 cells. 
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